Sundheds- og Ældreudvalget 2018-19 (1. samling)
SUU Alm.del
Offentligt
2017082_0001.png
Completed
Rank
Title
Bilag 1
Study Results Conditions
Interventions
Locations
URL
Talampanel for Amyotrophic
1 Lateral Sclerosis (ALS)
No Results
Available
ALS
Drug: Talampanel|Other: placebo
CA Medical Center for Movement Disorders-Forbes Norris MDA/ALS Research Center, San Francisco, California, United States|University of Kansas Medical Center - Dept of Neurology, Kansas City, Kansas, United States|Johns Hopkins OPC - Meyer Bldg, Baltimore, Maryland, United States|Massachusetts General
Hospital-Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University - Neurology Institute, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Academic Hospital University of
Leuven - ALS dept, Leuven, Belgium|ALS Centre, Vancouver, British Columbia, Canada|London Health Sciences Centre Motor Neuro Diseases Clinic, London, Ontario, Canada|Montreal Neurological Institute, Montreal, Quebec, Canada|C.H.U. La Timone - Service de Neurologie, Marseille Cedex 5, France|C.H.U. de
Montpellier - Hopital Gui de Chauliac - Service des Explorations Neurologiques, Montpellier Cedex 5, France|Hopital La Pitie Salpetriere - Federation de Neurologie, Paris, France|Universitaetsklinik Berlin-Charite, Campus Virchow Klinikum, Neurologische Klinik, Berlin, Germany|Berufsgenossenschaftliche Klinik
Bergmannsheil, Neurologische Klinik, Bochum, Germany|Universitaet Ulm, Ulm, Germany|Semmelweis University, Department of Neurology, Budapest, Hungary|Sourasky MC -EMG Unit, Tel Aviv, Israel|Fondazione "S.Maugeri" Clinica della Riabilitazione IRCCS-Istituto Scientifico di Lissone, Lissone (MI),
Italy|Centro Clinico NEMO, Milano, Italy|Azienda Ospedaliero Universitaria San Giovanni Battista di Torino - Dipartimento di Neuroscienze, Torino, Italy|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Carlos III, Madrid, Spain
https://ClinicalTrials.gov/show/NCT00696332
Evaluation of Metabolomic
Analysis in Early Diagnosis of
2 ALS
Safety of Caprylic Triglycerides
3 in ALS: A Pilot Study
No Results
Available
No Results
Available
ALS
Procedure: lumbar puncture
Pôle Neurosciences et Spécialités ,Service de Neurologie,CHU d'Angers, Angers, France|Service de Neurologie et Pathologie du Mouvement Clinique de Neurologie, Pôle des Neurosciences et de l'Appareil Locomoteur INSERM U 837, Lille, France|Service de Neurologie et Centre SLA, CHU de Limoges, EA3174
Université de Limoges - Faculté de médecine, Limoges, France|Centre SLA, CHU Gui de Chauliac, Université de Montpellier 1, Montpellier, France|Centre de Recherche de l'Institut du Cerveau et de la moëlle UPMC Paris 6,Département des Maladies du Système Nerveux, Paris, France|Service de
neurologie, CHU La Milétrie, POITIERS, Faculté de Médecine, Poitiers, France|University Hospital, Strasbourg, France|CHRU -TOURS-Service de Neurologie, Tours, France
https://ClinicalTrials.gov/show/NCT01962311
ALS
Dietary Supplement: Axona
Weill Cornell Medical Center, New York, New York, United States
https://ClinicalTrials.gov/show/NCT02716662
A Study for Patients Who
Completed VITALITY-ALS (CY
4 4031)
No Results
Available
ALS Reversals - Lunasin
5 Regimen
Has Results
Amyotrophic
Lateral
Sclerosis (ALS) Drug: tirasemtiv
ALS
(Amyotrophic
Lateral
Drug: Lunasin Regimen|Other: Historical
Sclerosis)
control
St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California, Irvine, Orange, California, United States|UC Davis Medical Center, Sacramento, California, United States|Forbes Norris
MDA/ALS Research Center, San Francisco, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, United States|Hospital for Special Care, New Britain, Connecticut, United States|George Washington
University Medical Center, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Miami, Miller School of Medicine, Miami, Florida, United States|Carol & Frank Morsani Center for Advanced Health Care - University of South Florida, Tampa, Florida, United
States|The Emory Clinic, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United
States|University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin County Medical
Center, Minneapolis, Minnesota, United States|St. Louis University, Department of Neurology & Psychiatry, Saint Louis, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hospital for Special Surgery,
New York, New York, United States|Neurological Institute, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United States|Duke Neurological Disorders Clinic, Durham, North Carolina,
United States|Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Providence Brain and Spine Inst. ALS Center, Portland, Oregon, United States|Penn State Milton S. Hershey
Medical Center, Hershey, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Clinical Research Center, Nashville, Tennessee, United States|Texas Neurology, PA, Dallas, Texas, United States|UTHSCSA - First Outpatient
Research Unit, San Antonio, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|West Virginia University Hospitals, Morgantown, West Virginia, United States|Froedtert Memorial Lutheran
Hospital, Milwaukee, Wisconsin, United States|UZ Leuven, Leuven, Vlaams Brabant, Belgium|University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada|QE II Health Sciences, Nova Scotia Health
Authority, Halifax, Nova Scotia, Canada|McMaster University Medical Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Sunnybrook Health Sciences Center, Toronto, Ontario, Canada|Hopital Notre-Dame/CHUM, Montreal, Quebec, Canada|Montreal Neurological
Institute and Hospital, Montreal, Quebec, Canada|CHU de Quebec - Univerite' Laval, Quebec, Canada|Hopital Dupuytren, service de neurologie, Limoges Cedex, France|Hopital Gui de chauliac, Montpellier Cedex 5, France|CHU de Nice - Hopital Pasteur 2, Nice Cedex 1, France|Hopital Bretonneau, Tours cedex 9,
France|University of Ulm, Department of Neurology, Ulm, Baden-Wuerttemberg, Germany|Hannover Medical School, Department of Neurology, Hannover, Lower Saxony, Germany|Charite Campus Virchow-Klinikum, Department of Neurology, Berlin, Germany|Clinical Research Centre Beaumont Hospital, Dublin,
Ireland|IRCCS Istituto Auxologico Italiano - U.O. Neurologia, Milan, Lombardy, Italy|Centro Clinico NEMO - Fondazione Serena Onlus, ASST Grande Ospedale Metropolitano Niguarda, Ospedale Niguarda, Milan, Lombardy, Italy|Dipartimento di Neuroscienze "Rita Levi Moltalcini" A.O.U. Citta della Salute e della
Scienza di Torino P.O. "Molinette", Torino, Piemonte, Italy|University Medical Center Utrecht, Utrecht, Netherlands|Hospital Santa Maria - Centro Hospitalar Lisboa Norte, Lisboa, Portugal|Hospital San Rafael, Madrid, Spain|King's College Hospital NHS Foundation Trust, London, United Kingdom
https://ClinicalTrials.gov/show/NCT02936635
Duke Medicine / Neurology, Durham, North Carolina, United States
https://ClinicalTrials.gov/show/NCT02709330
Immunosuppression in
Amyotrophic Lateral Sclerosis
6 (ALS)
Has Results
Amyotrophic Drug: Basiliximab|Drug:
Lateral
Methylprednisolone|Drug: Prednisone|Drug:
Sclerosis (ALS) Tacrolimus|Drug: Mycophenolate mofetil
Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States
Amyotrophic
Lateral
Other: Adaptation and training to Non
Sclerosis (ALS) Invasive Ventilation (NIV)
https://ClinicalTrials.gov/show/NCT01884571
New Perspectives of Adaptation
7 to NIV in ALS
Phase 2, Randomized, Double
Blind, Placebo Controlled
Multicenter Study of
Autologous MSC-NTF Cells in
8 Patients With ALS
No Results
Available
Michele Vitacca, Lumezzane, Brescia, Italy|Paolo Banfi, Milan, Italy
https://ClinicalTrials.gov/show/NCT02537132
No Results
Available
Amyotrophic
Biological: Autologous MSC-NTF
Lateral
Sclerosis (ALS) cells|Biological: Placebo
Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States
https://ClinicalTrials.gov/show/NCT02017912
1
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0002.png
A Pilot Study of RNS60 in
Amyotrophic Lateral Sclerosis
9 (ALS)
No Results
Available
ALS
Drug: RNS60
Massachusetts General Hospital, Boston, Massachusetts, United States
https://ClinicalTrials.gov/show/NCT02525471
Clinical Trial Nuedexta in
10 Subjects With ALS
Has Results
Amyotrophic
Lateral
Sclerosis (ALS) Drug: Nuedexta|Drug: Matching Placebo
Amyotrophic
Lateral
Sclerosis (ALS) Other: PET Scanning
California Pacific Medical Center, San Francisco, California, United States|Georgetown University Medical Center, Washington D.C., District of Columbia, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United
States|Neurology Associates, P.C., Lincoln, Nebraska, United States|The Cleveland Clinic, Cleveland, Ohio, United States|Providence ALS Center, Portland, Oregon, United States
https://ClinicalTrials.gov/show/NCT01806857
11 PET Imaging in ALS Patients
No Results
Available
Johns Hopkins University, Baltimore, Maryland, United States
https://ClinicalTrials.gov/show/NCT02236897
A Phase II Multi-centre,
Extension Study to Investigate
the Long Term Safety of ONO-
2506PO in Patients Diagnosed
With Amyotrophic Lateral
12 Sclerosis (ALS)
No Results
Available
Amyotrophic
Lateral
Sclerosis (ALS) Drug: ONO-2506PO
Prof. Maloteaux, UCL Saint-Luc, Brussels, Belgium|Prof. Wim Robberecht, UZ Leuven, Leuven, Belgium|Prof. Alain Destee, Hopital Roger Salengro - Clinique Neurologique, Neurologie A, Lille Cedex, France|Prof. Philippe Couratier, Hopital Duruytren, Limoges Cedex, France|Prof. Jan Pouget, Hopital de la Timone,
Marseille, France|Prof. William Camu, Hopital de Chauliac, Montpellier cedex 5, France|Prof. Claude Desnuelle, Hopital 1-Archet 1, Nice cedex 3, France|Prof. Vincent Meininger, Hopital LaPitie Salpetriere, Paris, France|Dr. Thomas Meyer, Charite Campus Virchow, ALS Ambulanz, Berlin, Germany|Prof. Torsten
Grehl, Neurologische Ambulanz Universitatsklinik Bergmannsheil, Bochum, Germany|Professor Dieter Heuss, Poliklinik der Universitat Erlangen-Nurnberg, Neurologische Klinik, Erlangen, Germany|Prof. Stephan Zierz, Martin Luther Universitat Halle-Wittenberg, Klinikum der Medizinischen Fakultat,
Universitatsklinik und Poliklinik fur Neurologie, Halle, Germany|Prof. Reinhard Dengler, Medizinische Hochschule Hannover, Neurologische Klinik, Hannover, Germany|Prof Gian Domenico Borasio, Interdisziplinares Zentrum fur Palliativmedizin, Munchen, Germany|Prof. Albert Ludolph, Klinik und Poliklinikfur
Neurologie der Universitat Ulm-Univeritatsklinikum Ulm, Ulm, Germany|Dr. Berthold Schrank, Deutsche Klinik fur Diagnostik, Fachbereich Neurologie, Wiesbarden, Germany|Prof. Vincenzo Silani, Dipartimento di Neurologia e Laboratorio di Neuroscienze - Universita di Milano - IRCCS - Istituto Auxologico Italiano,
Milano, Italy|Dr. Gabriele Mora, Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS, Pavia, Italy|Prof. Adriano Chio, Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette, Torino, Italy|Prof Marianne de Visser, Academic Medical Centre
(AMC) Amsterdam - Dept of Neurology, Amsterdam, Netherlands|Prof. Leonard H Van Den Berg, University Medical Center Utrecht, Utrecht, Netherlands|Dr. Markus Weber, Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic, St. Gallen, Switzerland|Prof. Nigel Leigh, Academic Neuroscience Centre, London,
United Kingdom|Prof. Douglas Mitchell, Royal Preston Hospital, Preston, United Kingdom|Dr. Chris McDermott, Royal Hallamshire Hospital, Sheffield, United Kingdom
https://ClinicalTrials.gov/show/NCT00694941
Clinical Trial Ceftriaxone in
13 Subjects With ALS
Has Results
Amyotrophic
Lateral
Sclerosis|ALS
Drug: ceftriaxone|Other: placebo
Phoenix Neurological Associates, Phoenix, Arizona, United States|University of California, Davis, Davis, California, United States|University of California, San Francisco- Fresno, Fresno, California, United States|Loma Linda University School of Medicine (CA), Loma Linda, California, United States|Cedars-Sinai Medical
Center, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine - MDA ALS Neuromuscular Center, Orange, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of
California, San Francisco, San Francisco, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Hospital for Special Care, New Britain, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|Mayo Clinic
Jacksonville, Jacksonville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|ALS Center at Emory University, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|Northwestern University Medical School, Chicago, Illinois, United
States|Indiana University (Regenstrief Health Center), Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United
States|Lahey Clinic, Burlington, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Saint Mary's Healthcare, Grand Rapids, Michigan, United States|Hennepin County Medical Center (Berman Center), Minneapolis, Minnesota, United States|St. Louis University, St. Louis,
Missouri, United States|Washington University, St. Louis, Missouri, United States|Bryan LGH Medical Center (University of Nebraska), Lincoln, Nebraska, United States|UMDNJ- Robert Wood Johnson School of Medicine, New Brunswick, New Jersey, United States|Albany Medical Center, Albany, New York, United
States|Beth Israel Medical Center (NY), New York, New York, United States|Cornell Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North
Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Clinic (Providence Clinic), Portland, Oregon, United States|Pennsylvania
State University, Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College of Medicine (Hahnemann Campus), Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Hospital, Pittsburgh, Pennsylvania, United
States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Texas Neurology, Dallas, Texas, United States|Methodist Neurological Institute, Houston, Texas, United
States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|University of Calgary, Calgary, Alberta, Canada|Univeristy of Alberta ALS Clinic, Edmonton, Alberta, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|London
Health Sciences Center, University Campus, London, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|CHUM (Centre Hospitalier de l'Université de Montréal), Notre-Dame Hospital, Montreal, Quebec, Canada|Montreal Neurological Institute (McGill University), Montreal, Quebec,
Canada|Laval University, Quebec City, Quebec, Canada
https://ClinicalTrials.gov/show/NCT00349622
2
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0003.png
Placebo Controlled Study of
ONO2506PO in the Presence of
Riluzole in Patients With
Amyotrophic Lateral Sclerosis No Results
14 (ALS)
Available
Amyotrophic
Lateral
Sclerosis (ALS) Drug: ONO-2506PO
L. Boltzmann Forschungsinstitut, Neurologische Abteilung, Kaiser Franz Josef Hospital, Wien, Wien, Austria|UCL Saint-Luc, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Hopital Roger Salengro - Clinique Neurologique, Neurologie A, Lille Cedex, France|Hopital Duruytren, Limoges Cedex, France|Hopital de la
Timone, Marseille, France|Hopital de Chauliac, Montpellier cedex 5, France|Hopital l-Archet 1, Nice cedex 3, France|Hopital LaPitie Salpetriere, Paris, France|Charite Campus Virchow, ALS Ambulanz, Berlin, Germany|Neurologische Universitatsklinik Bergmannsheil, Bochum, Germany|Poliklinik der Universitat
Erlangen-Nurnberg, Neurologische Klinik, Erlangen, Germany|Martin-Luther-Universitat Halle-Wittenberg, Klinikum der Medizinischen Fakultat, Universitatsklinik und Poliklinik fur Neurologie, Halle, Germany|Medizinische Hochschule Hannover, Neurologische Klinik, Hannover, Germany|Interdisziplinares Zentrum
fur Palliativmedizin, Munchen, Germany|Klinik und Poliklinik fur Neurologie der Universitat Ulm-Universitatsklinikum Ulm, Ulm, Germany|Deutsche Klinik fur Diagnostik, Fachbereich Neurologie, Wiesbaden, Germany|Dipartimento di Neurologia e Laboratorio di Neuroscienze - Universita di Milano - IRCCS - Istituto
Auxologico Italiano, Milano, Italy|Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS, Pavia, Italy|Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette, Torino, Italy|Academic Medical Centre (AMC) Amsterdam - Dept of Neurology,
Amsterdam, Netherlands|University Medial Center Utrecht, Utrecht, Netherlands|Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic, St. Gallen, Switzerland|Academic Neuroscience Centre, London, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|University of Sheffield - Academic Neurology
Unit, Sheffield, United Kingdom
https://ClinicalTrials.gov/show/NCT00403104
A Study in Patients With
Amyotrophic Lateral Sclerosis
15 (ALS)
Phase 3 Study of MCI-186 for
Treatment of Amyotrophic
16 Lateral Sclerosis
No Results
Available
Amyotrophic
Lateral
Sclerosis (ALS) Drug: E0302 (mecobalamin)|Drug: Placebo
Amyotrophic
Lateral
Drug: MCI-186|Drug: Placebo|Drug: MCI-
Sclerosis (ALS) 186 in open label phase
Amyotrophic
Lateral
Sclerosis|ALS
Nagoya-shi, Aichi, Japan|Akita-shi, Akita, Japan|Aomori-shi, Aomori, Japan|Chiba-shi, Chiba, Japan|Touon-shi, Ehime, Japan|Fukuoka-shi, Fukuoka, Japan|Kitakyusyu-shi, Fukuoka, Japan|Fukushima-shi, Fukushima, Japan|Maebashi-shi, Gunma, Japan|Higashihiroshima-shi, Hiroshima, Japan|Miyoshi-shi,
Hiroshima, Japan|Otake-shi, Hiroshima, Japan|Sapporo-shi, Hokkaido, Japan|Kanazawa-shi, Ishikawa, Japan|Ichinoseki-shi, Iwate, Japan|Sagamihara-shi, Kanagawa, Japan|Yokohama-shi, Kanagawa, Japan|Nangoku-shi, Kochi, Japan|Kyoto-shi, Kyoto, Japan|Tsu-shi, Mie, Japan|Sendai-shi, Miyagi, Japan|Watari-
gun, Miyagi, Japan|Nagano-shi, Nagano, Japan|Higashisonogi-gun, Nagasaki, Japan|Kashiwazaki-shi, Niigata, Japan|Niigata-shi, Niigata, Japan|Tsukubo-gun, Okayama, Japan|Ginowan-shi, Okinawa, Japan|Toyonaka-shi, Osaka, Japan|Hasuda-shi, Saitama, Japan|Saitama-shi, Saitama, Japan|Otsu-shi, Shiga,
Japan|Hamamatsu-shi, Shizuoka, Japan|Shizuoka-shi, Shizuoka, Japan|Shimotsuke-shi, Tochigi, Japan|Tokushima-shi, Tokushima, Japan|Yoshinogawa-shi, Tokushima, Japan|Bunkyo-ku, Tokyo, Japan|Kodaira-shi, Tokyo, Japan|Ota-ku, Tokyo, Japan|Wakayama-shi, Wakayama, Japan|Yonezawa-shi, Yamagata,
Japan|Shimonoseki-shi, Yamaguchi, Japan|Yanai-shi, Yamaguchi, Japan
https://ClinicalTrials.gov/show/NCT00444613
Has Results
Osaka, Japan
https://ClinicalTrials.gov/show/NCT01492686
Phase II Study Using
Thalidomide for the Treatment No Results
17 of ALS
Available
Drug: Thalidomide
Dartmouth Hichcock Medical Center, Lebanon, New Hampshire, United States
https://ClinicalTrials.gov/show/NCT00140452
A Long-Term Study in Patients
With Amyotrophic Lateral
18 Sclerosis (ALS)
No Results
Available
Amyotrophic
Lateral
Sclerosis (ALS) Drug: E0302 (mecobalamin)
Nagoya-shi, Aichi, Japan|Aomori-shi, Aomori, Japan|Chiba-shi, Chiba, Japan|Touon-shi, Ehime, Japan|Fukuoka-shi, Fukuoka, Japan|Kitakyushi-shi, Fukuoka, Japan|Fukushima-shi, Fukushima, Japan|Maebashi-shi, Gunma, Japan|Higashihiroshima-shi, Hiroshima, Japan|Miyoshi-shi, Hiroshima, Japan|Otake-shi,
Hiroshima, Japan|Sapporo-shi, Hokkaido, Japan|Kanazawa-shi, Ishikawa, Japan|Ichinoseki-shi, Iwate, Japan|Sagamihara-shi, Kanagawa, Japan|Yokohama-shi, Kanagawa, Japan|Nangoku-shi, Kochi, Japan|Kyoto-shi, Kyoto, Japan|Tsu-shi, Mie, Japan|Sendai-shi, Miyagi, Japan|Watari-gun, Miyagi, Japan|Nagano-shi,
Nagano, Japan|Higashisonogi-gun, Nagasaki, Japan|Kashiwazaki-shi, Niigata, Japan|Niigata-shi, Niigata, Japan|Tsukubo-gun, Okayama, Japan|Ginowan-shi, Okinawa, Japan|Toyonaka-shi, Osaka, Japan|Hasuda-shi, Saitama, Japan|Saitama-shi, Saitama, Japan|Hamamatsu-shi, Shizuoka, Japan|Shizuoka-shi,
Shizuoka, Japan|Shimotsuke-shi, Tochigi, Japan|Tokushima-shi, Tokushima, Japan|Yoshinogawa-shi, Tokushima, Japan|Bunkyo-ku, Tokyo, Japan|Kodaira-shi, Tokyo, Japan|Ota-ku, Tokyo, Japan|Wakayama-shi, Wakayama, Japan|Yonezawa-shi, Yamagata, Japan|Shimonoseki-shi, Yamaguchi, Japan|Yanai-shi,
Yamaguchi, Japan
https://ClinicalTrials.gov/show/NCT00445172
3
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0004.png
19
20
21
22
Trial of Safety and Efficacy of
Rasagiline in Patients With
Amyotrophic Lateral Sclerosis
(ALS)
Optimizing NIPPV Use for
Patients With ALS
Expanded Controlled Study of
Safety and Efficacy of MCI-186
in Patients With Amyotrophic
Lateral Sclerosis (ALS)
Intravenous Injection of
Adipose Derived Mesenchymal
Stem Cell for ALS
Has Results
No Results
Available
Amyotrophic
Lateral
Sclerosis (ALS) Drug: rasagiline
ALS
Behavioral: Data Card Report
Phoenix Neurological Institute, Phoenix, Arizona, United States|California Pacific Medical Center, San Francisco, California, United States|University of Iowa, Iowa City, Iowa, United States|University Of Kansas Medical Center, Kansas City, Kansas, United States|University of Minnesota, Minneapolis, Minnesota,
United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Tennessee, Memphis, Tennessee, United States|The Methodist Hospital System, Houston, Texas, United States|McGill University, Montreal,
Quebec, Canada
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
https://ClinicalTrials.gov/show/NCT01232738
https://ClinicalTrials.gov/show/NCT01035476
Has Results
No Results
Available
Amyotrophic
Lateral
Sclerosis (ALS) Drug: MCI-186|Drug: Placebo of MCI-186
Amyotrophic
Lateral
Sclerosis
Biological: mesenchymal stem cells
National Hospital Organization Miyagi National Hospital, Watari-gun, Miyagi-ken, Japan
https://ClinicalTrials.gov/show/NCT00424463
Royan Institute, Tehran, Iran, Islamic Republic of
https://ClinicalTrials.gov/show/NCT02492516
A Multicenter, Dose Ranging
Safety and Pharmacokinetics
23 Study of Arimoclomol in ALS
Tamoxifen Therapy in
Amyotrophic Lateral Sclerosis
[ALS]
Intrathecal Transplantation of
Mesenchymal Stem Cell in
Patients With ALS
Intravenous Transplantation of
Mesenchymal Stem Cell in
Patients With ALS
Masitinib in Combination With
Riluzole for the Treatment of
Patients Suffering From
Amyotrophic Lateral Sclerosis
(ALS)
Efficacy and Safety Study of
MCI-186 for Treatment of
Amyotrophic Lateral Sclerosis
(ALS)
Efficacy and Safety Study of
MCI-186 for Treatment of
Amyotrophic Lateral Sclerosis
(ALS) Who Met Severity
Classification III
Effect of Intrathecal
Administration of
Hematopoietic Stem Cells in
Patients With Amyotrophic
Lateral Sclerosis (ALS)
No Results
Available
Amyotrophic
Lateral
Sclerosis (ALS) Drug: arimoclomol
University of California, Irvine Medical Center, Irvine, California, United States|University of Miami School of Medicine, Miami, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Hennepin Faculty
Associates/Berman Center, Minneapolis, Minnesota, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University, Durham, North Carolina, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College of
Medicine, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
https://ClinicalTrials.gov/show/NCT00244244
24
No Results
Available
No Results
Available
No Results
Available
25
26
Amyotrophic
Lateral
Sclerosis (ALS) Drug: Tamoxifen
University of Wisconsin, Madison, Wisconsin, United States
Amyotrophic
Lateral
Sclerosis
Biological: intrathecal injection
Royan Institute, Tehran, Iran, Islamic Republic of
Amyotrophic
Lateral
Sclerosis
Biological: intra venous injection of stem cell Royan Institute, Tehran, Iran, Islamic Republic of
https://ClinicalTrials.gov/show/NCT00214110
https://ClinicalTrials.gov/show/NCT01771640
https://ClinicalTrials.gov/show/NCT01759797
27
No Results
Available
Amyotrophic
Lateral
Drug: Masitinib (4.5)|Drug: Riluzole|Drug:
Sclerosis (ALS) Placebo|Drug: Masitinib (3.0)
Amyotrophic
Lateral
Sclerosis (ALS) Drug: MCI-186|Drug: Placebo of MCI-186
Hospital Carlos III, Madrid, Spain
https://ClinicalTrials.gov/show/NCT02588677
28
Has Results
https://ClinicalTrials.gov/show/NCT00330681
29
Has Results
Amyotrophic
Lateral
Sclerosis (ALS) Drug: MCI-186|Drug: Placebo of MCI-186
https://ClinicalTrials.gov/show/NCT00415519
30
No Results
Available
Amyotrophic
Lateral
Sclerosis
Biological: Intrathecal autologous stem cell
Servicio HematologÃ-a Hospital Universitario, Monterrey, Nuevo León, Mexico
https://ClinicalTrials.gov/show/NCT01933321
4
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0005.png
A Study of NP001 in Subjects
With Amyotrophic Lateral
31 Sclerosis (ALS)
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: NP001|Drug: Placebo
Mayo Clinic, Scottsdale, Scottsdale, Arizona, United States|UC, Irvine, Irvine, California, United States|UCLA, Los Angeles, California, United States|California Pacific Med Center Forbes Norris MDA/ALS Research and Treatment Center, San Francisco, California, United States|Mayo Clinic, Jacksonville, Jacksonville,
Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|University of Kansas Medical Center, Landon Center on Aging, Kansas City, Kansas, United States|University of Kentucky, Department of Neurology, Lexington, Kentucky, United States|Massachusetts General Hospital, Charlestown,
Massachusetts, United States|Columbia University, New York, New York, United States|SUNY Upstate Medical University, Syracuse, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University, Dept of Neurology, Durham, North Carolina, United
States|Cleveland Clinic, Cleveland, Ohio, United States|Providence ALS Center, Portland, Oregon, United States|Methodist Hospital Research Institute, Methodist Neurologic Institute, Houston, Texas, United States|Providence Saint Peter Hospital, Centralia, Washington, United States
https://ClinicalTrials.gov/show/NCT01281631
A Trial of Tocilizumab in ALS
32 Subjects
Neuromuscular Magnetic
33 Stimulation in ALS Patients
No Results
Available
No Results
Available
ALS|Amyotrop
hic Lateral
Sclerosis|Lou
Gehrig's
Disease|Motor
Neuron
Barrow Neurological Institute, Phoenix, Arizona, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Penn State
Disease
Drug: Tocilizumab|Other: Placebo
College of Medicine Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Amyotrophic
Lateral
Device: Neuromuscular magnetic stimulation
Sclerosis
(NMMS)
https://ClinicalTrials.gov/show/NCT02469896
https://ClinicalTrials.gov/show/NCT03618966
Gilenya in Amyotrophic Lateral
34 Sclerosis (ALS)
Has Results
Safety Study of High Doses of
35 Zinc in ALS Patients
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: Gilenya|Other: Placebo
University of California, Irvine, Orange, California, United States|Georgia Regents University, Augusta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Methodist Neurological Institute, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT01786174
Drug: Zinc and Copper
Phoenix Neurological Associates, Phoenix, Arizona, United States
https://ClinicalTrials.gov/show/NCT01259050
SOD1 Inhibition by
Pyrimethamine in Familial
Amyotrophic Lateral Sclerosis
36 (ALS)
Double-blind Placebo
Controlled Pilot Trial in
Amyotrophic Lateral Disease
37 (ALS)
Has Results
Familial
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
ALS
(Amyotrophic
Lateral
Sclerosis)
Drug: Pyrimethamine
Weill Cornell Medical Center/New York Presbyterian Hospital, New York, New York, United States|Methodist Neurological Institute, Houston, Texas, United States|Universitäts- und Rehabilitationskliniken Ulm, Ulm, Germany|Milano Neurological Institute, Milan, Italy|Umea University, Umea, Sweden
https://ClinicalTrials.gov/show/NCT01083667
No Results
Available
Drug: GM604|Drug: Placebo comparator
Massachusetts General Hospital, Boston, Massachusetts, United States|Columbia Medical Center NY, New York, New York, United States
https://ClinicalTrials.gov/show/NCT01854294
Safety and Feasibility of the
38 EyeControl Device
A Long-term Extension Study of
TCH346 and Placebo
Administered Once Daily in
Patients With Amyotrophic
39 Lateral Sclerosis(ALS)
The Effect of GCSF in the
40 Treatment of ALS Patients
No Results
Available
Device: EyeControl device
https://ClinicalTrials.gov/show/NCT02891629
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: TCH346
Drug: Granulocyte Colony Stimulating
Factor|Drug: Placebo
Novartis, East Hanover, New Jersey, United States
https://ClinicalTrials.gov/show/NCT00230074
Iranian Neurology Research Center of Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
https://ClinicalTrials.gov/show/NCT01825551
41
42
43
44
Trial of Resistance and
Endurance Exercise in
Amyotrophic Lateral Sclerosis
(ALS)
Acetylcholine Receptors From
Human Muscles as
Pharmacological Target for ALS
Feasibility of Telesurveillance
and Home Cough Assistance for
Amyotrophic Lateral Patients
(ALS)
Safety and Efficacy Study of
Autologous Bone Marrow
Derived Stem Cell Treatment in
Amyotrophic Lateral Sclerosis
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis|ALS
Amyotrophic
Lateral
Sclerosis
Other: Resistance Exercise|Other: Endurance
Exercise|Other: Stretching/Range-of-Motion Cedars-Sinai Medical Center, Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States|Carolinas Medical Center, Charlotte, North Carolina, United States
Drug: endocannabinoid
palmitoylethanolamide (PEA)|Drug: Riluzole
https://ClinicalTrials.gov/show/NCT01521728
https://ClinicalTrials.gov/show/NCT02645461
No Results
Available
Other: telesurveillance
Michele Vitacca, Lumezzane, BS, Italy
https://ClinicalTrials.gov/show/NCT00613899
Has Results
Biological: HYNR-CS inj|Other: Control group Hanyang University Hospital, Seoul, Korea, Republic of
Other: Sport therapy|Other: Osteopathic
treatment
https://ClinicalTrials.gov/show/NCT01363401
Sport Therapy and Osteopathy No Results
45 Manipulative Treatment in ALS Available
https://ClinicalTrials.gov/show/NCT02548663
5
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0006.png
A Pilot Study of Inosine in
Amyotrophic Lateral Sclerosis
46 (ALS)
Developing a Discrimination
47 Model to Diagnose ALS
A New Eye-based
Communication Device for ALS
48 Patients
Noninvasive Ventilation in ALS
Patients With Mild Respiratory
49 Involvement
Has Results
No Results
Available
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: Inosine
Diagnostic Test: MRI(magnetic resonance
imaging)
Massachusetts General Hospital, Boston, Massachusetts, United States
https://ClinicalTrials.gov/show/NCT02288091
University of Michigan Hospital, Ann Arbor, Michigan, United States
https://ClinicalTrials.gov/show/NCT01995903
Device: EOL (Eye On Line)
Device: noninvasive positive pressure
ventilation
Groupe Hospitalier Pitie Salpetriere, Paris, France
https://ClinicalTrials.gov/show/NCT02313402
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
https://ClinicalTrials.gov/show/NCT00386464
Safety and Efficacy Study of
Creatine and Tamoxifen in
Volunteers With Amyotrophic
50 Lateral Sclerosis (ALS)
Memantine Therapy in
51 Amyotrophic Lateral Sclerosis
Has Results
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: creatine|Drug: tamoxifen
University of Kansas Medical Center, Kansas City, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical Center, Worcester, Massachusetts, United States|Washington University at St. Louis, St. Louis, Missouri, United States|SUNY Upstate
Medical University, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Pennsylvania State University, Hershey Medical Center, Hershey, Pennsylvania, United States|University of Washington Medical Center, Seattle, Washington, United States|Medical College of
Wisconsin, Milwaukee, Wisconsin, United States
https://ClinicalTrials.gov/show/NCT01257581
Drug: Memantine
Phoenix Neurological Associates, LTD, Phoenix, Arizona, United States
https://ClinicalTrials.gov/show/NCT01020331
Accurate Screening Tools for
Dysphagia in Amyotrophic
52 Lateral Sclerosis (ALS)
No Results
Available
Amyotrophic
Lateral
Sclerosis
Device: Micro Mouth Pressure
Meter|Device: Iowa Oral Performance
Instrument|Device: Electrical Impedance
Myography|Drug: Capsaicin|Procedure:
Videofluoroscopic Swallowing
Study|Procedure: Pulmonary Function
Testing|Other: Swallowing Related Quality of
Life Questionnaire|Other: Functional Oral
Intake Scale|Other: Amyotrophic Lateral
Sclerosis Functional Rating Scale-
Revised|Other: Eating Assessment Tool-
10|Other: Communicative Effectiveness
Survey|Other: The Center for Neurologic
Studies Bulbar Function Scale
University of Florida, Gainesville, Florida, United States
https://ClinicalTrials.gov/show/NCT02710162
Safety and Efficacy Study of
NP001 in Patients With
Amyotrophic Lateral Sclerosis
(ALS) and Systemic
53 Inflammation
Ibudilast (MN-166) in Subjects
With Amyotrophic Lateral
54 Sclerosis (ALS)
Marrow Stromal Cells Secreting
Neurotrophic Factors (MSC-
NTF), in Patients With
Amyotrophic Lateral Sclerosis
55 (ALS)
CARE Canadian ALS Riluzole
56 Evaluation
Human Neural Stem Cell
Transplantation in Amyotrophic
57 Lateral Sclerosis (ALS)
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: NP001|Drug: Placebo
Drug: Placebo (for MN-166)|Drug: MN-
166|Drug: riluzole
St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California, Irvine, Department of Neurology, Orange, California, United
States|Forbes Norris MDA/ALS Research Center, CPMC, San Francisco, California, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Emory University, Department of Neurology, Atlanta, Georgia, United
States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Albert B. Chandler Medical Center, Lexington, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Clinical & Translational Science Institute, University of Minnesota,
Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Carolinas Medical Center, Neurosciences Instutite-Neurology, Charlotte, North Carolina, United States|Duke Neurological
Disorders Clinic at Morreene Road, Durham, North Carolina, United States|Cleveland Clinic Foundation-Cleveland Clinic Hospital, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Providence Brain & Spine Institute, ALS Center, Portland, Oregon,
United States|Houston Methodist Neurological Institute, Houston, Texas, United States|University of Texas Health Sciences Center San Antonio, San Antonio, Texas, United States|Montreal Neurological Institute, Montreal, Quebec, Canada
https://ClinicalTrials.gov/show/NCT02794857
Carolinas Healthcare System, Dept. of Neurology, Charlotte, North Carolina, United States
https://ClinicalTrials.gov/show/NCT02238626
No Results
Available
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Biological: MSC_NTF cells transplantation by
multiple intramuscular injections at 24
separate sites, in addition to a single
intrathechal injection into the CSF
Hadassah Medical Organization, Jerusalem, Israel
https://ClinicalTrials.gov/show/NCT01777646
Drug: Riluzole
Sanofi-Aventis, Laval, Quebec, Canada
https://ClinicalTrials.gov/show/NCT00542412
Biological: Human Neural Stem Cells
Azienda Ospedaliera Santa Maria, Terni, Italy
https://ClinicalTrials.gov/show/NCT01640067
6
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0007.png
Clinical Trial of Ezogabine
58 (Retigabine) in ALS Subjects
Trial of Early Noninvasive
Ventilation for Amyotrophic
59 Lateral Sclerosis (ALS)
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: Ezogabine|Drug: Placebo
Device: BiPAP® S/T System|Other: sham-
NIPPV
Barrow Neuological Institute, Phoenix, Arizona, United States|Cedars-Sinai, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Augusta University (Georgia Regents Medical Center), Augusta, Georgia, United
States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Hospital for Special Surgery, New
York, New York, United States|Duke University Hospital, Durham, North Carolina, United States|Penn State College of Medicine Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
https://ClinicalTrials.gov/show/NCT02450552
University of Michigan, Ann Arbor, Michigan, United States
https://ClinicalTrials.gov/show/NCT00580593
Effect of Motor Rehabilitation
Treatment on Amyotrophic
60 Lateral Sclerosis (ALS)
No Results
Available
Amyotrophic
Lateral
Sclerosis
Procedure: Standard motor rehabilitation
treatment|Procedure: Intensive motor
rehabilitation treatment
Department of Neuroscience, S. Anna Hospital, Ferrara, Italy|Department of Neuroscience, S.Agostino-Estense Hospital, Modena, Italy|Department of Neuroscience, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
https://ClinicalTrials.gov/show/NCT02306109
Clinical Trial of High Dose
61 CoQ10 in ALS
Autologous Cultured
Mesenchymal Bone Marrow
Stromal Cells Secreting
Neurotrophic Factors (MSC-
62 NTF), in ALS Patients.
Has Results
Amyotrophic
Lateral
Sclerosis|Lou
Gehrig's
Disease
Drug: coenzyme Q10|Drug: Placebo
University of Arkansas for Medical Sciences, Department of Neurology, Little Rock, Arkansas, United States|California Pacific Medical Center, San Francisco, California, United States|University of California at San Francisco, San Francisco, California, United States|University of Colorado Health Sciences, Dept of
Neurology, Denver, Colorado, United States|Yale University School of Medicine, Department of Neurology, New Haven, Connecticut, United States|Northwestern University, Department of Neurology,, Chicago, Illinois, United States|University of Chicago, Department of Neurology, Chicago, Illinois, United
States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Dept of Neurology, College of Medicine, Lexington, Kentucky, United States|Brigham and Women's Hospital , Department of Neurology, Boston, Massachusetts, United States|Baystate Medical Center, Division of
Critical Care Research, Springfield,, Massachusetts, United States|Minneapolis Medical Research Foundation, ,, Minneapolis, Minnesota, United States|Washington University in St. Louis School of Medicine, Department of Neurology, St. Louis, Missouri, United States|Columbia Presbyterian Medical Center, The
Neurological Institute, New York, New York, United States|State University of New York Upstate Medical, Neurology Department, Syracuse, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Drexel University, Dept of Neurology, Philadelphia, Pennsylvania, United
States|University of Texas, Health Science Center at San Antonio, Division of Neurology, San Antonio, Texas, United States|University of Vermont, Neurology Department, Burlington, Vermont, United States
https://ClinicalTrials.gov/show/NCT00243932
No Results
Available
Amyotrophic
Lateral
Sclerosis
Biological: MSC-NTF cells transplantation
(IM)|Biological: MSC-NTF cells
transplantation (IT)
Hadassah Medical Organization, Jerusalem, Israel
https://ClinicalTrials.gov/show/NCT01051882
Safety and Efficacy of
TRO19622 as add-on Therapy
to Riluzole Versus Placebo in
Treatment of Patients Suffering
From Amyotrophic Lateral
No Results
63 Sclerosis (ALS)
Available
Amyotrophic
Lateral
Sclerosis
University Hospital Gasthuisberg - Dept Neurology - Herestraat 49, Leuven, Belgium|HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel, Bron Cedex, France|CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de
Neurologie et Pathologie du Mouvement, Lille, France|Centre SLA Limoges - Service de Neurologie, Limoges, France|Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires, Marseille, France|Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac, Montpellier,
France|CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA, Nice, France|Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux, Paris, France|Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum,
Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen, Berlin, Germany|Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg, Halle, Germany|Neurologische Klinik Medizinische Hochschule, Hannover, Germany|Universitäts- und
Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik, Ulm, Germany|Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10, Madrid, Spain|King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry, London, United Kingdom|Academic Neurology
Drug: Olesoxime|Drug: Placebo Comparator Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences, Sheffield, United Kingdom
https://ClinicalTrials.gov/show/NCT00868166
7
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0008.png
Open-Label, Safety and
Tolerability Extension Study of
KNS-760704 in Amyotrophic
64 Lateral Sclerosis (ALS) (CL211)
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: KNS-760704
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center, Los Angeles, California, United States|The Forbes Norris MDA/ALS Research Center, San Francisco, California, United States|University of Miami Miller School of
Medicine, Miami, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Massachusettes General Hospital, Boston, Massachusetts, United States|Washington University School of Medicine,
Saint Louis, Missouri, United States|Bryan LGH Medical Center East, Lincoln, Nebraska, United States|Columbia University, Lou Gehrig MDA/ALS Research Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Penn State Hershey Medical Center, Hershey,
Pennsylvania, United States|Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Sciences Center of
San Antonio, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|University of Washington, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT00931944
Safety and Tolerability Study of
KNS-760704 in Amyotrophic
No Results
65 Lateral Sclerosis (ALS)
Available
Amyotrophic
Lateral
Sclerosis
Drug: KNS-760704|Drug: Placebo
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center, Los Angeles, California, United States|The Forbes Norris MDA/ALS Research Center, San Francisco, California, United States|University of Colorado Health Sciences
Center, Aurora, Colorado, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Massachusettes General Hospital, Boston,
Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Bryan LGH Medical Center East, Lincoln, Nebraska, United States|Columbia University, Lou Gehrig MDA/ALS Research Center, New York, New York, United States|SUNY Upstate Medical University,
Syracuse, New York, United States|Oregon Health Sciences University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh,
Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Sciences Center of San Antonio, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia,
United States|University of Washington, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT00647296
Safety Extension Study of
66 TRO19622 in ALS
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: TRO19622
University Hospital Gasthuisberg - Dept Neurology - Herestraat 49, Leuven, Belgium|HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel, Bron Cedex, France|CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de
Neurologie et Pathologie du Mouvement, Lille, France|Centre SLA Limoges - Service de Neurologie, Limoges, France|Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires, Marseille, France|Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac, Montpellier,
France|CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA, Nice, France|Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux, Paris, France|Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum,
Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen, Berlin, Germany|Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg, Halle, Germany|Neurologische Klinik Medizinische Hochschule, Hannover, Germany|Universitäts- und
Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik, Ulm, Germany|Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10, Madrid, Spain|King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry, London, United Kingdom|Academic Neurology
Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences, Sheffield, United Kingdom
https://ClinicalTrials.gov/show/NCT01285583
8
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0009.png
Phase 3 Study of
67 Dexpramipexole in ALS
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: Dexpramipexole|Drug: Placebo
Barrow Neurological Institute - St. Joseph's Hospital, Phoenix, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of California at San Francisco - Fresno, Fresno, California, United States|University of California, Irvine, Orange, California, United
States|University of California, Davis, Sacramento, California, United States|California Pacific Medical Center, San Francisco, California, United States|Hospital for Special Care, New Britain, Connecticut, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of
Medicine, Miami, Florida, United States|University of South Florida Medical Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa,
United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States|St. Mary's Health Care, Grand Rapids, Michigan, United
States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Neurology Associates, P.C., Lincoln, Nebraska, United States|University of Nevada School
of Medicine, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Columbia University, New York, New York, United States|Research Foundation of the State University of New York, Syracuse, New York, United States|Carolinas Medical Center, Charlotte,
North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence ALS
Center, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|ALS Center at Penn, Philadelphia, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh,
Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Neurology, Dallas, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|University of Texas Health Sciences Center, San Antonio, Texas, United States|University of Utah,
Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|University of Washington, Seattle, Washington, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane
and Women's Hospital, Herston, Queensland, Australia|Calvary Health Care Bethlehem, Melbourne, Victoria, Australia|AZ St-Lucas, Gent, Belgium|UZ Leuven, Leuven, Belgium|Univ of Calgary / Foothills MC, Calgary, Alberta, Canada|CHUM - Hopital Notre Dame, Montreal, Quebec, Canada|Mcgill University,
Montreal, Quebec, Canada|London Health Sciences Centre, London, Canada|Sunnybrook and Women's College and Health Sciences Centre, Toronto, Canada|University of British Columbia, Vancouver, Canada|CHRU de Lille - Hôpital Roger Salengro, Lille, France|CHU de Limoges - Hôpital Dupuytren, Limoges,
France|Centre Hospitalier La Timone, Marseille, France|CHU Gui de Chauliac, Montpellier, France|CHU de Nice - Hôpital de l'Archet 1, Nice, France|Hôpital La Pitié Salpétrière, Paris, France|Charité - Universitätsmedizin Berlin, Berlin, Germany|Bergmannsheil Gmbh, Bochum, Germany|Medizinische
Hochschule Hannover (MHH), Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|University of Ulm, RKU, Ulm, Germany|Beaumont Hospital, Dublin, Ireland|Academisch Medisch Centrum, Amsterdam, Netherlands|UMC St. Radboud, Nijmegen, Netherlands|Universitair Medisch Centrum Utrecht,
Utrecht, Netherlands|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital La Paz, Madrid, Spain|Hospital Carlos III, Madrid, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden|Queen Elizabeth
Hospital, Birmingham, United Kingdom|Walton Centre for Neurology & Neurosurgery, Liverpool, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Newcastle University Hospital - Clinical Ageing Research Unit, Newcastle, United Kingdom|John Radcliffe Hospital, Oxford,
United Kingdom|Sheffield Institute for Transnational Neuroscience, Sheffield, United Kingdom
https://ClinicalTrials.gov/show/NCT01281189
Study of Safety, Tolerability &
Efficacy of CK-2017357 in
Amyotrophic Lateral Sclerosis
68 (ALS)
The Effect of Memantine on
Functional Outcomes and
Motor Neuron Degeneration in
Amyotrophic Lateral Sclerosis
69 (ALS)
Mesenchymal Stem Cells for
Treatment of Amyotrophic
70 Lateral Sclerosis (ALS)
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: CK-2017357|Other: Placebo
tablets|Drug: Riluzole
Barrow Neurology, Phoenix, Arizona, United States|University of California, San Diego, La Jolla, California, United States|UC Irvine ALS & Neuromuscular Center, Orange, California, United States|Coordinated Clinical Research, San Diego, California, United States|California Pacific Medical Center Forbes Norris
MDA/ALS Research Center, San Francisco, California, United States|Hospital for Special Care, New Britain, Connecticut, United States|The George Washington University, Washington, District of Columbia, United States|Mayo Clinic Florida Department of Neurology, Jacksonville, Florida, United States|Emory
University, School of Medicine, Atlanta, Georgia, United States|Georgia Health Sciences University, Augusta, Georgia, United States|Indiana University Department of Neurology, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas, Kansas
City, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United
States|Henry Ford Hospital, Detroit, Michigan, United States|St Mary's Healthcare, Grand Rapids, Michigan, United States|Hennepin County Medical Center - Berman Center for Research, Minneapolis, Minnesota, United States|Saint Louis University, St. Louis, Missouri, United States|Washington University, St.
Louis, Missouri, United States|Neurology Associates, Lincoln, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hospital for Special Surgery, New York, New York, United States|University of Rochester, Rochester, New York, United States|SUNY Upstate Medical
University, Syracuse, New York, United States|Carolinas Medical Center Department of Neurology, Charlotte, North Carolina, United States|Duke University, Durham, North Carolina, United States|Wake Forest University, School of Medicine, Winston-Salem, North Carolina, United States|Ohio State University
Department of Neurology, Columbus, Ohio, United States|Providence ALS Center, Portand, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn State Hershey Neuroscience Clinics, Hershey, Pennsylvania, United States|Drexel Neurology, Philadelphia, Pennsylvania,
United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Neurology, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas,
United States|UTHSCSA Department of Neurology, San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|West Virginia University Department of Neurology, Morgantown, West Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United
States|Heritage Medical Research, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada|QE II Health Sciences Centre, Halifax, Nova
Scotia, Canada|McMaster University Medical Centre, Hamilton, Ontario, Canada|Queen's University : Kingston General, Kingston, Ontario, Canada|London Health Sciences, London, Ontario, Canada|Univ. of Toronto - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Hôpital Notre Dame (CHUM)
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|Montreal Neurological Institute, Montreal, Quebec, Canada|CHU de Quebec: Hopital l'Enfant-Jesus, Quebec, Canada|CHRU de Lille - Hôpital Roger Salengro, Lille, France|CHU de Limoges - Hôpital Dupuytren, Limoges, France|Hôpital La
Timone Adulte, Marseille, France|CHU Montepellier, Montpellier, France|Hôpital Archet 1, Nice, France|Hôpital de la Salpêtrière, Paris, France|Hôpital Bretonneau, Tours, France|Charite Universitätsmedizin, Berlin, Germany|Hannover Medical School, Hannover, Germany|University of Ulm, Ulm,
Germany|Trinity College, Beaumont Hospital, Dublin, Ireland|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Carlos III, Madrid, Spain|Barts and the London MND & the Centre Royal London Hospital, Whitechapel, London, United Kingdom|Walton Centre for Neurology and Neurosurgery,
Liverpool, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Plymouth Hospitals NHS Trust, Plymouth, United Kingdom|Sheffield Institute for Translational Neuroscience, Sheffield, United Kingdom
https://ClinicalTrials.gov/show/NCT01709149
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: Memantine
Biological: autologous mesenchymal stem
cells
Calgary ALS Neuromuscular Clinic, Calgary, Alberta, Canada|University of Alberta ALS Clinic, Edmonton, Alberta, Canada
https://ClinicalTrials.gov/show/NCT00409721
Mayo Clinic, Rochester, Minnesota, United States
https://ClinicalTrials.gov/show/NCT01142856
Single-Ascending-Dose
Safety/Tolerability of NP001 in
Amyotrophic Lateral Sclerosis No Results
71 (ALS)
Available
Nocturnal PtcCO2 Monitoring
in Patients With Amyotrophic
72 Lateral Sclerosis (ALS)
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: NP001|Drug: Placebo
California Pacific Medical Center, San Francisco, California, United States|University of Kansas Medical Center - Landon Center on Aging, Kansas City, Kansas, United States|Department of Neurology; University of Kentucky Medical Center, Lexington, Kentucky, United States
https://ClinicalTrials.gov/show/NCT01091142
No Results
Available
Device: PtcCO2
PEREZ, Lille, France|Pôle des maladies respiratoires et service EFR- Centre hospitalier Regional Universitaire, Lille, France
https://ClinicalTrials.gov/show/NCT00879593
A Study to Evaluate the Effects
of Multiple Doses of CK-
2017357 in Patients With
Amyotrophic Lateral Sclerosis
73 (ALS)
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: Placebo|Drug: CK-2017357
California Pacific Medical Center, San Francisco, California, United States|Mayo Florida, Jacksonville, Florida, United States|University of Kansas, Kansas City, Kansas, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Columbia University Medical Center, New York, New York, United
States|SUNY Upstate Medical Center, Syracuse, New York, United States|Carolinas Neuromuscular ALS-MND Center, Charlotte, North Carolina, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
https://ClinicalTrials.gov/show/NCT01378676
9
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0010.png
Insulin-like Growth Factor-1 in
Amyotrophic Lateral Sclerosis
74 (ALS) Trial
Has Results
Amyotrophic
Lateral
Sclerosis
Mayo Clinic in Scottsdale, Scottsdale, Arizona, United States|California Pacific Medical Center, San Francisco, California, United States|Mayo Clinic in Jacksonville, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University
of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi, Jackson, Mississippi, United States|Beth
Israel Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of
Drug: Insulin like growth factor, type 1|Drug: Pennsylvania, Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Methodist Hospital, Houston, Texas, United States|West Virginia University, Morgantown, West Virginia, United States|Froedtert and Medical College Clinics, Milwaukee, Wisconsin, United States|University of Puerto Rico, San Juan,
Placebo
Puerto Rico
https://ClinicalTrials.gov/show/NCT00035815
Dose Titration Study to Test
Safety and Effects of CK-
2017357 in Patients With
Amyotrophic Lateral Sclerosis
75 (ALS)
No Results
Available
Focal Accumulation of Iron in
Cerebral Regions in Early ALS
(Amyotrophic Lateral Sclerosis) No Results
76 Patients
Available
Amyotrophic
Lateral
Sclerosis
Drug: CK-2017357|Drug: Placebo
ALS
(Amyotrophic
Lateral
Sclerosis)|Iron
Overload
Drug: Deferiprone
University of California at San Francisco, Fresno Campus, Central California Neurological Institute, Fresno, California, United States|Coordinated Clinical Research, La Jolla, California, United States|University of California at Irvine, ALS and Neuromuscular Center, Orange, California, United States|Hospital for Special
Care, New Britain, Connecticut, United States|Massachusetts General Hospital, Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States|Washington University, St. Louis, Missouri, United States|Cornell Faculty, Hospital for Special Surgery, New York, New York, United States|Duke University
School of Medicine, Division of Neurology, Durham, North Carolina, United States|Ohio State University, Department of Neurology, Columbus, Ohio, United States|Providence ALS Center, Portland, Oregon, United States|University of Texas Health Science Center, Department of Neurology, San Antonio, Texas,
United States
https://ClinicalTrials.gov/show/NCT01486849
Hôpital Roger Salengro, CHRU de Lille, Lille, France
https://ClinicalTrials.gov/show/NCT02164253
A Study of CK-2017357 in
Patients With Amyotrophic
No Results
77 Lateral Sclerosis (ALS)
Available
Study of Standard Noninvasive
Positive Pressure Ventilation
(NIPPV) and Low Expiratory
78 Pressure NIPPV in ALS Patients Has Results
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: Placebo|Drug: 250 mg CK-
2017357|Drug: 500 mg CK-2017357
Phoenix Neurological Associates, Ltd., Phoenix, Arizona, United States|University Neurology Associates, Fresno, California, United States|California Pacific Medical Center, San Francisco, California, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|University of Kentucky, Lexington, Kentucky,
United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University, St. Louis, Missouri, United States|SUNY Upstate Medical Center, Syracuse, New York, United States|Duke University, Durham, North Carolina,
United States|Providence ALS Center, Portland, Oregon, United States|Drexel University College of Medicine, Dept of Neurology, Philadelphia, Pennsylvania, United States|Penn State, University Park, Pennsylvania, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas,
United States|University of Vermont, Burlington, Vermont, United States
https://ClinicalTrials.gov/show/NCT01089010
Device: Viasys® Healthcare, Pulmonetic
Systems, lap-top ventilator (LTV machine)
University of Michigan, Ann Arbor, Michigan, United States
https://ClinicalTrials.gov/show/NCT01154283
10
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0011.png
Mexiletine for the Treatment of
79 Muscle Cramps in ALS
Has Results
Muscle
Cramps in
Amyotrophic
Lateral
Sclerosis
Drug: Mexiletine|Drug: Placebo
UCD Telehealth Network - Lake Almanor Clinic, Chester, California, United States|UCSD Department of Neurosciences ALS Clinical Trials (ACT) Program, La Jolla, California, United States|UCLA Neuromuscular Research Program, Los Angeles, California, United States|UCD Telehealth Network, Multiple Locations,
California, United States|UC Irvine Health ALS & Neuromuscular Center, Orange, California, United States|UC, Davis Medical Center ALS Clinic, Sacramento, California, United States
https://ClinicalTrials.gov/show/NCT01811355
Clinical Trial of SB-509 in
Subjects With Amyotrophic
80 Lateral Sclerosis (ALS)
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: SB-509
Coordinated Clinical Research, La Jolla, California, United States|University of California, Irvine; MDA ALS and Neuromuscular Center,, Orange, California, United States|California Pacific Medical Center (CPMC), The Forbes Norris MDA/ALS Research Center, San Francisco, California, United States|The University of
Kansas Medical Center (KU), Kansas City, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|Nerve and Muscle Center of Texas, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT00748501
Study Evaluating TCH346 and
Placebo Administered Once
Daily in Patients With
Amyotrophic Lateral Sclerosis
81 (ALS)
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: TCH346
Novartis USA, East Hanover, New Jersey, United States|Novartis Belgium, Vilvoorde, Belgium|Novartis CANADA, Dorval, Quebec, Canada|Novartis France, Rueil-Malmaison, France|Novartis Germany, Nuernberg, Germany|Novartis Italy, Saronno, Italy|Novartis Netherlands, Arnhem, Netherlands|Novartis
Switzerland, Bern, Switzerland|Novartis UK, Frimley, United Kingdom
https://ClinicalTrials.gov/show/NCT00072709
Clinical Trial of Glatiramer
Acetate in Amyotrophic Lateral No Results
82 Sclerosis (ALS)
Available
Amyotrophic
Lateral
Sclerosis
Drug: 40 mg glatiramer acetate|Drug:
Placebo
Teva Benelux, Leuven, Belgium|Teva France, Paris, France|Teva Germany, Morfelden-Walldorf, Germany|Teva Israel, Tel Aviv, Israel|Teva Italy, Milano, Italy|Teva UK, Aylesbury, United Kingdom
https://ClinicalTrials.gov/show/NCT00326625
Toxin Treatment for
Amyotrophic Lateral Sclerosis
83 (ALS) Related Sialorrhea
No Results
Available
No Results
Available
No Results
Available
No Results
Available
84 EH301 for the Treatment of ALS
Exercise and Disease
Progression in Amyotrophic
85 Lateral Sclerosis Patients
Combination Therapy in
Amyotrophic Lateral Sclerosis
86 (ALS)
Sialorrhea|Am
yotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Département de Neurologie, Hôpital de l'Hôtel-Dieu, CHU d'Angers, Angers cedex 9, France|Centre SLA, Groupement Hospitalier Est, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France|Service de Neurologie Vastel, Hôpital Côte de Nacre, CHU de Caen, Caen cedex 9,
France|Service de Neurologie, Hôpital Gabriel Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand cedex 1, France|Centre SLA, Service de Neurologie A et pathologies du mouvement, Hôpital Roger Salengro, CHU de Lille, Lille, France|Service de Neurologie, Hôpital Dupuytren, CHU de Limoges, Limoges,
France|Service de Neurologie, Hôpital de la Timone, CHU de Marseille, Marseille cedex 5, France|Service de Neurologie, Hôpital Central, CHU de Nancy, Nancy, France|Centre de Référence maladies Neuromusculaires, Service de Médecine Physique et Réadaptation, Hôpital de l'Archet 1, CHU de Nice,
Nice cedex 3, France|Fédération des Maladies du Système Nerveux, Groupement Hospitalier Pitié Salpêtrière, AP-HP, Paris cedex 13, France|Service de Neurologie, CHU de Saint-Etienne, Saint-Etienne cedex 2, France|Département de Neurologie, Hôpital de Hautepierre, CHRU de Strasbourg,
Drug: Botox injection|Drug: Placebo injection Strasbourg, France|Service d'Explorations Fonctionelles Neuro-Musculaires, Hôpital Rangueil, CHU de Toulouse, Toulouse, France
https://ClinicalTrials.gov/show/NCT01551940
Other: EH301|Other: Placebo
Other: standard care|Other: moderate
exercise
Drug: Pioglitazone and Tretinoin|Drug:
Tretinoin and Pioglitazone HCL|Drug:
Placebo
Universidad Católica de Valencia San Vicente Mà rtir, Valencia, Spain
https://ClinicalTrials.gov/show/NCT03489200
https://ClinicalTrials.gov/show/NCT03326622
Phoenix Neurological Associates, LTD, Phoenix, Arizona, United States
https://ClinicalTrials.gov/show/NCT00919555
11
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0012.png
Study of Rasagiline in Patients
With Amyotrophic Lateral
87 Sclerosis
Muscle Training of Patients
With Amyotrophic Lateral
88 Sclerosis (ALS)
Trial of Sodium Valproate in
89 Amyotrophic Lateral Sclerosis
Study of the Effects
Strengthening Exercises in
90 Individuals With ALS
No Results
Available
No Results
Available
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: Rasagiline|Drug: Placebo
Department of Neurology, University of Ulm, Ulm, Baden-Württemberg, Germany|Department of Neurology, Technische Universität München, Muenchen, Bayern, Germany|Department of Neurology, Universty of Regensburg, Regensburg, Bayern, Germany|Department of Neurology, University of
Wuerzburg, Wuerzburg, Bayern, Germany|Department of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Hessen, Germany|Department of Neurology, University of Rostock, Rostock, Mecklenburg-Vorpommern, Germany|Department of Neurology, University of Goettingen, Goettingen, Niedersachsen,
Germany|Department of Neurology, Medical School Hannover, Hannover, Niedersachsen, Germany|Neurologische Universitätsklinik Bergmannsheil, Bochum, Nordrhein-Westfalen, Germany|Department of Neurology, Universty of Muenster, Muenster, Nordrhein-Westfalen, Germany|Department of Neurology,
Universty of Bonn, Bonn, Nordrhrein-Westfalen, Germany|Department of Neurology, University of Halle-Wittenberg, Halle/Saale, Sachsen-Anhalt, Germany|Department of Neurology, TU Dresden, Dresden, Sachsen, Germany|Department of Neurology, University of Jena, Jena, Thueringen, Germany|Department
of Neurology, Humboldt University, Berlin, Germany
https://ClinicalTrials.gov/show/NCT01879241
Other: Muscle training
Department of Clinical Research, Odense University Hospital, University of Southern Denmark, Odense C, Fyn, Denmark
https://ClinicalTrials.gov/show/NCT01504009
Drug: Sodium Valproate
UMC Utrecht, Utrecht, Netherlands
https://ClinicalTrials.gov/show/NCT00136110
Procedure: Exercise
Cleveland Clinic Foundation, Cleveland, Ohio, United States
https://ClinicalTrials.gov/show/NCT00204464
Safety, Tolerability, and Activity
Study of ISIS SOD1Rx to Treat
Familial Amyotrophic Lateral
Sclerosis (ALS) Caused by SOD1 No Results
91 Gene Mutations
Available
Familial
Amyotrophic
Lateral
Sclerosis
Drug: ISIS 333611
Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital-East, Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Methodist Neurological Institute, Houston, Texas, United
States
https://ClinicalTrials.gov/show/NCT01041222
Safety and Biomarker Study of
92 EPI-589 in Subjects With ALS
Clinical Trial of Vitamin E to
Treat Muscular Cramps in
93 Patients With ALS
Controlled Crossover Trial With
THC (Delta 9-
Tetrahydrocannabinol) for the
Treatment of Cramps in
Amyotrophic Lateral Sclerosis
94 (ALS)
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: EPI-589
Cedar's Sinai, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States
https://ClinicalTrials.gov/show/NCT02460679
Dietary Supplement: Vitamin E
London Health Sciences Centre, London, Ontario, Canada
https://ClinicalTrials.gov/show/NCT00372879
No Results
Available
Cramps|Amyo
trophic Lateral
Sclerosis
Drug: Dronabinol
Kantonsspital St.Gallen, St.Gallen, Switzerland
https://ClinicalTrials.gov/show/NCT00812851
Safety Study of Oral Sodium
Phenylbutyrate in Subjects With
ALS (Amyotrophic Lateral
95 Sclerosis)
Placebo-controlled Trial of
Arimoclomol in SOD1 Positive
Familial Amyotrophic Lateral
96 Sclerosis
Impact of Early Non Invasive
Ventilation in Amyotrophic
97 Lateral Sclerosis (ALS) Patients
R(+)PPX High Dose Treatment
98 of ALS
Safety Study of VM202 to Treat
99 Amyotrophic Lateral Sclerosis
Repetitive Transcranial
Magnetic Stimulation (rTMS) in
100 Amyotrophic Lateral Sclerosis
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: sodium phenylbutyrate
VA Medical Center, Iowa City, Iowa City, Iowa, United States|VA Medical Center, Lexington, Lexington, Kentucky, United States|VA Maryland Health Care System, Baltimore, Baltimore, Maryland, United States|Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Bedford, Massachusetts, United States|VA
Medical Center, Jamaica Plain Campus, Boston, Massachusetts, United States|VA Medical Center, Syracuse, Syracuse, New York, United States|VA Medical Center, Durham, Durham, North Carolina, United States|VA Medical Center, Cincinnati, Cincinnati, Ohio, United States|VA Pittsburgh Health Care System,
Pittsburgh, Pennsylvania, United States|Michael E. DeBakey VA Medical Center (152), Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT00107770
No Results
Available
No Results
Available
No Results
Available
No Results
Available
No Results
Available
Drug: Arimoclomol|Drug: Placebo
University of Miami Miller School of Medicine, Miami, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States
https://ClinicalTrials.gov/show/NCT00706147
Device: Home pressure ventilator model Vivo
40 (BREAS Medical AB)
Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
Drug: R(+) pramipexole dihydrochloride
monohydrate
https://ClinicalTrials.gov/show/NCT01641965
University of Virginia, Charlottesville, Virginia, United States
https://ClinicalTrials.gov/show/NCT00600873
Genetic: VM202
Procedure: Real rTMS of the
brain|Procedure: Sham rTMS of the brain
Northwestern University, Chicago, Illinois, United States
https://ClinicalTrials.gov/show/NCT02039401
Institute of neurology Università Cattolica, Rome, Italy
https://ClinicalTrials.gov/show/NCT00833820
12
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0013.png
Effects of ODM-109 on
Respiratory Function in Patients
With Amyotrophic Lateral
101 Sclerosis
and Dose-ranging Study of 3
Oral Doses of TCH346 in
Patients With Amyotrophic
102 Lateral Sclerosis
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Charite Universitatsmedizin Berlin, Berlin, Germany|Medical School Hannover, Hannover, Germany|University Clinical Jena, Jena, Germany|University Hospital of Ulm, Ulm, Germany|Beaumont Hospital, Dublin, Ireland|University Medical Centre Utrecht, Utrecht, Netherlands|Royal Sussex County Hospital,
Drug: ODM-109|Drug: Placebo for ODM-109 Brighton, United Kingdom|The Walton Centre, Liverpool, United Kingdom|London Kings College Hospital, London, United Kingdom|Royal London Hospital, London, United Kingdom|University of Sheffield, Sheffield, United Kingdom
https://ClinicalTrials.gov/show/NCT02487407
No Results
Available
Drug: TCH346
Neurological Institute, New York, New York, United States
https://ClinicalTrials.gov/show/NCT00036413
First Time in Human Study of
GSK1223249 in Amyotrophic
103 Lateral Sclerosis
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: PLACEBO|Drug: GSK1223249
GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United
States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Paris, France|GSK Investigational Site, Verona, Veneto, Italy|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK
Investigational Site, London, United Kingdom
https://ClinicalTrials.gov/show/NCT00875446
Creatine for the Treatment of
104 Amyotrophic Lateral Sclerosis
Exploratory Study of
Biotelemetry in Amyotrophic
105 Lateral Sclerosis
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Spinal Cord
Injury
(SCI)|Amyotro
phic Lateral
Sclerosis (ALS)
Has Results
Drug: creatine monohydrate
Device: Faros Sensor (FS) and LifeInsight
Hub|Device: Fast Fix electrode
patch|Procedure: Quantitative Measure of
Speech (Core Phase Only)
California Pacific Medical Center, San Francisco, California, United States|Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of New Mexico - Medical Center, Albuquerque, New Mexico, United
States|University of Texas Health and Science Center, San Antonio, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States
https://ClinicalTrials.gov/show/NCT00070993
GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Oxford, United Kingdom
https://ClinicalTrials.gov/show/NCT02447952
Brain and Nerve Stimulation for
Hand Muscles in Spinal Cord
No Results
106 Injury and ALS
Available
Device: Transcranial magnetic
stimulation|Device: Median nerve
stimulation|Device: Cervical transcutaneous
stimulation
James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States
https://ClinicalTrials.gov/show/NCT02469675
A Study to Explore the Safety
and Tolerability of Acthar in
Patients With Amyotrophic
107 Lateral Sclerosis
Has Results
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: Repository corticotropin injection
Device: Anodal bilateral motor cortex and
cathodal spinal tDCS|Device: Sham bilateral
motor cortex and sham spinal tDCS
Questcor Investigational Site, Birmingham, Alabama, United States|Questcor Investigational Site, Phoenix, Arizona, United States|Questcor Investigational Site, San Francisco, California, United States|Questcor Investigational Site, Stanford, California, United States|Questcor Investigational Site, Jacksonville,
Florida, United States|Questcor Investigational Site, Miami, Florida, United States|Questcor Investigational Site, Tampa, Florida, United States|Questcor Investigational Site, Atlanta, Georgia, United States|Questcor Investigational Site, Kansas City, Kansas, United States|Questcor Investigational Site, Rochester,
Minnesota, United States|Questcor Investigational Site, Lincoln, Nebraska, United States|Questcor Investigational Site, Hershey, Pennsylvania, United States|Questcor Investigational Site, Pittsburgh, Pennsylvania, United States|Questcor Investigational Site, Memphis, Tennessee, United States|Questcor
Investigational Site, Dallas, Texas, United States|Questcor Investigational Site, Houston, Texas, United States|Questcor Investigational Site, San Antonio, Texas, United States
https://ClinicalTrials.gov/show/NCT01906658
Rehabilitative Trial With tDCS in
108 Amyotrophic Lateral Sclerosis
Compassionate Treatment : An
Exploratory Clinical Trial to
Assess Treatment of
109 Amyotrophic Lateral Sclerosis
Study of Dopamine and
Serotonin Transporters in
Patients With Amyotrophic
110 Lateral Sclerosis and Controls
No Results
Available
AO Spedali Civili, Brescia, BS, Italy
https://ClinicalTrials.gov/show/NCT03293394
No Results
Available
Procedure: Autologous Adipose-Tissue
Derived Stem Cells
China Medical University Beigang Hospital, Beigang, Yunlin, Taiwan
https://ClinicalTrials.gov/show/NCT02383654
No Results
Available
Drug: SPECT : 123 I-FP-CIT (DATSCAN) and
123I-ADAM
Salpêtrière Hospital, Paris, France|Bretonneau Hospital, Tours, France
https://ClinicalTrials.gov/show/NCT01160263
13
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0014.png
Safety/Efficacy of AVP-923 in
the Treatment of Emotional
Lability (Uncontrolled Crying & No Results
111 Laughing) in Patients With ALS Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: AVP-923
Loma Linda University Dept. of Neurology, Loma Linda, California, United States|UCLA School of Medicine Dept. of Neurology, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Colorado Health Sciences, Denver, Colorado, United
States|University of Miami Dept. of Neurology, Miami, Florida, United States|Northwestern Medical School, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Columbia-Presbyterian Center
Neurological Institute, New York, New York, United States|State University of New York, Syracuse, New York, United States|Carolinas Medical Center Carolinas Neuromuscular/ALS-MDA Center, Charlotte, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United
States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|MCP-Hahnemann University Dept. of Neurology, Philadelphia, Pennsylvania, United States|Penn Neurological Institute, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center @ San Antonio, San Antonio, Texas, United
States|University of Wisconsin ALS Clinical Research Center, Madison, Wisconsin, United States
https://ClinicalTrials.gov/show/NCT00021697
Growth Hormone in
112 Amyotrophic Lateral Sclerosis
No Results
Available
Drug: Growth Hormone (Somatropin)|Drug:
Placebo
Diparimento di Scienze Neurologiche, Naples, Italy|Istituto Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Naples, Italy
https://ClinicalTrials.gov/show/NCT00635960
Virtual Task in Amyotrophic
113 Lateral Sclerosis
Influence of the Vitamin D
Blood Levels on the
114 Amyotrophic Lateral Sclerosis
Effects of Nocturnal Non-
invasive Ventilation in Patients
115 With Amyotrophic Lateral
Effect of Lithium Carbonate in
Patients With Amyotrophic
116 Lateral Sclerosis
No Results
Available
No Results
Available
No Results
Available
No Results
Available
Neuromuscular Transmission in No Results
117 Amyotrophic Lateral Sclerosis Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Device: Acquisition on TouchScreen|Device:
Acquisition on Kinect|Device: Acquisition on
LeapMotion|Device: Acquisition on
TouchScreen Control Group|Device:
Acquisition on Kinect Control Group|Device:
Acquisition on LeapMotion Control Group
Escola de Artes,Ciencias e Humanidades da Universidade d Sao Paulo, Sao Paulo, Brazil
https://ClinicalTrials.gov/show/NCT03113630
Procedure: Blood test
UH Montpellier, Montpellier, France
https://ClinicalTrials.gov/show/NCT01823380
Device: non-invasive ventilation
Peilin Lee, Taipei, Taiwan
https://ClinicalTrials.gov/show/NCT00958048
Drug: lithium
Pitié-Salpêtrière Hospital, Paris, France
https://ClinicalTrials.gov/show/NCT00925847
Procedure: Anconeus Muscle biopsy
Bruneteau Gaelle, Paris, France
https://ClinicalTrials.gov/show/NCT00847847
Study of Ozanezumab
(GSK1223249) Versus Placebo
in the Treatment of
118 Amyotrophic Lateral Sclerosis
Has Results
Amyotrophic
Lateral
Sclerosis
Drug: Ozanezumab|Drug: Placebo
GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Grand Rapids, Michigan, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Randwick, New South Wales, Australia|GSK
Investigational Site, Herston, Queensland, Australia|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK
Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Lille cedex, France|GSK Investigational Site, Limoges cedex, France|GSK Investigational Site, Montpellier cedex 5, France|GSK Investigational Site, Nice cedex 3, France|GSK Investigational Site, Paris cedex 13, France|GSK Investigational Site,
Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Berlin,
Germany|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Verona, Veneto, Italy|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Miyagi, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul,
Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Preston, Lancashire, United Kingdom|GSK Investigational Site, Brighton, United Kingdom|GSK Investigational Site, Edgbaston,, United Kingdom
https://ClinicalTrials.gov/show/NCT01753076
14
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0015.png
High Fat/High Calorie Trial in
119 Amyotrophic Lateral Sclerosis
G-CSF Treatment for
Amyotrophic Lateral Sclerosis:
A RCT Study Assessing Clinical
120 Response
Study of Myobloc in the
Treatment of Sialorrhea
(Drooling) in Patients With
Amyotrophic Lateral Sclerosis
121 (ALS)
Memantine for Disability in
Amyotrophic Lateral Sclerosis
122 (MEDALS)
Has Results
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Barrow Neurological Institute/St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of California at Irvine, Irvine, California, United States|California Pacific Medical Center, University of California at San Francisco, San Francisco, California, United States|Sarasota Memorial Hospital,
Dietary Supplement: Oxepa|Dietary
Sarasota, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Neurology Clinical Trials Unit, Massachusetts General Hospital, Boston, Massachusetts, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Columbia Presbyterian Medical Center, New
Supplement: Jevity 1.5|Dietary Supplement: York, New York, United States|Carolinas Medical Center Neuromuscular/ALS-MDA Center, Charlotte, North Carolina, United States|Oregan Health and Science University, Portland, Oregon, United States|Drexel University, Philadelphia, Pennsylvania, United States|Methodist Neurological Institute, Houston, Texas,
Jevity 1.0
United States|University of Vermont, Burlington, Vermont, United States
https://ClinicalTrials.gov/show/NCT00983983
No Results
Available
Drug: Granulocyte Colony Stimulating
Factor|Drug: NS
Dongsheng Fan, Beijing, Beijing, China
https://ClinicalTrials.gov/show/NCT00397423
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis|Sialo
rrhea
Amyotrophic
Lateral
Sclerosis
Drug: Botulinum toxin type B
(Myobloc)|Procedure: Injection of salivary
glands
Drug: Memantine (Ebixa)|Drug:
riluzole|Drug: Placebo
Procedure: Laminectomy and bone marrow
stem cells transplantation|Procedure:
Intrathecal infusion of autologous bone
marrow stem cells|Procedure: Intrathecal
infusion of placebo (saline solution).
University of Kansas Medical Center/Neurology, 1008 Wescoe, Kansas City, Kansas, United States|Carolinas MDA Neuromuscular/ALS Center; Carolinas Medical System; 1540 Garden Terrace, Charlotte, North Carolina, United States
https://ClinicalTrials.gov/show/NCT00125203
Department of Neurology - Hospital de Santa Maria, Lisbon, Portugal
https://ClinicalTrials.gov/show/NCT00353665
Clinical Trial on The Use of
Autologous Bone Marrow Stem
Cells in Amyotrophic Lateral
No Results
123 Sclerosis (Extension CMN/ELA) Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
https://ClinicalTrials.gov/show/NCT01254539
R(+) Pramipexole in Early
124 Amyotrophic Lateral Sclerosis
No Results
Available
Drug: R(+) pramipexole dihydrochloride
monohydrate
David Lacomis MD, Pittsburgh, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States
https://ClinicalTrials.gov/show/NCT00140218
Combination Therapy Selection
Trial in Amyotrophic Lateral
125 Sclerosis
Transplantation of Autologous
Peripheral Blood Mononuclear
Cells for Amyotrophic Lateral
126 Sclerosis
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: Celecoxib|Drug: Creatine|Drug:
Minocycline
Phoenix Neurological Associates, Phoenix, Arizona, United States|UCLA, Los Angeles, California, United States|University of California Irvine, Orange, California, United States|California Pacific Medical Center, San Francisco, California, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Medical
College of Georgia, Augusta, Georgia, United States|University of Illinois, Chicago, Illinois, United States|University of Kansas, Kansas City, Kansas, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, Missouri, United States|UMDNJ, New Brunswick, New
Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Beth Israel, New York, New York, United States|Columbia University, New York, New York, United States|Duke University, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon,
United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Vermont, Burlington, Vermont, United States
https://ClinicalTrials.gov/show/NCT00355576
No Results
Available
Open-label Study to Evaluate
Safety, Tolerability and PK of
127 BHV-0223 in ALS
No Results
Available
Amyotrophic
Lateral
Sclerosis
Biological: PBMC autotransplantation
Amyotrophic
Lateral
Sclerosis|ALS|
Lou Gehrig
Disease|Lou
Gehrig's
Disease|Lou-
Gehrigs
Disease|Motor
Neuron
Disease,
Amyotrophic
Lateral
Sclerosis
Drug: BHV-0223
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
https://ClinicalTrials.gov/show/NCT03085706
Holy Cross Neuroscience Research Institute, Fort Lauderdale, Florida, United States|Somnos/Neurology Associates Clinical Research, Lincoln, Nebraska, United States|Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United States|Wesley Neurology Clinic, Cordova, Tennessee, United
States|Texas Neurology, Dallas, Texas, United States
https://ClinicalTrials.gov/show/NCT03520517
15
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0016.png
128
129
130
131
132
133
134
A Safety and Tolerability Study
of Intracerebroventricular
Administration of sNN0029 to
Patients With Amyotrophic
Lateral Sclerosis
Clinical Trial on the Use of
Autologous Bone Marrow Stem
Cells in Amyotrophic Lateral
Sclerosis
Efficacy and Tolerability of
Tauroursodeoxycholic Acid in
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Plasma
Exchange With Albumin in
Patients With Amyotrophic
Lateral Sclerosis
Nightime NIV Initiation in
Amyotrophic Lateral Sclerosis in
an Outpatient Setting
Immuno-modulation in
Amyotrophic Lateral Sclerosis-
a Phase II Study of Safety and
Activity of Low Dose Interleukin-
2
Creation of a Bank of Fibroblast
From Patients With
Amyotrophic Lateral Sclerosis:
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: sNN0029|Drug: Placebo
Procedure: Laminectomy and bone marrow
stem cells transplantation|Procedure:
Autologous bone marrow cells collection
Drug: tauroursodeoxycholic acid
(TUDCA)|Drug: Placebo
University Hospital Leuven, Department of Neurology, Leuven, Belgium
https://ClinicalTrials.gov/show/NCT00800501
No Results
Available
Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
https://ClinicalTrials.gov/show/NCT00855400
Has Results
Fondazione IRCCS Istituto neurologico Carlo Besta, Milan, Italy
https://ClinicalTrials.gov/show/NCT00877604
No Results
Available
No Results
Available
Biological: Albumin
Hospital Universitari Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
https://ClinicalTrials.gov/show/NCT02479802
Procedure: Nightime NIV initiation
https://ClinicalTrials.gov/show/NCT02759003
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: Placebo|Drug: 1.0 MIU IL-2 per
day|Drug: 2.0 MIU IL-2 per day
CHRU de Montpellier - Hôpital Gui de Chauliac, Montpellier, France
https://ClinicalTrials.gov/show/NCT02059759
Procedure: skin biopsy
Centre référent maladies rares SLA, Paris, France
https://ClinicalTrials.gov/show/NCT01639391
Mexiletine in Sporadic
Amyotrophic Lateral Sclerosis
135 (SALS)
Has Results
A P300 Brain Computer
Interface Keyboard to Control
Assistive Technology For Use by
People With Amyotrophic
136 Lateral Sclerosis
Has Results
Clinical Trial of Creatine in
137 Amyotrophic Lateral Sclerosis
No Results
Available
Sporadic
Amyotrophic
Lateral
Sclerosis
Drug: Mexiletine|Drug: Placebo
UCLA, Neuromuscular Research Center, Los Angeles, California, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts (Worcester)
Memorial Medical Center, Worcester, Massachusetts, United States|Washington University Medical School, Saint Louis, Missouri, United States|SUNY Upstate Medical Center, Syracuse, New York, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|University of Texas
Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Washington Medical Center, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT01849770
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Device: P300 Brain Computer Interface
Keyboard
University of Michigan, Ann Arbor, Michigan, United States
https://ClinicalTrials.gov/show/NCT01119001
Drug: Creatinine
University of Vermont, Burlington, Vermont, United States
https://ClinicalTrials.gov/show/NCT00005766
Safety and Efficacy of AVP-923
138 in PBA Patients With ALS or MS Has Results
Pseudobulbar
Affect (PBA)
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Neuromuscular Research Center, Scottsdale, Arizona, United States|South Coast Clinical Trials, Anaheim, California, United States|UCI Medical Center, Irvine, California, United States|Center for Neurologic Study, La Jolla, California, United
States|UCLA School of Medicine, Los Angeles, California, United States|The Forbes Norris MDA/ALS Research Center - California Pacific Medical Center, San Francisco, California, United States|The ALS Center at UCSF, San Francisco, California, United States|University of Colorado at Denver & Health Science Center,
Aurora, Colorado, United States|Neuroscience Center, Ft. Lauderdale, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Suncoast Neuroscience Associates, St. Petersburg, Florida, United States|The ALS Center at Emory University, Atlanta,
Georgia, United States|Neurology Specialists of Decatur of Decatur, Decatur, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Consultants in Neurology, Northbrook, Illinois, United States|University of Kentucky Health Care - Dept. of Neurology, Lexington, Kentucky, United
States|The John Hopkins Universitiy, Baltimore, Maryland, United States|Massachusets General Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan,
United States|St.Louis University - Neuromuscular Clinic, St. Louis, Missouri, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|Neurology Associates, Lincoln, Nebraska, United States|Universitiy of Nevada, Las Vegas, Nevada, United States|Upstate Clinical Research, Albany, New
York, United States|Jacobs Neurological Institute, Buffalo, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Neurological Institute - Columbia Presbyterian Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke
Universitiy Medical Center, Durham, North Carolina, United States|Department of Neurology - The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State Universitiy, Columbus, Ohio, United States|Oregon Health Science University, Portland, Oregon, United States|Drexel University - Department
of Neurology, Philadelphia, Pennsylvania, United States|The ALS Center - Penn Neurological Institute - The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|The Methodist Hospital - Baylor College of Medicine, Houston, Texas, United
States|Department of Neuropsychiatry - Texas Tech University, Lubbock, Texas, United States|University of Texas Health Science Center, San Antonio, Texas, United States|Universitiy of Vermont, Burlington, Vermont, United States|West Virginia University, Morgantown, West Virginia, United States|Dean
Drug: dextromethorphan hydrobromide 20 Foundation, Madison, Wisconsin, United States|FACENE, Buenos Aires, Ciudad de Buenos Aires, Argentina|IADIN, Buenos Aires, Ciudad de Buenos Aires, Argentina|Hospital Italiano, Buenos Aires, Ciudad de Buenos Aires, Argentina|INEBA, Buenos Aires, Ciudad de Buenos Aires, Argentina|Hospital Ramos Mejia,
mg and quinidine sulfate 10 mg|Drug:
Buenos Aires, Ciudad de Buenos Aires, Argentina|Hospital Britanico, Buenos Aires, Ciudad de Buenos Aires, Argentina|Policlinico Bancario, Buenos Aires, Ciudad de Buenos Aires, Argentina|FLENI, Buenos Aires, Ciudad de Buenos Aires, Argentina|Instituto Medico Rodriguez Alfici, Godoy Cruz, Mendoza,
dextromethorphan hydrobromide 30 mg and Argentina|Instituto de Neurociencias Rosario, Rosario, Santa Fe, Argentina|Hospital Militar Regional de Cordoba, Cordoba, Argentina|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, M G, Brazil|Hospital da Restauração, Recife, PE, Brazil|Hospital de ClÃ-nicas-UFPR, Curitiba, PR, Brazil|Hospital
quinidine sulfate 10 mg|Drug: Placebo
Universitário Clementino Fraga Filho, Rio de Janeiro, RJ, Brazil|Hospital Moinhos de Vento, Porto Alegre, RS, Brazil|Hospital das ClÃ-nicas da Faculdade de Medicina da Universidade São Paulo, Sao Paulo, SP, Brazil
https://ClinicalTrials.gov/show/NCT00573443
16
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0017.png
Ventilatory Investigation of
Tirasemtiv and Assessment of
Longitudinal Indices After
139 Treatment for a Year
Clinical Trial of Creatine in
Amyotrophic Lateral Sclerosis
140 [ALS]
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
St. Joseph's Hospital & Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States|University of California San Diego, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California, Irvine, Orange, California, United States|University of
California Davis Medical Center, Sacramento, California, United States|Forbes Norris MDA/ALS Research Center, San Francisco, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, United
States|Hospital for Special Care, New Britain, Connecticut, United States|George Washington University Medical Center, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Carol and Frank Morsini Center for Advanced
Health Care - University of South Florida, Tampa, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana,
United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of
Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Hospital and Health System, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Saint
Louis University, Saint Louis, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Neurology Associates, Lincoln, Nebraska, United States|Dartmouth Hitchcock Medical Center Dept of Neurology, Lebanon, New Hampshire, United States|Hospital for Special Surgery, New York, New
York, United States|Neurological Institute Columbia University Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Neurosciences Institute: Neurology - Charlotte, Charlotte, North Carolina, United States|Duke Neurological Disorders Clinic,
Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States|Oregon Health and
Science Center, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|The Penn Comprehensive Neuroscience Center, Philadelphia, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Vanderbilt
University Medical Center, Nashville, Tennessee, United States|Texas Neurology, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center, San Antonio, Texas, United States|University of Virgina Health System, Charlottesville, Virginia, United
States|University of Washington Medical Center, Seattle, Washington, United States|West Virginia University Department of Neurology, Morgantown, West Virginia, United States|Froedtert Memorial Lutheran Hospital, Department of Neurology, Milwaukee, Wisconsin, United States|UZ Leuven - Campus
Gasthuisberg, Leuven, Vlaams Brabant, Belgium|University of Calgary, Calgary, Alberta, Canada|Edmonton Kaye Clinic, Edmonton, Alberta, Canada|Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada|QE II Health Sciences Centre, NHI Site, Halifax, Nova Scotia, Canada|McMaster University
Medical Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Notre-Dame Hospital/CHUM, Montreal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|CHU de Quebec -
Universite Laval Hopital de l'Enfant-Jesus, Quebec, Canada|Hopital R. Salengro, CHRU Lille, Lille Cedex, France|CHU Dupuytren, Limoges cedex, France|Hopital de la Timone, Marseille, France|Hopital Gui de Chauliac, Montpellier, France|CHU de Nice - Hopital Pasteur 2, Nice Cedex 1, France|Hopital de la
Salpetriere, Paris, France|Bretonneau University Hospital, Tours Cedex 9, France|University of Ulm, Department of Neurology, Ulm, Baden-Wuerttemberg, Germany|Hannover Medical School, Department of Neurology, Hannover, Lower Saxony, Germany|Charite Campus Virchow-Klinikum, Neurology
Department, Berlin, Germany|Clinical Research Centre, Beaumont Hospital, Dublin, Ireland|IRCCS Istituto Auxologico Italiano - U.O. Neurologia, Milan, Italy|Centro Clinico NEMO - Fondazione Serena Onlus, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy|Dipartimento di Neuroscienze "Rita Levi
Drug: tirasemtiv|Drug: Placebo tablets|Drug: Moltalcini" A.O.U. Citta della Salute e della Scienza di Torino P.O. "Molinette", Torino, Italy|University Medical Center Utrecht, Utrecht, Netherlands|Hospital Santa Maria-Centro Hospitalar Lisboa Norte, Lisboa, Portugal|Hospital San Rafael, Madrid, Spain|Derriford Hospital, Plymouth, Devon, United
Riluzole 50 MG
Kingdom|Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom|Clinical Research Centre, Royal London Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom
https://ClinicalTrials.gov/show/NCT02496767
Drug: Creatine
Washington University, St. Louis, Missouri, United States
https://ClinicalTrials.gov/show/NCT00005674
Minocycline to Treat
141 Amyotrophic Lateral Sclerosis
No Results
Available
Escitalopram (Lexapro) for
142 Depression MS or ALS
Modafinil for Treatment of
143 Fatigue in ALS Patients
Has Results
Amyotrophic
Lateral
Sclerosis
Drug: minocycline
Major
Depression|M
ultiple
Sclerosis|Amy
otrophic
Lateral
Sclerosis
Drug: escitalopram
Mayo Clinic, Scottsdale, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California Department of Neurology, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Univ. of Colorado Health Sciences Center,
Denver, Colorado, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Illinois, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City,
Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Hennepin County Med Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, St. Louis, Missouri, United States|UMDNJ/Robert Wood Johnson
Medical Center, New Brunswick, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Columbia Unversity, Eleanor and Lou Gehrig MDA/ALS Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University,
Durham, North Carolina, United States|Wake Forest University, Winston- Salem, North Carolina, United States|Metro Health Clinic, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Drexel
University College of Medicine, Hahnemann Campus, Philadelphia, Pennsylvania, United States|University of Texas Southwestern, Dallas, Texas, United States|Methodist Hospital, Houston, Texas, United States|University of Texas Health Sciences Center, San Antonio, Texas, United States|University of Utah, Salt
Lake City, Utah, United States|University of Vermont, Burlington, Vermont, United States|Virginia Mason Medical Center, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT00047723
University of South Carolina School of Medicine, Columbia,, South Carolina, United States
https://ClinicalTrials.gov/show/NCT00965497
Has Results
Fatigue
Drug: Modafinil|Drug: Placebo
New York State Psychiatric Institute-Columbia University, New York, New York, United States
https://ClinicalTrials.gov/show/NCT00614926
144
145
146
147
148
Safety and Efficacy on Spasticity
Symptoms of a Cannabis Sativa
Extract in Motor Neuron
Disease
A Study to Investigate the
Safety, Tolerability, and
Pharmacokinetics of ALS-
008176 in Healthy Japanese
Adult Participants
Escalated Application of
Mesenchymal Stem Cells in
Amyotrophic Lateral Sclerosis
Patients
Bioavailability of GDC-0134 and
the Effect of Food and Proton
Pump Inhibitor on
Pharmacokinetics of GDC-0134
in Healthy Female Participants
Differential Study of Muscle
Transcriptome
No Results
Available
Motor Neuron
Disease|Amyo
trophic Lateral Drug: Cannabis Sativa extract Oromucosal
Sclerosis (ALS) spray
San Raffaele Scientific Institute, Milan, Italy|Fondazione Salvatore Maugeri IRCCS, Istituto Scientifico, Milan, Italy|NEuroMuscular Omnicentre (NEMO), Fondazione Serena - H CÃ granda, Milan, Italy|Universita' Degli Studi Di Padova, Azienda Ospedaliera Di Padova, Neurologic Department;, Padova, Italy
https://ClinicalTrials.gov/show/NCT01776970
No Results
Available
Respiratory
Drug: ALS-008176 (250 mg)|Drug: ALS-
Syncytial Virus 008176 (500 mg)|Drug: ALS-008176 (750
Infections
mg)|Other: Placebo
Fukuoka, Japan
https://ClinicalTrials.gov/show/NCT02478333
No Results
Available
Motor Neuron Biological: Autologous Mesenchymal stem
Disease
cells (MSCs)
Hospital e Maternidade Dr Christovao da Gama, Santo Andre, Sao Paulo, Brazil|Instituto de Ensino e Pesquisas - IEP-São Lucas, Sao Paulo, SP, Brazil
https://ClinicalTrials.gov/show/NCT02987413
No Results
Available
No Results
Available
Dexpramipexole and Cimetidine No Results
149 Drug Drug Interaction (DDI)
Available
Amyotrophic
Lateral
Sclerosis
ALS|SMA|SB
MA
Amyotrophic
Lateral
Sclerosis
Drug: Reference capsule GDC-0134|Drug:
Prototype capsule GDC-0134|Drug:
rabeprazole
Procedure: Muscle biopsy
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
Centre d'évaluation Thérapeutique, Dr LACOMBLEZ, Paris, France
https://ClinicalTrials.gov/show/NCT03237741
https://ClinicalTrials.gov/show/NCT01984957
Drug: Dexpramipexole|Drug: Cimetidine plus
Dexpramipexole
Research Site, Overland Park, Kansas, United States
https://ClinicalTrials.gov/show/NCT01536249
17
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0018.png
Study to Evaluate the QTC
Interval in Healthy Volunteers
Dosed With Dexpramipexole
(QTC = Electrocardiogram (ECG)
Interval Measured From the
Onset of the QRS Complex to
the End of the T Wave
No Results
150 Corrected for Heart Rate)
Available
Dexpramipexole SAD/MAD
151 Study
Dexpramipexole Japanese PK
152 Study
An In-home Study of Brain
153 Computer Interfaces
No Results
Available
No Results
Available
Has Results
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: Dexpramipexole|Drug:
Dexpramipexole Placebo|Drug: Moxifloxacin Research Site, Overland Park, Kansas, United States
Drug: Dexpramipexole|Drug:
Dexpramipexole Placebo
https://ClinicalTrials.gov/show/NCT01511029
Research Site, Overland Park, Kansas, United States
https://ClinicalTrials.gov/show/NCT01449578
Drug: Single dose reduced|Drug: Single dose
standard|Drug: Multiple Dose
Research Site, London, United Kingdom
Device: Brain Computer Interface for
Wheelchair Tilt Control
https://ClinicalTrials.gov/show/NCT01424163
University of Michigan, Ann Arbor, Michigan, United States
https://ClinicalTrials.gov/show/NCT01123200
A Study of ALS-008176 in
154 Infants Hospitalized With RSV
No Results
Available
Study to Assess the Taste
Profile of Different ALS-008176
Oral Liquid Formulations in
155 Healthy Adult Participants
Study to Evaluate the Effect of
ALS-008176 on Cardiac
Repolarization Interval in
156 Healthy Participants
A Phase 1, Open-Label Study of
the Absorption, Metabolism,
Excretion and Absolute
157 Bioavailability of ALS-008176
A Phase 2a Study to Evaluate
ALS-008176 in the Virus
158 Challenge Model
No Results
Available
Respiratory
Syncytial Virus
Infections
Drug: ALS-008176|Drug: Placebo
Drug: Formulation A (ALS-008176)|Drug:
Formulation B (ALS-008176)|Drug:
Formulation C (ALS-008176)|Drug:
Formulation D (ALS-008176)|Drug:
Formulation E (ALS-008176)|Drug:
Formulation F (ALS-008176)|Drug:
Formulation G1 (ALS-008176)|Drug:
Formulation G2 (ALS-008176)|Drug:
Formulation G3 (ALS-008176)|Drug:
Formulation H1 (ALS-008176)|Drug:
Formulation H2 (ALS-008176)|Drug:
Healthy
Formulation H3 (ALS-008176)
Children's of Alabama, Birmingham, Alabama, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Long Beach Memorial Medical Center/Miller Children's and Women's Hospital of Long Beach, Long Beach, California, United States|Children's Hospital of Orange
County, Orange, California, United States|The University of California at San Diego, San Diego, California, United States|LSU Health Sciences Center, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Children's Mercy, Kansas City, Missouri, United
States|University of Rochester, Rochester, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Children's
Hospital/University of Tennessee, Memphis, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle,
Washington, United States|The Canberra Hospital, Canberra, Australia|Monash Medical Center, Melbourne, Australia|Women's and Children's Hospital, North Adelaide, Australia|The Royal Children's Hospital Melbourne, Parkville, Australia|Princess Margaret Hospital, Perth, Australia|The Children's Hospital
Research Institute of Manitoba, Winnipeg, Manitoba, Canada|Canadian Centre for Vaccinology IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Hospital Dr. Exequiel Gonzalez Cortes, San
Miguel, Santiago, Chile|Complejo Asistencial Dr Sotero del Rio, Santiago, Chile|Hospital Padre Hurtado, Santiago, Chile|Fundacion Cardio Infantil Instituto de Cardiologia, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|CHU Pellegrin / Pneumologie pediatrique, Bordeaux, France|Hopital Necker,
Paris, France|Hirosaki National Hospital, Hirosaki-shi, Aomori, Japan|Chiba Children's Hospital, Chiba-shi, Chiba, Japan|Ota Memorial Hospital, Ota, Gunma, Japan|Gunma Children's Medical Center, Shibukawa-shi, Gunma, Japan|NHO Fukuyama Medical Center, Fukuyama, Hiroshima, Japan|Hokkaido P.W.F.A.C.
Asahikawa-Kosei General Hospital, Asahikawa-shi, Hokkaido, Japan|NHO Kanazawa Medical Center, Kanazawa, Ishikawa, Japan|NHO Shikoku Medical Center for Children and Adults, Takamatsu, Kagawa, Japan|Okinawa Chubu Hospital, Urumi, Okinawa, Japan|Nakano Children's Hospital, Osaka-city, Osaka,
Japan|National Hospital Organization Saitama National Hospital, Wako, Saitama, Japan|Tokyo Metropolitan Children's Medical Center, Fuchu-shi, Tokyo, Japan|National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan|Fukuoka Children's Hospital, Fukuoka, Japan|NHO Fukuoka Hospital,
Fukuoka, Japan|Kochi Health Sciences Center, Kochi, Japan|Saitama Children's Medical Center, Saitama, Japan|Christchurch Clinical Study Trust, Christchurch, New Zealand|Hawke's Bay Hospital, Hastings, New Zealand|Wellington Hospital, Wellington, New Zealand|Hospital Materno Infantil Jose Dominog de
Obaldila, David, Chiriqui, Panama|Hospital de Especialidades Pediatricas "Omar Torrijos Herrera", Panama City, Panama|Hospital del Nino, Panama City, Panama|Institute for Mother and Child Care "Alfred Rusescu", Bucharest, Romania|2 Military Hospital, Cape Town, South Africa|Kingsbury Hospital, Cape Town,
South Africa|Tygerberg Academic Hospital, Cape Town, South Africa|Linkou Chang Gung Medical Hospital, Taipei, Taiwan|MacKay Memorial Hospital, Taipei, Taiwan|Chulalongkorn University Department of Pediatrics, Bangkok, Thailand|Phramongkutklao Hospital Department of Pediatrics, Bangkok,
Thailand|Siriraj Hospital, Mahidol University Department of Pediatrics, Bangkok, Thailand|Khon Kaen University Department of Pediatrics, Khon Kaen, Thailand|Bristol Royal Hospital for Children, Bristol, England, United Kingdom|Alder Hey Children's Hospital, Liverpool, England, United Kingdom|St. George's
University of London, London, England, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, England, United Kingdom|Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom|Children's Hospital of Wales, Cardiff, Wales, United Kingdom|Birmingham Children's
Hospital, Birmingham, United Kingdom|Royal Alexandra Children's Hospital, Brighton, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom|Queens Medical Center, Nottingham, United Kingdom|University of Oxford, Oxford, United Kingdom
https://ClinicalTrials.gov/show/NCT02202356
Nottingham, United Kingdom
https://ClinicalTrials.gov/show/NCT02813460
No Results
Available
Healthy
Drug: ALS-008176|Drug: Placebo|Drug:
Moxifloxacin
Tempe, Arizona, United States
https://ClinicalTrials.gov/show/NCT02833831
No Results
Available
Respiratory
Syncytial Virus
Infections
Drug: ALS-008176|Drug: ALS-008112
Respiratory
Syncytial Virus
Infections
Drug: ALS-008176|Drug: vehicle
Amyotrophic
Lateral
Sclerosis|Mot
or Neuron
Disease|Lou
Gehrig's
Disease
Behavioral: Treadmill Exercise
Respiratory
Syncytial Virus
Infections
Drug: ALS-008176|Drug: Placebo
Quotient Clinical, Nottingham, United Kingdom
https://ClinicalTrials.gov/show/NCT02231671
No Results
Available
Retroscreen Virology Ltd, London, United Kingdom
https://ClinicalTrials.gov/show/NCT02094365
Supported Treadmill
Ambulation Training (STAT) for
Patients Diagnosed With
No Results
159 Amyotrophic Lateral Aclerosis Available
Study of Single and Multiple
Doses of ALS-008176 in Healthy No Results
160 Volunteers
Available
Carolinas ALS Clinical Resarch Center, Charlotte, North Carolina, United States
https://ClinicalTrials.gov/show/NCT00956488
Investigational Site, Rennes, France
https://ClinicalTrials.gov/show/NCT01906164
18
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0019.png
A Phase 2a Study to Evaluate
Orally Administered ALS-
008176 in Adults Hospitalized
With a Respiratory Syncytial
161 Virus
First in Human Study of ALS-
002200; Single Dose, Food
Effect in Healthy Volunteers;
Multiple Doses in Chronic
162 Hepatitis C Genotype 1
A P300 Brain Computer
Interface to Operate Power
163 Wheelchair Tilt
No Results
Available
Respiratory
Syncytial Virus
Infections
Drug: ALS-008176|Drug: Placebo
Lake Internal Med. Assoc., Eustis, Florida, United States|The Research Center, Inc., Hialeah, Florida, United States|JDH Medical Group LLC, Miami, Florida, United States|St Lucie Medical Center, Port Saint Lucie, Florida, United States|Tampa Genereal Hospital, Tampa, Florida, United States|Infectious Disease
Specialists of Atlanta, Atlanta, Georgia, United States|Kentucky Lung Clinic, PSC, Hazard, Kentucky, United States|Bronson Methodist Hosp. Ped, Kalamazoo, Michigan, United States|William Beaumont Hospital, Troy, Michigan, United States|University of Missouri- Clinical Research Center, Columbia, Missouri,
United States|Washington Univ School of Med, Saint Louis, Missouri, United States|Westmead Hospital, Northmead, New South Wales, Australia|Cairns Hospital, Cairns, Queensland, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland,
Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Monash Heal.-Monash Lung&Sleep, Clayton, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Wellington Regional Hospital, Newtown, Wellington, New Zealand|Raffles Hospital, Singapore,
Singapore|Taipei Med. Uni-Shuang Ho Hosp, New Taipei City, Taiwan
https://ClinicalTrials.gov/show/NCT02673476
No Results
Available
Hepatitis C,
Chronic
Drug: ALS-002200|Drug: Placebo
Biotrial, Rennes, Brittany, France|Biotrial, Paris, France|Arensia, Chisinau, Moldova, Republic of|Arensia, Bucharest, Romania
https://ClinicalTrials.gov/show/NCT01590407
Has Results
Healthy|Amyo
trophic Lateral
Sclerosis
Device: Using a BCI to control wheelchair tilt
Chronic
Stroke|Amyotr
ophic Lateral Drug: granulocyte - colony stimulating factor
Sclerosis
(G-CSF)|Drug: erythropoetin (EPO)
Department of neurology, University Hospital of Muenster, Muenster, Nordrhein-Westfalen, Germany
https://ClinicalTrials.gov/show/NCT01123148
Influence of G-CSF and EPO on
Associative Learning and Motor No Results
164 Skills
Available
https://ClinicalTrials.gov/show/NCT00298597
Evaluation of a Tongue
Operated Assistive Technology
for Individuals With Severe
165 Paralysis
Has Results
Quadriplegia|S
pinal Cord
Procedure: Tongue Piercing|Device: Usability
Injury|ALS
assessment
Georgia Institute of Technology, Atlanta, Georgia, United States|Shepherd Center, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rehabilitation Institute of Chicago, Chicago, Illinois, United States
Amyotrophic
Lateral
Sclerosis|Rena Drug: Dexpramipexole (dose 1)|Drug:
l Insufficiency Dexpramipexole (dose 2)
https://ClinicalTrials.gov/show/NCT01124292
No Results
166 Dexpramipexole Renal PK Study Available
Research Site, Orlando, Florida, United States|Research Site, Brooklyn Center, Minnesota, United States
https://ClinicalTrials.gov/show/NCT01424176
Antithymocyte Globulin and
Cyclosporine in Treating Low
Risk Patients With
167 Myelodysplastic Syndrome
No Results
Available
Myelodysplasti Drug: Antithymocyte globulin|Drug:
c Syndrome
Cyclosporine
Hospital de Cabueñes, Asturias, Spain|Hospital germans Trias i Pujol, Badalona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Ntra Sra del Rossell, Cartagena, Spain|Hospital Materno Infantil de Las Palmas, Las Palmas de Gran Canaria, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Morales
Messeguer, Murcia, Spain|Hospital de Navarra, Pamplona, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital Clinico Universitario, Zaragoza, Spain
https://ClinicalTrials.gov/show/NCT00488436
Eltrombopag in Combination
With Rabbit Anti-thymocyte
Globulin/Cyclosporine A in
Naive Aplastic Anemia (AA)
168 Subjects
No Results
Available
Cytopaenia
Biological: Eltrombopag|Biological: Rabbit
ATG|Biological: CsA
Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Ibaraki, Japan|Novartis Investigative Site, Ishikawa, Japan|Novartis Investigative Site, Miyagi, Japan|Novartis Investigative Site, Okayama, Japan|Novartis Investigative Site, Osaka, Japan|Novartis
Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Tochigi, Japan|Novartis Investigative Site, Tokyo, Japan
https://ClinicalTrials.gov/show/NCT02404025
Allogeneic Hematopoietic Stem
Cell Transplantation Using a
Non-myeloablative Preparative
Regimen of Total Lymphoid
Irradiation and Anti-thymocyte
Globulin for Older Patients
With Relapsed Lymphoid
No Results
169 Malignancies
Available
Anti-thymocyte Globulin and
Cyclosporine as First-Line
Therapy in Treating Patients
170 With Severe Aplastic Anemia
Has Results
Haemato-
lymphoid
Malignancies
or Syndromes
in Whom
Allogeneic
Stem Cell
Transplantatio Drug: total lymphoid irradiation and anti-
n is Warranted thymocyte globulin
Besançon University Hospital, Besançon, France|Lille University Hospital, Lille, France|Lyon University Hospital, Lyon, France|Nantes University Hospital, Nantes, France
https://ClinicalTrials.gov/show/NCT01566656
Aplastic
Anemia
Drug: cyclosporine|Biological: anti-
thymocyte globulin
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
https://ClinicalTrials.gov/show/NCT01231841
19
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0020.png
Antithymocyte Globulin and
Sirolimus in Treating Patients
With Relapsed Multiple
171 Myeloma
Antithymocyte Globulin and
Cyclosporine to Treat
172 Myelodysplasia
Anti-Thymocyte Globulin,
Cyclosporine, and RAD in Islet
173 Transplantation
No Results
Available
Drug/Agent
Toxicity by
Tissue/Organ|
Multiple
Myeloma and
Biological: anti-thymocyte globulin|Drug:
Plasma Cell
Neoplasm
sirolimus
Myelodysplasti
c Syndrome
Type 1
Diabetes
Mellitus|Hypo
glycemia
Drug: Antithymocyte globulin|Drug:
Cyclosporine
Biological: Allogeneic Islets of
Langerhans|Drug: Everolimus|Drug: anti-
thymocyte globulin|Drug: Cyclosporine
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
https://ClinicalTrials.gov/show/NCT00317798
Has Results
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
https://ClinicalTrials.gov/show/NCT00005937
No Results
Available
University of Minnesota, Minneapolis, Minnesota, United States
https://ClinicalTrials.gov/show/NCT00286624
174
175
176
177
178
179
Efficacy and Safety of Two Anti-
T-lymphocyte Immune Globulin
(ATG-F) Induction Regimens in
Anew Kidney Transplant
Patients
Antithymocyte Globulin and
Cyclosporine in Treating
Patients With Myelodysplastic
Prospective Phase II Study of
Rabbit Antithymocyte Globulin
(ATG, Thymoglobuline®,
Genzyme) With Ciclosporin for
Patients With Acquired Aplastic
Anaemia
Study of APN201 (Liposomal
Recombinant Human Cu/Zn-
Superoxide Dismutase) for the
Prevention of Radiation-
induced Dermatitis in Women
With Breast Cancer
A Randomized Trial of
Antithymocyte Globulin Versus
Cyclosporine to Treat the
Cytopenia of Myelodysplastic
Syndrome
Cyclophosphamide and Anti-
thymocyte Globulin Followed
By Methotrexate and
Cyclosporine in Preventing
Chronic Graft-Versus-Host
Disease in Patients With Severe
Aplastic Anemia Undergoing
Donor Bone Marrow Transplant
No Results
Available
No Results
Available
De Novo
Kidney
Transplant
Patients
Drug: ATG-F
Beijing, China|Changchun, China|Chengdu, China|Guangzhou, China|Hangzhou, China|Jinan, China|Nanjing, China|Shanghai, China|Shenyang, China|Tianjin, China|Wenzhou, China|Wuhan, China|Xi'an, China|Zhengzhou, China
https://ClinicalTrials.gov/show/NCT02267512
Myelodysplasti
c Syndromes Drug: ATG + CSA|Behavioral: Supportive care Universitaetsspital-Basel, Basel, Switzerland
https://ClinicalTrials.gov/show/NCT00004208
No Results
Available
Acquired
Aplastic
Anaemia
Drug: Rabbit ATG, Thymoglobuline
(Genzyme)
https://ClinicalTrials.gov/show/NCT01530555
No Results
Available
Radiation
Induced
Dermatitis
Drug: APN201|Drug: Placebo
Medical University Graz; Department of Therapeutic Radiology and Oncology, Graz, Austria
https://ClinicalTrials.gov/show/NCT01513278
No Results
Available
Has Results
Hematologic
Diseases|Myel
odysplastic
Drug: Antithymocyte globulin|Drug:
Syndromes
Cyclosporine
Warren G. Magnuson Clinical Center (CC), Bethesda, Maryland, United States
Drug: cyclophosphamide|Biological: anti-
thymocyte globulin|Drug:
cyclosporine|Procedure: allogeneic bone
marrow transplantation|Drug:
methotrexate|Genetic: DNA analysis|Other:
flow cytometry|Genetic: polymorphism
Aplastic
analysis|Other: laboratory biomarker
Anemia
analysis
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
https://ClinicalTrials.gov/show/NCT00001839
https://ClinicalTrials.gov/show/NCT00343785
180
181
182
183
184
Donor Stem Cell Transplant
After Busulfan, Fludarabine,
Methylprednisolone, and
Antithymocyte Globulin in
Treating Patients With Bone
Marrow Failure Syndrome
Donor Stem Cell Transplant
After Busulfan, Fludarabine,
and Antithymocyte Globulin in
Treating Patients With
Hematologic Cancer or
Myelodysplastic Syndrome
Allogeneic Transplantation
Using Total Lymphoid
Irradiation (TLI) and Anti-
Thymocyte Globulin (ATG) for
Older Patients With
Hematologic Malignancies
Study Comparing ABX-CBL
(Monoclonal Antibody) Versus
Atgam in Patients With Steroid
Resistant Acute Graft Versus
Host Disease
Recombinant Humanized Anti-
IL-2 Receptor Antibody
(Daclizumab) Versus
Antithymocyte Globulin (ATG)
to Treat the Cytopenia of
Myelodysplastic Syndrome
(MDS)
No Results
Available
Leukemia|My
elodysplastic
Syndromes|No
nmalignant
Neoplasm|Par
oxysmal
Nocturnal
Hemoglobinuri Procedure: nonmyeloablative allogeneic
a
hematopoietic stem cell transplantation
Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of
https://ClinicalTrials.gov/show/NCT00731328
No Results
Available
Procedure: nonmyeloablative allogeneic
Leukemia|My hematopoietic stem cell
elodysplastic transplantation|Procedure: peripheral blood
Syndromes
stem cell transplantation
Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of
https://ClinicalTrials.gov/show/NCT00732316
Has Results
Drug: Cyclosporine|Drug: Anti-Thymocyte
Blood
Globulin|Drug: mycophenolate mofetil|Drug:
Cancer|Leuke Granulocyte-Colony Stimulating
mia
Factor|Radiation: Total Lymphoid Irradiation Stanford University School of Medicine, Stanford, California, United States
https://ClinicalTrials.gov/show/NCT00185640
No Results
Available
Graft Vs Host
Disease
Drug: ABX-CBL
Abgenix, Inc, Fremont, California, United States
https://ClinicalTrials.gov/show/NCT00035880
No Results
Available
Myelodysplasti
c Syndromes Drug: Daclizumab
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
https://ClinicalTrials.gov/show/NCT00072969
Phase III Randomized Study of
Cyclophosphamide With or
Without Antithymocyte
Globulin Before Bone Marrow
Transplantation in Patients
185 With Aplastic Anemia
No Results
Available
Aplastic
Anemia
Drug: Anti-thymocyte globulin|Drug:
Cyclophosphamide|Procedure: Bone marrow
transplantation
Roswell Park Cancer Institute, Buffalo, New York, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States
https://ClinicalTrials.gov/show/NCT00004474
20
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0021.png
IMM 0212: Busulfan With
Fludarabine and Antithymocyte
Globulin as Preparative
Therapy for Hematopoietic
Stem Cell Transplant for the
Treatment of Severe Congenital No Results
186 T-Cell Immunodeficiency
Available
Trial of Ascertaining Individual
Preferences for Loved One's
187 Role in End-of-Life
No Results
Available
ATG in Haploidentical HSCT for
Acute Graft-versus-host Disease No Results
188 Prophylaxis
Available
T-Cell Immune
Deficiency
Diseases|Seve
re Combined
Immunodeficie
ncy
Amyotrophic
Lateral
Sclerosis|GI
Cancer|Pancre
atic Cancer
Hematopoietic
Stem Cell
Transplantatio
n|Antithymocy
te
Globulin|Viral
Infection
Drug: Busulfan, Fludarabine and ATG
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
https://ClinicalTrials.gov/show/NCT00228852
Other: TAILORED Patient Family Decision
Making|Other: standard of care
Johns Hopkins University, Baltimore, Maryland, United States
https://ClinicalTrials.gov/show/NCT01160367
Drug: ATG
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
https://ClinicalTrials.gov/show/NCT01883180
Phase II Study of Leuprolide and
Testosterone for Men With
Kennedy's Disease or Other
189 Motor Neuron Disease
Pupillography as Screening Tool
190 for Brain Insulin Resistance
No Results
Available
No Results
Available
Spinal
Muscular
Atrophy|Amyo
trophic Lateral
Sclerosis|Spin
obulbar
Muscular
Atrophy
Drug: leuprolide|Drug: testosterone
Drug: human insulin|Drug:
Obesity
placebo|Diagnostic Test: Pupillography
https://ClinicalTrials.gov/show/NCT00004771
University of Tuebingen, Department of Internal Medicine IV, Tübingen, Germany
https://ClinicalTrials.gov/show/NCT03651661
Cluster Randomized Trial of
Stepped Care Intervention vs.
Treatment as Usual for Patients
191 With Depression
Home Use of Cupping Massage
192 in Chronic Neck Pain
No Results
Available
No Results
Available
Depression
Neck Pain
Behavioral: Active monitoring|Behavioral:
Bibliotherapy|Behavioral: Online self-
help|Behavioral: Outpatient
psychotherapy|Procedure: Psychiatric
treatment|Behavioral: Combined
psychotherapy and psychopharmacological
treatment|Other: Control group: treatment
as usual
Procedure: cupping massage|Procedure:
Progressive muscle relaxation
Centre for Psychosocial Medicine, Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Klinik für Naturheilkunde, Essen, Germany
https://ClinicalTrials.gov/show/NCT01731717
https://ClinicalTrials.gov/show/NCT01500330
Levetiracetam for Cramps,
Spasticity and Neuroprotection No Results
193 in Motor Neuron Disease
Available
Antithymocyte Globulin in
Treating Patients Undergoing
Stem Cell Transplant for
194 Multiple Myeloma
Motor Neuron
Disease|Amyo
trophic Lateral
Sclerosis|Prim
ary Lateral
Sclerosis|Prog
ressive
Muscular
Atrophy
Biological: Levetiracetam
Multiple
Myeloma and
Plasma Cell
Neoplasm
Biological: anti-thymocyte globulin
Duke University ALS Clinic - 932 Morreene Road, Durham, North Carolina, United States
https://ClinicalTrials.gov/show/NCT00324454
No Results
Available
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT00378768
Anti-Thymocyte Globulin and
Etanercept in Treating Patients
With Myelodysplastic
No Results
195 Syndromes
Available
Rabbit Antithymocyte Globulin
Versus Campath-1H for
196 Treating Severe Aplastic
Has Results
Leukemia|My
elodysplastic
Syndromes|M
yelodysplastic/
Myeloprolifera Biological: anti-thymocyte
tive Diseases globulin|Biological: etanercept
Aplastic
Anemia
St. Joseph Cancer Center, Bellingham, Washington, United States|Olympic Medical Center, Port Angeles, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT00217386
Drug: Campath-1H|Drug: r-ATG|Drug: CsA
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
https://ClinicalTrials.gov/show/NCT00065260
The Use of Daclizumab and Anti-
Thymocyte Globulin in Lung
No Results
197 Transplantation
Available
Anti-thymocyte Globulin to
Help Prevent Rejection in
Kidney and Pancreas
198 Transplantation
Has Results
Patients Active
and Listed for
Lung
Transplantatio
n
Drug: Zenapax
Johns Hopkins University Hospital, Baltimore, Maryland, United States
https://ClinicalTrials.gov/show/NCT00181142
Drug: Alemtuzumab|Drug: Anti-Thymocyte
Graft Rejection Globulin
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
https://ClinicalTrials.gov/show/NCT00331162
Combination Therapy of Cord
Blood and G-CSF for Patients
With Brain Injury or
199 Neurodegenerative Disorders
No Results
Available
Brain
Injury|Cerebra
l
Palsy|Amyotro
phic Lateral
Sclerosis|Parki Procedure: Umbilical cord blood
nson's Disease therapy|Biological: Filgrastim
Biological: anti-thymocyte globulin|Drug:
busulfan|Drug: fludarabine
Multiple
phosphate|Procedure: allogeneic bone
Myeloma and marrow transplantation|Procedure:
Plasma Cell
nonmyeloablative allogeneic hematopoietic
Neoplasm
stem cell transplantation
CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of
https://ClinicalTrials.gov/show/NCT02236065
Fludarabine, Busulfan,
Antithymocyte Globulin, and
Donor Stem Cell Transplant in
Treating Patients With Multiple
Myeloma That Has Not
No Results
200 Responded to Treatment
Available
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France
https://ClinicalTrials.gov/show/NCT00802568
21
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0022.png
Fludarabine, Busulfan, and
Antilymphocyte Globulin
Followed by Donor Stem Cell
Transplant in Treating Older
Patients With Hematological
201 Cancer
No Results
Available
Chronic
Myeloprolifera
tive
Disorders|Leu
kemia|Lymph
oma|Multiple
Myeloma and
Plasma Cell
Neoplasm|My
elodysplastic
Syndromes|M
yelodysplastic/
Myeloprolifera
tive
Neoplasms
Biological: therapeutic immune
globulin|Drug: busulfan|Drug: fludarabine
phosphate|Procedure: allogeneic
hematopoietic stem cell transplantation
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France
https://ClinicalTrials.gov/show/NCT00806767
Donor Stem Cell Transplant
After Busulfan, Fludarabine,
and Antithymocyte Globulin in
Treating Patients With
202 Hematological Cancer
No Results
Available
Leukemia|My
elodysplastic
Syndromes|M
yelodysplastic/
Myeloprolifera
tive
Neoplasms
Biological: anti-thymocyte globulin|Drug:
busulfan|Drug: fludarabine phosphate|Drug:
leucovorin calcium|Drug:
methotrexate|Procedure: allogeneic bone
marrow transplantation|Procedure:
allogeneic hematopoietic stem cell
transplantation|Procedure:
nonmyeloablative allogeneic hematopoietic
stem cell transplantation
Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of
https://ClinicalTrials.gov/show/NCT00627666
Busulfan, Cyclophosphamide,
and Antithymocyte Globulin
Followed by Donor Stem Cell
Transplant in Treating Patients
203 With Hematologic Cancer
Has Results
Graft Versus
Host
Disease|Leuke
mia|Lymphom
a|Multiple
Myeloma and
Plasma Cell
Neoplasm|My
elodysplastic
Syndromes|M
yelodysplastic/
Myeloprolifera
tive
Diseases|Seco
ndary
Myelofibrosis
Biological: anti-thymocyte globulin|Drug:
busulfan|Drug: cyclophosphamide|Drug:
mycophenolate mofetil|Drug:
tacrolimus|Genetic: polymerase chain
reaction|Genetic: polymorphism
analysis|Other: flow cytometry|Other:
laboratory biomarker analysis|Other:
pharmacogenomic studies|Other:
pharmacological study|Procedure: allogeneic
bone marrow transplantation|Procedure:
allogeneic hematopoietic stem cell
transplantation|Procedure: peripheral blood
stem cell transplantation
https://ClinicalTrials.gov/show/NCT00611351
Multi-Center Trial of Anti-
Thymocyte Globulin in
Treatment of Aplastic Anemia
and Other Hematologic
204 Disorders
No Results
Available
Anemia,
Aplastic|Hema
tologic
Diseases|Panc
ytopenia|Bloo Drug: antilymphocyte serum|Drug:
d Disease
nandrolone
https://ClinicalTrials.gov/show/NCT00000597
Sirolimus, Tacrolimus, and
Antithymocyte Globulin in
Preventing Graft-Versus-Host
Disease in Patients Undergoing
a Donor Stem Cell Transplant
205 For Hematological Cancer
Has Results
Chronic
Myeloprolifera
tive
Disorders|Graf
t Versus Host
Disease|Infecti
on|Leukemia|
Lymphoma|M
ultiple
Myeloma and
Plasma Cell
Neoplasm|My
elodysplastic
Syndromes|M
yelodysplastic/
Myeloprolifera
tive
Neoplasms|Pr
ecancerous
Condition|Sec
ondary
Myelofibrosis|
Small Intestine
Cancer
Biological: anti-thymocyte globulin|Drug:
cyclophosphamide|Drug: etoposide|Drug:
fludarabine phosphate|Drug:
melphalan|Drug: methotrexate|Drug:
sirolimus|Drug: tacrolimus|Procedure:
allogeneic hematopoietic stem cell
transplantation|Procedure: hematopoietic
stem cell transplantation|Procedure:
nonmyeloablative allogeneic hematopoietic
stem cell transplantation|Procedure:
peripheral blood stem cell
transplantation|Radiation: total-body
irradiation
Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States
https://ClinicalTrials.gov/show/NCT00589563
22
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0023.png
Sirolimus, Tacrolimus, and
Antithymocyte Globulin in
Preventing Graft-Versus-Host
Disease in Patients With
Hematologic Cancer Who Are
Undergoing Donor Stem Cell
206 Transplant
Has Results
Fludarabine Phosphate,
Busulfan, and Anti-Thymocyte
Globulin Followed By Donor
Peripheral Blood Stem Cell
Transplant, Tacrolimus, and
Methotrexate in Treating
Patients With Myeloid
207 Malignancies
No Results
Available
Busulfan, Antithymocyte
Globulin, and Fludarabine
Followed By a Donor Stem Cell
Transplant in Treating Young
Patients With Blood Disorders,
Bone Marrow Disorders,
Chronic Myelogenous Leukemia
in First Chronic Phase, or Acute
Myeloid Leukemia in First
No Results
208 Remission
Available
Chronic
Myeloprolifera
tive
Disorders|Leu
kemia|Lymph
oma|Multiple
Myeloma and
Plasma Cell
Neoplasm|My
elodysplastic
Syndromes|M
yelodysplastic/
Myeloprolifera
tive
Neoplasms
Accelerated
Phase Chronic
Myelogenous
Leukemia|Adu
lt Acute
Myeloid
Leukemia in
Remission|Ad
ult Acute
Myeloid
Leukemia With
11q23 (MLL)
Abnormalities|
Adult Acute
Myeloid
Leukemia With
Del(5q)|Adult
Acute Myeloid
Leukemia With
Inv(16)(p13;q2
2)|Adult Acute
Myeloid
Leukemia With
t(15;17)(q22;q
12)|Adult
Acute Myeloid
Leukemia With
t(16;16)(p13;q
Congenital
Amegakaryocy
tic
Thrombocytop
enia|Diamond-
blackfan
Anemia|Fanco
ni
Anemia|Leuke
mia|Severe
Congenital
Neutropenia|T
hrombocytope
nia
Leukemia|Lym
phoma|Multip
le Myeloma
and Plasma
Cell
Neoplasm|My
elodysplastic
Syndromes
Biological: rituximab|Drug: busulfan|Drug:
carmustine|Drug: cyclophosphamide|Drug:
cytarabine|Drug: etoposide|Drug:
fludarabine phosphate|Drug:
melphalan|Radiation: total body irradiation
(TBI)|Drug: anti-thymocyte globulin IV
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
https://ClinicalTrials.gov/show/NCT00691015
Drug: fludarabine phosphate|Drug:
busulfan|Biological: anti-thymocyte
globulin|Drug: tacrolimus|Drug:
methotrexate|Procedure: peripheral blood
stem cell transplantation|Procedure:
allogeneic hematopoietic stem cell
transplantation|Other: laboratory biomarker
analysis
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT01056614
Biological: anti-thymocyte globulin|Drug:
busulfan|Drug: fludarabine
phosphate|Procedure: allogeneic bone
marrow transplantation|Procedure:
peripheral blood stem cell
transplantation|Procedure: umbilical cord
blood transplantation|Radiation: radiation
therapy
UCSF Comprehensive Cancer Center, San Francisco, California, United States
https://ClinicalTrials.gov/show/NCT00305708
Low-Dose Fludarabine,
Busulfan, and Anti-Thymocyte
Globulin Followed By Donor
Umbilical Cord Blood
Transplant in Treating Patients
With Advanced Hematologic
No Results
209 Cancer
Available
Biological: anti-thymocyte
globulin|Biological: sargramostim|Drug:
busulfan|Drug: fludarabine phosphate|Drug:
mycophenolate mofetil|Drug:
tacrolimus|Procedure: umbilical cord blood
transplantation
UCSF Comprehensive Cancer Center, San Francisco, California, United States
https://ClinicalTrials.gov/show/NCT00301951
Fludarabine and Busulfan
Followed by Donor Peripheral
Stem Cell Transplant and
Antithymocyte Globulin,
Tacrolimus, and Methotrexate
in Treating Patients With
210 Myeloid Cancer
No Results
Available
Chronic
Myeloprolifera
tive
Disorders|Graf
t Versus Host
Disease|Leuke
mia|Myelodys
plastic
Syndromes|M
yelodysplastic/
Myeloprolifera
tive Diseases
Biological: anti-thymocyte globulin|Drug:
busulfan|Drug: fludarabine phosphate|Drug:
methotrexate|Drug: tacrolimus|Procedure:
allogeneic hematopoietic stem cell
transplantation|Procedure: peripheral blood
stem cell transplantation
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT00346359
Reduced-Intensity Busulfan and
Fludarabine With or Without
Antithymocyte Globulin
Followed by Donor Stem Cell
Transplant in Treating Patients
With Hematologic Cancer or
211 Other Disease
Has Results
Chronic
Myeloprolifera
tive
Disorders|Leu
kemia|Lymph
oma|Multiple
Myeloma and
Plasma Cell
Neoplasm|My
elodysplastic
Syndromes
Biological: anti-thymocyte
globulin|Biological: sargramostim|Biological:
therapeutic allogeneic lymphocytes|Drug:
busulfan|Drug: fludarabine phosphate|Drug:
methotrexate|Drug: tacrolimus|Procedure:
nonmyeloablative allogeneic hematopoietic
stem cell transplantation|Procedure:
peripheral blood stem cell transplantation
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
https://ClinicalTrials.gov/show/NCT00448201
23
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0024.png
With Clofarabine, Busulfan and
Antithymocyte Globulin (ATG)
for Adult Patients With High-
risk Acute Myeloid
Leukemia/Myelodysplastic
Syndromes (AML/MDS) or
Acute Lymphoblastic Leukemia No Results
212 (ALL)
Available
Phase II Pilot Study of
Cyclophosphamide and Rabbit
Anti-Thymocyte Globulin as
Salvage Therapy in Patients
No Results
213 With Diffuse Systemic Sclerosis Available
MDS|AML|AL Drug: Clofarabine in combination with IV
L|BAL
busulfan and ATG
Hôpital Edouard Herriot, Lyon, France|Institut Paoli Calmettes, Marseille, France|Nantes University hospital, Nantes, France|Hôpital Saint Louis, Paris, France|CHU Haut-Lévêque, Pessac, France|CHRU Hautepierre, Strasbourg, France
https://ClinicalTrials.gov/show/NCT00863148
Systemic
Sclerosis
Drug: anti-thymocyte globulin|Drug:
cyclophosphamide
University of Colorado Cancer Center, Denver, Colorado, United States|Duke University Medical Center, Durham, North Carolina, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT00016458
Combination Chemotherapy
and Antithymocyte Globulin in
Reducing Graft-Versus-Host
Disease in Patients Undergoing
Donor Stem Cell
Transplantation For
Myelodysplastic Syndrome or No Results
214 Myeloproliferative Disorder
Available
Chronic
Myeloprolifera
tive
Disorders|Graf
t Versus Host
Disease|Leuke
mia|Myelodys
plastic
Syndromes|M
yelodysplastic/
Myeloprolifera
tive Diseases
Biological: anti-thymocyte globulin|Drug:
busulfan|Drug: cyclophosphamide|Drug:
cyclosporine|Drug: methotrexate|Procedure:
allogeneic bone marrow
transplantation|Procedure: peripheral blood
stem cell transplantation
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT00054340
Phase I Pilot Study of Total-
Body Irradiation, Anti-
Thymocyte Globulin and
Cyclophosphamide Followed By
Syngeneic or Autologous
Peripheral Blood Stem Cell
Transplantation in Patients
No Results
215 With Multiple Sclerosis
Available
Multiple
Sclerosis
Drug: anti-thymocyte globulin|Drug:
cyclophosphamide|Drug: filgrastim|Drug:
prednisone|Procedure: peripheral blood
stem cell transplantation|Procedure:
irradiation
City of Hope National Medical Center, Duarte, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Washington University Barnard Cancer Center, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke
University Medical Center, Durham, North Carolina, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT00014755
Pilot Study of Total Body
Irradiation in Combination With
Cyclophosphamide, Anti-
thymocyte Globulin, and
Autologous CD34-Selected
Peripheral Blood Stem Cell
Transplantation in Children
With Refractory Autoimmune
216 Disorders
Safety and Efficacy Study of
Thymoglobulin Versus IL2
217 Receptor Antagonists
Biological Therapy in Treating
Patients With Myelodysplastic
218 Syndrome
No Results
Available
Systemic
Sclerosis|Syste
mic Lupus
Erythematosus
|Dermatomyo
sitis|Juvenile
Rheumatoid
Arthritis|Autoi
mmune
Procedure: Stem Cell
Diseases
Transplantation|Device: CD34 selection
End Stage
Renal Disease
Leukemia|My
elodysplastic
Syndromes
Drug: Rabbit Antithymocyte globulin|Drug:
Daclizumab
Biological: anti-thymocyte
globulin|Biological: etanercept
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT00010335
Has Results
No Results
Available
Medical University of South Carolina, Charleston, South Carolina, United States
https://ClinicalTrials.gov/show/NCT00859131
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT00005853
Medical Treatment for
219 Diamond Blackfan Anemia
No Results
Available
Fanconi's
Anemia|Hema Drug: Antithymocyte globulin|Drug:
tologic Disease Cyclosporine
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
https://ClinicalTrials.gov/show/NCT00001749
S0020 Immunosuppressive
Therapy in Treating Patients
With Myelodysplastic
220 Syndrome
No Results
Available
Leukemia|My
elodysplastic Biological: anti-thymocyte globulin|Drug:
Syndromes
cyclosporine
MBCCOP - Gulf Coast, Mobile, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|Veterans Affairs Medical Center - Phoenix (Carl T. Hayden), Phoenix, Arizona, United States|Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States|Arizona Cancer Center, Tucson,
Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Veterans Affairs Medical Center - Little Rock (McClellan), Little Rock, Arkansas, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC/Norris Comprehensive Cancer
Center and Hospital, Los Angeles, California, United States|Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United
States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United
States|David Grant Medical Center, Travis Air Force Base, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Veterans Affairs Medical Center - Denver, Denver, Colorado, United States|MBCCOP - Howard University Cancer Center, Washington, District of Columbia,
United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|Dwight David Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|MBCCOP - University of
Illinois at Chicago, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital), Hines, Illinois, United States|Loyola University
Medical Center, Maywood, Illinois, United States|Genesis Medical Center, Davenport, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Veterans Affairs Medical Center - Wichita, Wichita, Kansas, United States|Veterans
Affairs Medical Center - Lexington, Lexington, Kentucky, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United
States|Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States|Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Veterans Affairs Medical Center - Boston (Jamaica Plain),
Jamaica Plain, Massachusetts, United States|Veterans Affairs Medical Center - Ann Arbor, Ann Arbor, Michigan, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer
Institute, Detroit, Michigan, United States|Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|CCOP - Beaumont, Royal Oak, Michigan, United States|Providence Hospital -
Southfield, Southfield, Michigan, United States|Veterans Affairs Medical Center - Biloxi, Biloxi, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Veterans Affairs Medical Center - Jackson, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB,
Keesler AFB, Mississippi, United States|Veterans Affairs Medical Center - Kansas City, Kansas City, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri,
United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Veterans Affairs Medical Center - Albuquerque, Albuquerque, New Mexico, United States|MBCCOP - University of New Mexico HSC, Albuquerque, New
Mexico, United States|Veterans Affairs Medical Center - Albany, Albany, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|CCOP - Southeast Cancer Control Consortium, Winston-
Salem, North Carolina, United States|Veterans Affairs Medical Center - Cincinnati, Cincinnati, Ohio, United States|Barrett Cancer Center, Cincinnati, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Veterans Affairs
Medical Center - Dayton, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Veterans Affairs Medical Center - Oklahoma City, Oklahoma City, Oklahoma, United States|Veterans Affairs Medical Center -
Portland, Portland, Oregon, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Oregon Cancer Institute, Portland, Oregon, United States|Veterans Affairs Medical Center - Charleston, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South
Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Veterans Affairs
Medical Center - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Veterans Affairs Medical Center - San Antonio (Murphy), San Antonio, Texas, United States|Veterans Affairs Medical Center - Temple, Temple, Texas, United
States|CCOP - Scott and White Hospital, Temple, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Veterans Affairs Medical Center - Salt Lake City, Salt Lake City, Utah, United States|CCOP - Virginia Mason Research Center, Seattle, Washington, United States|Veterans Affairs
Medical Center - Seattle, Seattle, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States
https://ClinicalTrials.gov/show/NCT00016419
24
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0025.png
Early Administration of ATG
Followed by
Cyclophosphamide, Busulfan
and Fludarabine Before a Donor
Stem Cell Transplant in Patients
221 With Hematological Cancer
Has Results
Myeloprolifera
tive
Disorders|Kidn
ey
Cancer|Leuke
mia|Lymphom
a|Multiple
Myeloma and
Plasma Cell
Neoplasm|My
elodysplastic
Syndromes|M
yelodysplastic/
Myeloprolifera
tive Diseases
Biological: anti-thymocyte globulin|Drug:
busulfan|Drug: cyclophosphamide|Drug:
fludarabine phosphate|Drug:
methotrexate|Drug: tacrolimus|Procedure:
nonmyeloablative allogeneic HSCT
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
https://ClinicalTrials.gov/show/NCT00787761
Phase 2 Study of Autologous
Followed by Nonmyeloablative
Allogeneic Transplantation
222 Using TLI & ATG
Has Results
Combination Drug Therapy
Followed by Single Drug Steroid
Free Therapy to Prevent Organ
Rejection in Kidney
223 Transplantation
Has Results
Human Leukocyte Antigen
(HLA)-Haploidentical
Hematopoietic Stem Cell
Transplantation for Patients
224 With Aplastic Anemia
Belatacept Compared to
Tacrolimus in Deceased Donor
225 Renal Transplant Recipients
Cyclophosphamide and rATG
With Hematopoietic Stem Cell
226 Support in Systemic
Comparing Therapies for the
Treatment of Severe Aplastic
227 Anemia
Transplantatio
n,
Homologous|T
ransplantation
,
Autologous|M
ultiple
Myeloma|Bloo
d and Marrow
Transplant
(BMT)
Procedure: Autologous peripheral blood
stem cells (auto-PBSC)
transplantation|Procedure: Allogeneic
peripheral blood stem cells (allo-PBSC)
transplantation|Drug: Filgrastim|Drug:
Cyclophosphamide|Drug: Melphalan|Drug:
Cyclosporine|Radiation: Total lymphoid
irradiation|Biological: Rabbit anti-thymocyte
globulin|Drug: Mycophenolate Mofetil
250mg|Drug: Solumedrol|Drug:
Diphenhydramine|Drug:
Acetaminophen|Drug: Hydrocortisone
Stanford University School of Medicine, Stanford, California, United States
https://ClinicalTrials.gov/show/NCT00899847
No Results
Available
No Results
Available
Has Results
No Results
Available
Kidney
Transplantatio
n
Drug: Sirolimus|Drug: Tacrolimus
Biological: anti-thymocyte
globulin|Biological: filgrastim|Drug:
Fludarabine|Drug:
Cyclophosphamide|Procedure: CD3±CD19
Aplastic
depleted hematopoietic stem cell
Anemia
transplantation
Drug: Belatacept|Drug: Tacrolimus|Drug:
Implant or
Mycophenolate|Drug: rATG|Drug:
Graft;
Methylprednisolone|Procedure: Renal
Rejection
transplant
SYSTEMIC
SCLERODERM Drug: standard of care|Procedure: stem cell
A
transplantation
Severe Aplastic Drug: antithymocyte globulin|Drug:
Anemia
cyclophosphamide|Drug: cyclosporine
Bone Marrow
Failure
Drug: Cyclophosphamide-fludarabine-anti
Syndromes
thymocyte globulin
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
https://ClinicalTrials.gov/show/NCT00076570
Asan Medical Center, Seoul, Korea, Republic of
https://ClinicalTrials.gov/show/NCT01105273
Columbia University Medical Center, New York, New York, United States
https://ClinicalTrials.gov/show/NCT02152345
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
https://ClinicalTrials.gov/show/NCT00278525
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
https://ClinicalTrials.gov/show/NCT00001626
Comparison of Cy-Atg Vs Cy-Flu-
Atg for the Conditioning
No Results
228 Therapy in Allo-HCT
Available
Improved Induction and
Maintenance
Immunosuppression in Kidney
229 Transplantation
Has Results
Asan Medical Center, Seoul, Korea, Republic of
https://ClinicalTrials.gov/show/NCT00774527
TLI & ATG for Non-
Myeloablative Allogeneic
Transplantation for MDS and
230 MPD
Combination Therapy of Severe
231 Aplastic Anemia
Delayed Mycophenolate
Mofetil in Single-Donor Islet
Allotransplantation in Type 1
232 Diabetes
Evaluate Effects and Safety of
Pre-load Myfortic® in
233 Transplant Patients
No Results
Available
No Results
Available
Drug: rabbit anti-thymocyte globulin|Drug:
End-stage
mycophenolate mofetil|Drug:
Renal Disease sirolimus|Drug: tacrolimus
The Nebraska Medical Center, Omaha, Nebraska, United States
Myeloprolifera
tive
Disorders|Bloo
d
Cancer|Myelo Procedure: Total Lymphoid Irradiation
(TLI)|Procedure: Anti-Thymocyte Globulin as
dysplastic
Syndromes
Conditioning (ATG)
Stanford University School of Medicine, Stanford, California, United States
Severe Aplastic
Anemia
Drug: Cyclosporine
Type 1
Diabetes|Hypo Biological: Allogeneic islets of Langerhans
glycemia
transplant
Kidney
Transplant
Recipients
Drug: mycophenolic acid
Healthy|Amyo
trophic Lateral
Sclerosis|Neur
omuscular
Disease|Spinal
Cord
Injury|Cerebra
l Palsy
Device: Brain Computer Interface Keyboard
https://ClinicalTrials.gov/show/NCT00556933
https://ClinicalTrials.gov/show/NCT00185796
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
https://ClinicalTrials.gov/show/NCT00001964
No Results
Available
University of Minnesota, Minneapolis, Minnesota, United States
https://ClinicalTrials.gov/show/NCT00285233
Has Results
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
https://ClinicalTrials.gov/show/NCT01336296
P300 Brain Computer Interface
Keyboard to Operate Assistive
234 Technology
Has Results
University of Michigan Direct Brain Interface Project, Ann Arbor, Michigan, United States|Wadsworth Center, Albany, New York, United States
https://ClinicalTrials.gov/show/NCT00860951
25
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0026.png
EZ-2053 in the Prophylaxis of
Acute Pulmonary Allograft
235 Rejection
Randomized Trial of Induction
Therapies in High
236 Immunological Risk Kidney
Has Results
Has Results
Chronic
Obstructive
Pulmonary|Idi
opathic
Pulmonary
Fibrosis|Cystic
Fibrosis|Bronc
hiectasis|Pulm
onary Vascular
Disease
Kidney
Transplantatio
n
Biological: Placebo|Biological: EZ-
2053|Biological: EZ-2053 5mg/kg
Drug: Rabbit Antithymocyte Globulin|Drug:
Velcade|Drug: Rituxan
Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Mayo Clinic, Jacksonville, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United
States|University of Iowa Hospital & Clinics, Iowa City, Iowa, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Barnes-Jewish Hospital, St. Louis, Missouri, United States|Cleveland Clinic, Cleveland, Ohio, United States|INTEGRIS Baptist Medical Center, Oklahoma City,
Oklahoma, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|University of
Texas Health Sciences Center, San Antonio, Texas, United States|The Alfred Hospital, Melbourne, Victoria, Australia|Medical University of Vienna, Vienna, Austria|University of Alberta, Edmonton, Alberta, Canada|Toronto General Hospital, Toronto, Canada
https://ClinicalTrials.gov/show/NCT00105183
The Christ Hospital, Cincinnati, Ohio, United States|The University Hospital, Cincinnati, Ohio, United States
https://ClinicalTrials.gov/show/NCT00782821
Safety/Efficacy of Induction
Agents With Tacrolimus, MMF,
and Rapid Steroid Withdrawal
237 in Renal Transplant Recipients Has Results
Drug: basiliximab|Drug: rabbit anti-
Kidney
thymocyte globulin|Drug: tacrolimus|Drug:
Transplantatio alemtuzumab|Drug: mycophenolate
n
mofetil|Drug: steroids
Birmingham, Alabama, United States|Los Angeles, California, United States|Palo Alto, California, United States|San Diego, California, United States|San Francisco, California, United States|San Francisco, California, United States|Denver, Colorado, United States|Washington, District of Columbia, United
States|Washington, District of Columbia, United States|Miami, Florida, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Livingston, New Jersey, United States|New Brunswick, New Jersey, United States|Hawthorne, New York, United States|New York, New
York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Danville, Pennsylvania, United States|Harrisburg, Pennsylvania, United States|Charleston, South Carolina,
United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States
https://ClinicalTrials.gov/show/NCT00113269
Scleroderma:
Cyclophosphamide or
238 Transplantation (SCOT)
Has Results
ECoG Direct Brain Interface for
Individuals With Upper Limb
239 Paralysis
Has Results
Scleroderma,
Systemic|Scler
osis|Autoimm
une Disease
Biological: mHSCT|Drug: cyclophosphamide
Tetraplegia|Sp
inal Cord
Injury|Brachial
Plexus
Injury|Muscul
ar
Dystrophy|ALS
|Brainstem
Device: Implantation of ECoG sensors on the
Stroke
brain surface
City of Hope National Medical Center, Duarte, California, United States|UCLA Medical School, Los Angeles, California, United States|University of Kentucky, Lexington, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston,
Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University, Durham, North Carolina, United States|University of Toledo Health Science Campus, Toledo, Ohio, United States|University of
Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas-Houston Medical School, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center
(FHCRC), Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|Dr. Markland Medical Professional Corporation, Saskatoon, Saskatchewan, Canada
https://ClinicalTrials.gov/show/NCT00114530
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
https://ClinicalTrials.gov/show/NCT01393444
26
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0027.png
Electronic-health Application To
Measure Outcomes REmotely No Results
240 Clinical Trial
Available
Neurodegener
ative
Disease|Weig
ht
Loss|Amyotro
phic Lateral
Sclerosis|Parki
nson's
Disease|Hunti
ngton's
Disease|Cache
xia
Behavioral: In-Person Nutritional Counseling
by a Registered Dietitian|Behavioral:
Nutritional counseling using an e-Health
Application
Massachusetts General Hospital, Boston, Massachusetts, United States
https://ClinicalTrials.gov/show/NCT02418546
Laughter Therapy Effects on
Mood, Stress and Self-efficacy
in People With Neurological
241 Diseases.
No Results
Available
Alzheimer's
Disease|Amyo
trophic Lateral
Sclerosis|Brain
Injury|Hunting
ton's
Disease|Multi
ple
Sclerosis|Parki
nson's
Disease|Stroke
|Spinal Cord
Injury
Other: Laughter Therapy
Evergreen Healthcare, Kirkland, Washington, United States
https://ClinicalTrials.gov/show/NCT02750982
Open-Label and Single-Arm
Study of MYOBLOC® in the
Treatment of Troublesome
242 Sialorrhea in Adults
Anemia Patients Unresponsive
to or With a Suboptimal
Response to Rabbit ATG/CsA
243 Treatment
No Results
Available
Sialorrhea
Drug: MYOBLOC
Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Scottsdale, Arizona, United States|Loma Linda, California, United States|Los Angeles, California, United States|Aurora, Colorado, United States|Atlantis, Florida, United States|Boca Raton, Florida, United States|Orlando, Florida, United States|Port
Charlotte, Florida, United States|Atlanta, Georgia, United States|Kansas City, Kansas, United States|Overland Park, Kansas, United States|Elkridge, Maryland, United States|Farmington Hills, Michigan, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Edison, New Jersey, United
States|Centerville, Ohio, United States|Tulsa, Oklahoma, United States|Greenville, South Carolina, United States|Cordova, Tennessee, United States|San Antonio, Texas, United States|Kirkland, Washington, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Grodno,
Belarus|Dnipropetrovsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Lviv, Ukraine|Odesa, Ukraine|Rivne, Ukraine|Uzhgorod, Ukraine|Zaporizhzhya, Ukraine
https://ClinicalTrials.gov/show/NCT02610868
Has Results
Anemia,
Aplastic|Anem Drug: h-ATG (ATGAM )|Drug: Cyclosporine
ia, Hypoplastic (Gengraf )
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
https://ClinicalTrials.gov/show/NCT00944749
Efficacy and Safety Study of
MYOBLOC® Followed by Open-
Label Multiple-Treatment With
MYOBLOC® in the Treatment
of Troublesome Sialorrhea in
No Results
244 Adult Subjects
Available
Improving Immunosuppressive
Treatment for Patients With
No Results
245 Severe Aplastic Anemia
Available
Telemedicine for Patients With
Chronic Respiratory
No Results
246 Insufficiency
Available
Sialorrhea
Drug: MYOBLOC|Other: PLACEBO
Loma Linda, California, United States|Los Angeles, California, United States|National City, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Boca Raton, Florida, United States|Port Charlotte, Florida, United States|Carmel, Indiana, United States|Baltimore,
Maryland, United States|Elkridge, Maryland, United States|Detroit, Michigan, United States|Saint Louis, Missouri, United States|Edison, New Jersey, United States|Albany, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|Tulsa, Oklahoma, United States|Port Royal,
South Carolina, United States|Cordova, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Kirkland, Washington, United States|Tacoma, Washington, United States|Irkutsk, Irkutsk Region, Russian Federation|Vsevolozhsk, Leningrad
Region, Russian Federation|St.Petersburg, Petrodvorets, Russian Federation|Krasnoyarsk, Russian Federation|Dnipropetrovsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Lviv, Ukraine|Rivne, Ukraine|Uzhgorod, Ukraine
https://ClinicalTrials.gov/show/NCT01994109
Severe Aplastic Drug: cyclosporine|Drug: Rapamune|Drug:
Anemia
ATG
Chronic
Respiratory
Failure
Device: telemedicine program
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
https://ClinicalTrials.gov/show/NCT00061360
Telemedicine Service, Fondazione S. Maugeri, IRCCS, Lumezzane, Brescia, Italy
https://ClinicalTrials.gov/show/NCT00563745
27
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0028.png
Safety Study of AVP-923 in the
Treatment of IEED (Involuntary
Emotional Expression Disorder)
Also Known as Pseudobulbar
Affect (Episodes of
Uncontrolled Crying and/or
No Results
247 Laughter)
Available
Fludarabine-Based Conditioning
for Allogeneic Marrow
No Results
Transplantation in Aplastic
248 Anemia
Available
Alzheimer's
Disease|Stroke
|Parkinson's
Disease|Trau
matic Brain
Injury
Drug: AVP-923
Barrow Neurological Institute, Phoenix, Arizona, United States|Center for Neurologic Study, La Jolla, California, United States|UCLA School of Medicine, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Research Center for Clinical Studies, Inc., Darien, Connecticut, United
States|George Washington University Medical Faculty Assoc., Washington, District of Columbia, United States|Neurological Associates, Ft. Lauderdale, Florida, United States|University of Miami Dept. of Neurology, Miami, Florida, United States|Miami Jewish Home & Hospital for the Aged, Miami, Florida, United
States|Allied Clinical Trials, Miami, Florida, United States|Renstar Medical Research, Plantation, Florida, United States|Suncoast Neuroscience Associates Inc., St. Petersburg, Florida, United States|Tampa, Florida, United States|Neurology & Headache Specialist of Atlanta, L.L.C., Decatur, Georgia, United
States|Consultants in Neurology LTD, Northbrook, Illinois, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|Neurological Associates, P.C., Lincoln, Nebraska, United States|Upstate Clinical Research, Albany, New York, United States|DENT Neurologic Group L.L.P., Amherst, New
York, United States|Hospital for Joint Diseases MS Care Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, PA, Raleigh, North Carolina, United
States|NeuroCare Center, Inc., Canton, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|University Memory and Aging Center, Cleveland, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Clinical Pharmaceutical Trials, Inc., Tulsa, Oklahoma,
United States|Lehigh Valley Neurosciences and Pain Research Center, Allentown, Pennsylvania, United States|Westmoreland Neurology, Greensburg, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|MCP-Hahnemann University, Philadelphia, Pennsylvania, United States|Penn Neurological
Institute, Philadelphia, Pennsylvania, United States|Neurological Associates of Delaware Valley, Upland, Pennsylvania, United States|Claghorn-Lesem Research Clinic, Bellaire, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont,
United States|Neurology and Neurosurgery Associates of Tacoma, Tacoma, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States
https://ClinicalTrials.gov/show/NCT00056524
Aplastic
Anemia
Drug: Antithymocyte Globulin|Drug:
Cyclophosphamide|Drug:
Fludarabine|Radiation: Total Body Irradiation
(TBI)|Procedure: Bone Marrow Transplant
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug: Gemcitabine|Drug: Fludarabine|Drug:
Melphalan|Drug: Antithymocyte
Globulin|Procedure: Allogeneic Stem Cell
Infusion|Drug: Tacrolimus|Drug: Filgrastim
(G-CSF)|Drug: Methotrexate
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT00474747
Allogeneic Blood Stem Cell
Transplantation and Adoptive
Immunotherapy for Hodgkin's
249 Disease
Intrabone Infusion of Cord
Blood in Adults With
250 Hematological Malignancies
Has Results
No Results
Available
Hodgkin's
Disease
https://ClinicalTrials.gov/show/NCT00385788
Hematological
Malignancies Procedure: Intrabone cord blood infusion
Hematology Institute "L. and A. Serà gnoli", S. Orsola-Malpighi University Hospital, Bologna, Italy
https://ClinicalTrials.gov/show/NCT00886522
Cord Blood Fucosylation to
Enhance Homing and
Engraftment in Patients With
251 Hematologic Malignancies
No Results
Available
Blood And
Marrow
Transplantatio
n|Leukemia|L
ymphoma|Tra
nsplantation
Infection|Tran
splantation,
Bone Marrow
Drug: Melphalan|Drug: Fludarabine|Drug:
Mycophenolate mofetil|Drug:
Tacrolimus|Procedure: Cord Blood
Infusion|Drug: Rituximab|Drug: ATG|Drug:
Busulfan|Drug: Clofarabine|Radiation: Total
Body Irradiation (TBI)
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT01471067
252
253
254
255
256
257
258
Alloreactive Haploidentical
Natural Killer (NK) Cells With
Busulfan and Fludarabine/ATG
Infusion of Allogeneic Umbilical
Cord Blood-Derived Cluster of
Differentiation Antigen 19
(CD19)-Specific T Cells
Plerixafor and Granulocyte
Colony-stimulating Factor (G-
CSF) With Busulfan,
Fludarabine and Thymoglobulin
Azacitidine After Allo Blood And
Marrow Transplantation (BMT)
for Chronic Myelogenous
Leukemia (CML)
Allogeneic Stem Cell
Transplantation for
Myelofibrosis and
Purine Analog-Based
Conditioning in Patients With
Severe Aplastic Anemia
Allogeneic Stem Cell
Transplantation for Acute
Myeloid Leukemia (AML) and
Myelodysplastic Syndrome
(MDS)
Has Results
Drug: Fludarabine|Drug:
Busulfan|Procedure: NK cell infusion:|Drug:
Leukemia|Chr Interleukin-2|Drug: Anti-Thymocyte
onic
Globulin|Procedure: Allogeneic related Stem
Myelogenous Cell Transplant|Drug: Tacrolimus|Drug:
Leukemia
Methotrexate|Drug: G-CSF
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT01390402
No Results
Available
Has Results
Leukemia|Lym Genetic: T-Cell Infusion|Procedure: Cord
phoma
Blood Infusion
Drug: Plerixafor|Drug: Filgrastim|Drug:
Stem Cell
Fludarabine|Drug: Busulfan|Procedure:
Transplantatio Allogeneic blood stem cell transplant|Drug:
n|Leukemia
ATG (Thymoglobulin)
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT01362452
UT MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT00822770
No Results
Available
Stem Cell
Drug: Fludarabine|Drug: Busulfan|Drug:
Transplantatio Thymoglobulin|Drug: Azacitidine|Procedure:
n|Leukemia
Stem Cell Transplant
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug: Busulfan|Drug: Fludarabine|Drug:
Thymoglobulin (ATG)
Drug: Fludarabine|Drug:
Aplastic
Cyclophosphamide|Drug: Antithymocyte
Anemia
Globulin
Drug: Thymoglobulin|Drug: Busulfan|Drug:
Myelodysplasti Fludarabine|Procedure: Alloreactive NK
c
Infusion|Drug: G-CSF|Drug:
Syndrome|Leu Tacrolimus|Drug: Methotrexate|Drug:
kemia
Interleukin-2
Myelofibrosis
https://ClinicalTrials.gov/show/NCT00813124
Has Results
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT00475020
Has Results
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT00427336
No Results
Available
UT MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT00402558
Allo Transplantation With
Mylotarg, Fludarabine and
Melphalan for AML, CML and
259 MDS
No Results
Available
Acute
Myelogenous
Leukemia|My
elodysplastic
Syndrome|Chr
onic
Drug: Mylotarg|Drug: Fludarabine|Drug:
Lymphocytic Melphalan|Drug: Anti-thymocyte
Leukemia
globulin|Procedure: Stem cell transplant
MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT00038831
Ongoing
Rank
Title
Study Results Conditions
Non-invasive Brain Stimulation
for the Treatment of
No Results
1 Depression Symptoms in ALS
Available
ALS
Interventions
Locations
URL
Device: rTMS
Hospital for Special Surgery, New York, New York, United States
https://ClinicalTrials.gov/show/NCT03373981
28
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0029.png
T Cell Phenotypes in
Amyotropic Lateral Sclerosis
2 (ALS), Influence of Vitamin D
Spinal Interneuron Excitability
3 in ALS
Development and Needs
Assessment and Efficiency of
Smart Communication System
4 for Patients With ALS.
No Results
Available
No Results
Available
ALS
ALS
ALS
(Amyotrophic
Lateral
Sclerosis)
Amyotrophic
Lateral
Sclerosis|ALS
Other: phenotyping Tcells|Other:
Supplementation in vitamin D
Device: Electrophysiology
University Hospital of Montpellier, Montpellier, France
Hopital Pitie Salpetriere, Paris, France
https://ClinicalTrials.gov/show/NCT02756104
https://ClinicalTrials.gov/show/NCT02429492
No Results
Available
Other: communication system
Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan
https://ClinicalTrials.gov/show/NCT03787420
Open Label Extension Study of No Results
5 AMX0035 in Patients With ALS Available
Safety and Efficacy of Repeated
Administrations of NurOwn®
6 in ALS Patients
A Study to Evaluate
Transplantation of Astrocytes
Derived From Human
Embryonic Stem Cells, in
Patients With Amyotrophic
7 Lateral Sclerosis (ALS)
Safety and Efficacy of
Ranolazine for the Treatment of
8 Amyotrophic Lateral Sclerosis
Non-invasive Ventilation in
Amyotrophic Lateral Sclerosis
9 (ALS) Using the iVAPS Mode
ALS Study Determining Various
Biomarkers and Strength
10 Comparison After Exercise
A Clinical Trial of Pimozide in
Patients With Amyotrophic
11 Lateral Sclerosis (ALS)
Intrathecal Autologous Adipose-
derived Mesenchymal Stromal
Cells for Amyotrophic Lateral
12 Sclerosis (ALS)
Drug: AMX0035
Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
https://ClinicalTrials.gov/show/NCT03488524
No Results
Available
Amyotrophic
Biological: NurOwn® (MSC-NTF
Lateral
Sclerosis (ALS) cells)|Other: Placebo
University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of
Massachusetts Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States
https://ClinicalTrials.gov/show/NCT03280056
No Results
Available
No Results
Available
ALS
(Amyotrophic
Lateral
Sclerosis)
Biological: AstroRx
Drug: Ranolazine 500 MG|Drug: Ranolazine
1000 MG
Hadassah Ein Kerem Medical Center, Jerusalem, Israel
https://ClinicalTrials.gov/show/NCT03482050
ALS
University of Kansas Medical Center, Kansas City, Kansas, United States
https://ClinicalTrials.gov/show/NCT03472950
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis (ALS) Device: Non-invasive home ventilation
Amyotrophic
Lateral
Sclerosis
Other: Resistance Exercise Program
Montreal Chest Institute, Montreal, Quebec, Canada
https://ClinicalTrials.gov/show/NCT01746381
University of Kansas Medical Center, Kansas City, Kansas, United States
https://ClinicalTrials.gov/show/NCT03201991
No Results
Available
ALS|Amyotrop Drug: Pimozide 2mg/day (current) or 4
hic Lateral
mg/day (study initiation)|Drug: Placebo Oral Dr. Lawrence Korngut -South Health Campus, Calgary, Alberta, Canada|Dr. Wendy Johnston, Edmonton, Alberta, Canada|Dr. Colleen O'Connell - Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada|Dr. John Turnbull McMaster University/Hamilton Health Services, Hamilton, Ontario,
Sclerosis
Tablet
Canada|Dr. Christen Shoesmith, London, Ontario, Canada|Dr. Lorne Zinman Sunnybrook Research Institute, Toronto, Ontario, Canada|Dr. Sandrine Larue - Reserche Sepmus Inc., Greenfield Park, Quebec, Canada|Dr. Genevieve Matte, Montréal, Quebec, Canada
ALS|Amyotrop
hic Lateral
Drug: Autologous Adipose-derived
Sclerosis
Mesenchymal Stromal Cells
Amyotrophic
Lateral
Sclerosis
Device: Custom Mask Interface
https://ClinicalTrials.gov/show/NCT03272503
No Results
Available
Mayo Clinic in Rochester, Rochester, Minnesota, United States
https://ClinicalTrials.gov/show/NCT03268603
A Pilot Study of the Utility of 3D No Results
13 Printed Masks for ALS Subjects Available
Michigan Medicine, Ann Arbor, Michigan, United States
https://ClinicalTrials.gov/show/NCT03519880
A Study to Evaluate Efficacy,
Safety and Tolerability of CK-
2127107 in Patients With
Amyotrophic Lateral Sclerosis
14 (ALS)
Intraspinal Transplantation of
Autologous ADRC in ALS
15 Patients
Cervical Electrical Stimulation
16 for ALS
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
No Results
Available
No Results
Available
Drug: CK-2127107|Drug: Placebo
Biological: Cell-based therapy of autologous
adipose derived regenerative cells
transplanted intraspinally and intrathecally in
ALS patients
Medical University of Warsaw, Warsaw, Poland
Device: CES at rest|Device: CES plus active
hand or wrist movements
St. Joseph's Hospital and Medical Center - Barrow Neurological Clinics, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California Irvine, Orange, California, United States|Forbes Norris MDA/ALS Research Center, San Francisco, California, United
States|Stanford Hospital and Clinics, Stanford, California, United States|University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, United States|Hospital for Special Care, New Britain, Connecticut, United States|George Washington University Medical Faculty Associates, Washington, District of
Columbia, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Carol & Frank Morsani Center for Advanced Healthcare - University of South Florida, Tampa, Florida, United States|Emory Clinic, Atlanta, Georgia, United States|Duchossois Center for
Advanced Medicine, Chicago, Illinois, United States|IU Health Neuroscience Center of Excellence, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University -
Outpatient Center, Baltimore, Maryland, United States|University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School, Worcester, Massachusetts, United States|Michigan Medicine, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United
States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Saint Louis University, Department of Neurology, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Neurology
Associates, P.C., Lincoln, Nebraska, United States|Hospital For Special Surgery, New York, New York, United States|Neurological Institute, Columbia University Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Neurosciences Institute,
Neurology - Charlotte, Charlotte, North Carolina, United States|Duke Neurological Disorders Clinic, Durham, North Carolina, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical
Center, Columbus, Ohio, United States|Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University School of Medicine,
Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Clinical Research Center, Nashville, Tennessee, United States|Texas Neurology, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|UTHSCSA Medical Arts and Research Center, San Antonio, Texas,
United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Health System, Charlottesville, Virginia, United States|VCU Health - Ambulatory Care Center (ACC), Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington,
United States|West Virginia University, Dept. of Neurology, Morgantown, West Virginia, United States|Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States|Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia|Department of Neurology, Westmead
Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|The Perron Institute for Neurological and Translation Science, Nedlands, Western Australia, Australia|University of Calgary,
Heritage Medical Research Center, Calgary, Alberta, Canada|Edmonton Kaye Clinic, Edmonton, Alberta, Canada|McMaster University Medical Centre, Hamilton, Ontario, Canada|London Health Sciences Centre University Hospital, London, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario,
Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Centre de recherche du Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, Canada|Saskatoon City Hospital, Saskatoon, Saskatchewan, Canada|CHU de Quebec-Universite Laval, Hopital de l'Enfant Jesus, Quebec,
Canada|Beaumont Hospital, Dublin, Ireland|University Medical Center Utrecht, Utrecht, Netherlands|Hospital San Rafael Servicio de Neurologia, Madrid, Spain
https://ClinicalTrials.gov/show/NCT03160898
https://ClinicalTrials.gov/show/NCT03296501
James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States
https://ClinicalTrials.gov/show/NCT03411863
The Effect of RNS60 on ALS
17 Biomarkers
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: RNS60
Massachusetts General Hospital, Boston, Massachusetts, United States|Azienda Opsedaliera Universitaria Consorziale Policlinico- Università degli studi di Bari, Bari, Italy|Spedali civili di Brescia, Brescia, Italy|ASST Valle Olona Presidio ospedaliero Gallarate, Gallarate, Italy|IRCCS Azienda Ospedaliera Universitaria
San Martino IST, Genova, Italy|Ospedale San Raffaele, Miano, Italy|Centro Clinico NEMO - Fondazione Serena Onlus, Milano, Italy|Presidio Ospedaliero Provinciale - Nuovo Ospedale Civile "S. Agostino Estense", Modena, Italy|Azienda Ospedaliera Universitaria della Seconda Univ. Degli Studi di Napoli (AOU-SUN),
Napoli, Italy|Azienda Ospedaliero Universitaria Maggiore della Carità , Novara, Italy|Azienda Ospedaliera di Padova-Università degli studi di Padova, Padova, Italy|Azienda Ospedaliera Universitaria Policlinico "P Giaccone", Palermo, Italy|Istituto Neurologico Nazionale "C. Mondino", Pavia, Italy|Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy|POLICLINICO UMBERTO I - Università di Roma "La Sapienza", Roma, Italy|IRCCS Casa sollievo della Sofferenza, San Giovanni Rotondo, Italy|Azienda Ospedaliera Universitaria Senese (AOUS), Siena, Italy|Azienda Ospedaliera "Santa Maria" di Terni, Terni, Italy|Azienda
Ospedaliero-Universitaria Città della Salute e della Scienza di Torino., Torino, Italy|Azienda Ospedaliera "Card. G. Panico", Tricase, Italy
https://ClinicalTrials.gov/show/NCT03456882
29
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0030.png
Effects of Oral Levosimendan
(ODM-109) on Respiratory
18 Function in Patients With ALS
Safety of Urate Elevation in
Amyotrophic Lateral Sclerosis
19 (ALS)
An Online Mindfulness
Intervention for People With
20 ALS and Their Caregivers
Treatment of FUS-Related ALS
With Betamethasone - The
21 TRANSLATE Study
Lung Volume Recruitment
Combined With Expiratory
22 Muscle Strength Training in ALS
HERV-K Suppression Using
Antiretroviral Therapy in
Volunteers With Amyotrophic
23 Lateral Sclerosis (ALS)
Cycle Treatment After 6
Months of 1st Cycle HLA-haplo
Matched Allogenic Bone
Marrow Derived Stem Cell
24 Treatment in ALS
A Study of IPL344 in the
25 Treatment of ALS Patients
No Results
Available
No Results
Available
No Results
Available
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Familial
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: Levosimendan|Drug: Placebo for
levosimendan
Phoenix Neurological Associates, Phoenix, Arizona, United States|Neuromuscular Research Center and Neuromuscular Clinic of Arizona, Phoenix, Arizona, United States|University of California San Diego, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University
of California Irvine, Orange, California, United States|California Pacific Medical Center, San Francisco, California, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|Hospital for Special Care, New Britain, Connecticut, United States|Hospital of Special Care, New
Britain, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|The George Washington Medical Faculty Associates - Foggy Bottom North Pavilion, Washington, District of Columbia, United States|Providence Holy Cross Medical Center, Fort Lauderdale, Florida, United
States|University of Florida, Gainesville, Florida, United States|University of Florida Health - Jacksonville, Jacksonville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University School of Medicine, Atlanta,
Georgia, United States|Augusta University, Augusta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|Kentucky Neuroscience Research, Louisville, Kentucky, United
States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Kalamazoo, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|HealthPartners Specialty Center, Saint Paul,
Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Neurology Associates, Lincoln, Nebraska, United States|Mount Sinai Beth Israel, New York, New York, United States|Hospital for Special Surgery, New York, New York, United States|Columbia Presbyterian
Hospital, New York, New York, United States|Neurosciences Institute - Neurology Charlotte, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|The Ohio
State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Providence Brain and Spine Institute, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University School of Medicine,
Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Texas Neurology, Dallas, Texas, United States|Nerve and Muscle Center of Texas, Houston, Texas, United States|University
of Utah - Imaging & Neurosciences Center, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Froedtert
Hospital, Milwaukee, Wisconsin, United States|Brain and Mind Centre, Camperdown, New South Wales, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Calvary Health Care Bethlehem, Caulfield South, Victoria,
Australia|Perron Institute for Neurological and Translational Science, Murdoch, Western Australia, Australia|Universität Innsbruck, Innsbruck, Tyrol, Austria|Salzkammergut-Klinikum Vöcklabruck, Vöcklabruck, Upper Austria, Austria|Medizinische Universität Wien, Wien, Austria|Universitaire Ziekenhuis
Leuven, Leuven, Flemish Brabant, Belgium|Centre Hospitalier Régional de la Citadelle, Liège, Liege, Belgium|Algemeen Ziekenhuis St. Lucas Gent, Gent, Oost-Vlaanderen, Belgium|Alberta Health Services - Neuromuscular Clinic, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Stan
Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada|Moncton Hospital, Southeast Regional Health Authority, Moncton, New Brunswick, Canada|McMaster University Medical Centre, Hamilton, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre De Recherche
Du Centre Hospitalier de l'Universite de Montreal - Hopital Notre-Dame, Montréal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada|Centre Hospitalier Affilie Universitaire de Quebec, Québec, Quebec, Canada|Neurologian Poliklinikka - Meilahden Tornisairaala 3,
Helsinki, Finland|Etelä-Karjalan keskussairaala, Lappeenranta, Finland|Turku University Hospital, Turku, Finland|Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Deutsche Klinik für Diagnostik, Wiesbaden, Hessen, Germany|Universitätsmedizin Rostock, Rostock, Mecklenburg-western-
pommerania, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Alfried Krupp Krankenhaus Rüttenscheid, Essen, Nordrhein-westfalen, Germany|Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany|Universitätsklinikum Carl Gustav Carus, Dresden,
Sachsen, Germany|Universitätsklinikum Jena, Jena, Thuringen, Germany|Charité Universitätsmedizin Berlin - Campus Virchow-Klinikum, Berlin, Germany|Beaumont Hospital - Ireland, Dublin, Ireland|Azienda Ospedaliera Universitaria-Maggiore della Carità di Novara, Novara, Italy|ICS Maugeri Spa SB, Pavia,
Italy|Azienda Ospedaliero-Universitaria Pisana Ospedale Santa Chiara, Pisa, Italy|Policlinico Umberto I di Roma, Roma, Italy|Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino, Torino, Italy|Academisch Medisch Centrum, Amsterdam, Noord-Holland, Netherlands|Universitair Medisch
Centrum Utrecht - Rudolf Magnus Instituut voor Neurowetenschappen, Utrecht, Netherlands|Hospital de Basurto, Bilbao, Vizcaya, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital San Rafael - Madrid, Madrid, Spain|Hospital Universitario y
Politécnico de La Fe, Valencia, Spain|Norrlands Universitetssjukhus, Umeå, Vasterbotten, Sweden|Centralsjukhuset Karlstad, Karlstad, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|Barts Health NHS Trust, London, England, United Kingdom|King's College Hospital NHS Foundation Trust,
London, England, United Kingdom|The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom
https://ClinicalTrials.gov/show/NCT03505021
Drug: Inosine|Drug: Placebo
Holy Cross Hospital, Fort Lauderdale, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States
https://ClinicalTrials.gov/show/NCT03168711
Behavioral: Mindfulness
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
Drug: Betamethasone sodium
phosphate/betamethasone acetate
(Celestone® Soluspan®), 30 mg IM once a
day for four days
University of Kentucky Medical Center, Lexington, Kentucky, United States
Procedure: Expiratory Muscle Strength
Training (EMST)|Procedure: EMST + Lung
Volume Recruitment (LVR)
University of Florida, Gainesville, Florida, United States|University of Minnesota, Minneapolis, Minnesota, United States
https://ClinicalTrials.gov/show/NCT03095989
https://ClinicalTrials.gov/show/NCT03707795
https://ClinicalTrials.gov/show/NCT03202017
No Results
Available
Drug: Darunavir|Drug: Ritonavir|Drug:
Raltegravir|Drug: Zidovudine
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
https://ClinicalTrials.gov/show/NCT02437110
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Biological: HYNRCS-Allo inj
Hanyang University Seoul Hospital, Cell Therapy Center for Neurologic Disorders, Seoul, Haengdang-dong, Seongdong-gu, Korea, Republic of
https://ClinicalTrials.gov/show/NCT03214146
Drug: IPL344
Hadassah Medical Center -Motor Neuron Disease Clinic, Jerusalem, Israel
https://ClinicalTrials.gov/show/NCT03652805
Clinical Trial of Ultra-high Dose
26 Methylcobalamin for ALS
CC100: Phase 1 Multiple-Dose
Safety and Tolerability in
27 Subjects With ALS
No Results
Available
No Results
Available
No Results
Available
28 Rapamycin Treatment for ALS
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Nagoya University Hospital, Nagoya, Aichi, Japan|Miyoshi Neurological Clinic, Miyoshi, Hiroshima, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Kobe Central Munincipal Medical center, Kobe, Hyogo, Japan|Ioh National Hospital, Kanazawa, Ishikawa, Japan|Kitasato University East
Hospital, Sagamihara, Kanagawa, Japan|Shiga Medical University Hospital, Otsu, Shiga, Japan|Chiba University Hospital, Chiba, Japan|Murakami Karindo Hospital, Fukuoka, Japan|Okayama University Hospital, Okayama, Japan|Tokushima University Hospital, Tokushima, Japan|Juntendo University Hospital, Tokyo,
Drug: methylcobalamin|Drug: saline solution Japan|Toho University Hospital, Tokyo, Japan|Teikyo University Hospital, Tokyo, Japan|Tokyo Metropolitan Neurological Hospital, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan
https://ClinicalTrials.gov/show/NCT03548311
Drug: CC100|Drug: Placebos
Indiana University, IU Health Physicians Neurology, Indianapolis, Indiana, United States
https://ClinicalTrials.gov/show/NCT03049046
Drug: Rapamycin|Drug: Placebo Oral Tablet
Centro Sla, Irccs A.O.U. S.Martino Ist, Genova, Genova, Italy|Centro Clinico Nemo, Fondazione Serena Onlus, Milano, Milano, Italy|Centro Sla, Irccs Fondazione Salvatore Maugeri, Milano, Milano, Italy|Centro Sla, Irccs Istituto Carlo Besta, Milano, Milano, Italy|Centro Sla, Ospedale Civile S. Agostino Estense, A.O.U.
Modena, Modena, Italy|Centro Sla, A.O.U. Maggiore Della Carita', Novara, Novara, Italy|Centro Sla, Universita' Di Padova, Padova, Italy|Centro Sla, Universita' Di Torino, Torino, Italy
https://ClinicalTrials.gov/show/NCT03359538
MIROCALS: Modifying Immune No Results
29 Response and OutComes in ALS Available
Amyotrophic
Lateral
Sclerosis
Drug: Riluzole|Drug: IL-2|Drug: 5% glucose
water solution
CHRU de Lille - Hôpital Roger Salengro, Lille, France|CHU de Limoges - Hôpital Dupuytren, Limoges, France|HCL - Hôpital Neurologique P. Wertheimer, Lyon, France|APHM - Hôpital de la Timone, Marseille, France|CHRU de Montpellier - Hôpital Gui de Chauliac, Montpellier Cedex 5, France|CHU de Nice -
Hôpital Pasteur, Nice, France|APHP - Groupe Hospitalier Pitié-Salpetrière, Paris Cedex 13, France|CENTRE HOSPITALIER DE SAINT BRIEUC - Hôpital Yves Le Foll, Saint Brieuc, France|CHU de Strasbourg - Hôpital de Hautepierre, Strasbourg, France|CHRU de Tours - Hôpital Bretonneau, Tours, France|Trafford
Centre for Biomedical Research, Brighton, United Kingdom|Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom|North-East London and Essex MND Regional Care Centre, London, United Kingdom|King's MND Care and Research Centre, London, United Kingdom|Centre
for Neuromuscular Diseases - National Hospital of Neurology, London, United Kingdom|Salford Royal NHS Foundation Trust, Neurology Dept, Manchester, United Kingdom|Sheffield Care and Research Centre, Sheffield, United Kingdom
https://ClinicalTrials.gov/show/NCT03039673
Long-Term Evaluation of
30 BIIB067
No Results
Available
No Results
31 ALS Treatment Extension Study Available
ALS Caused by
Superoxide
Dismutase 1
(SOD1)
Mutation
Drug: BIIB067
Amyotrophic
Lateral
Sclerosis
Drug: Cu(II)ATSM
Research Site, Phoenix, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, San Francisco, California, United States|Research Site, Orlando, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Baltimore, Maryland, United States|Research Site,
Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Leuven, Belgium|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Ulm, Baden Wuerttemberg,
Germany|Research Site, Sheffield, South Yorkshire, United Kingdom
https://ClinicalTrials.gov/show/NCT03070119
Macquarie University, Sydney, New South Wales, Australia
https://ClinicalTrials.gov/show/NCT03136809
A Study to Assess the Efficacy
and Safety of H.P. Acthar® Gel
in the Treatment of Subjects
With Amyotrophic Lateral
No Results
32 Sclerosis
Available
Amyotrophic
Lateral
Sclerosis
Drug: Acthar|Drug: Placebo
Neuromuscular Research Center, Phoenix, Arizona, United States|Mayo Clinic - Arizona, Scottsdale, Arizona, United States|University of California San Diego, La Jolla, California, United States|Loma Linda University Health System, Department of Neurology, Loma Linda, California, United States|Keck School of
Medicine, University of Southern California, Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|University of California Irvine Medical Center, Orange, California, United States|California Pacific Medical Center, San Francisco, California, United
States|University of California San Francisco, San Francisco, California, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|Georgetown University, Washington, District of Columbia, United States|George Washington University, Washington, District of Columbia,
United States|University of Florida - McKnight Brain Institute, Gainesville, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Indiana University-Neuroscience Center of
Excellence/Goodman Hall, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|John Hopkins Outpatient Center, Baltimore, Maryland, United States|University of
Massachusetts Medical School, Worcester, Massachusetts, United States|Mercy Health- Saint Mary's, Grand Rapids, Michigan, United States|Neurology Associates, Lincoln, Nebraska, United States|University of Nebraska Medical Center - Physicians Clinical Neurosciences Center, Omaha, Nebraska, United
States|Las Vegas Clinic, Las Vegas, Nevada, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Columbia Presbyterian Hospital, New York, New York, United States|Providence ALS Center, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center,
Hershey, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Wesley Neurology Clinic, Cordova, Tennessee, United States|Austin Neuromuscular Center, Austin, Texas, United States|Texas
Neurology, P.A., Dallas, Texas, United States|The Methodist Hospital, Houston, Texas, United States|University of Vermont Medical Center, Colchester, Vermont, United States|VCU Medical Center, Richmond, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Medical
College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States|Edmonton Kaye Clinic, Edmonton, Alberta, Canada|Recherche Sepmus inc, Greenfield Park, Quebec, Canada|Centre de recherché du Centre Hospitalier de l'Universite de Montreal (CRCHUM), Montréal, Quebec, Canada|Montreal
Neurological Institute & Hospital, Montréal, Quebec, Canada|Centro de Trastornos del Movimiento (CETRAM), Santiago, Metropolitana, Chile|Biomedica Research Group AV Salvador 149, oficina 1101, Santiago, Chile|Centro de Investigaciones ClÃ-nicas SAS, Cali, Colombia
https://ClinicalTrials.gov/show/NCT03068754
30
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0031.png
Open-label Clinical Trial of
33 Lacosamide in ALS
Brain Excitability and
Connectivity in Sensory-motor
34 Pathways in ALS
The Use of Airway Clearance
35 Devices in ALS
Riluzole Oral Soluble Film
Swallowing Safety in
36 Amyotrophic Lateral Sclerosis
No Results
Available
No Results
Available
No Results
Available
No Results
Available
Trial of Amivita in Amyotrophic No Results
37 Lateral Sclerosis
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis|Front
al Temporal
Dementia
Amyotrophic
Lateral
Sclerosis|Possi
ble
Amyotrophic
Sclerosis
Frontotempor
al Lobar
Degeneration|
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis|Mot
or Neuron
Disease
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Depression|A
myotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: Lacosamide
Device: functional MRI|Device: structural
MRI|Device: EEG/MEG
Device: High Frequency Chest Compression
Device (HFCC)|Device: Cough Assist
Chiba University Hospital, Chiba, Japan
https://ClinicalTrials.gov/show/NCT03186040
Hopital Pitie-Salpetriere, Paris, France
https://ClinicalTrials.gov/show/NCT03694132
Cedars-Sinai Medical Center, Los Angeles, California, United States
https://ClinicalTrials.gov/show/NCT02682030
Drug: Riluzole Oral Soluble film (ROSF) 50 mg University of Florida Center for Movement Disorders & Neuroscience, Gainesville, Florida, United States
https://ClinicalTrials.gov/show/NCT03679975
Drug: Amivita
Wujing People's Hospital, Changzhou, Jiangsu, China
https://ClinicalTrials.gov/show/NCT03103815
Therapy in Amyotrophic Lateral No Results
38 Sclerosis (TAME)
Available
Drug: Memantine|Drug: Placebo (for
Memantine)
Phoenix Neurological Associates, Phoenix, Arizona, United States|UC Irvine, Irvine, California, United States|University of Florida, Jacksonville, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kansas School of Medicine - Wichita, Wichita, Kansas, United
States|University of Kentucky, Lexington, Kentucky, United States|University of Missouri, Columbia, Missouri, United States|Columbia University, New York, New York, United States|University of Texas Southwestern, Dallas, Texas, United States|Nerve & Muscle Center of Texas, Houston, Texas, United
States|University of Washington, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT02118727
Tolerability and Efficacy of L-
Serine in Patients With
Amyotrophic Lateral Sclerosis
39 (ALS)
Predict to Prevent
Frontotemporal Lobar
Degeneration (FDT) and
Amyotrophic Lateral Sclerosis
40 (ALS)
No Results
Available
Drug: L-Serine
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
https://ClinicalTrials.gov/show/NCT03580616
No Results
Available
Behavioral: characterization
Groupe Hospitalier Pitié-Salpêtrière - Charles Foix, Paris, France
https://ClinicalTrials.gov/show/NCT02590276
Phase 1 Dose Escalation and PK
Study of Cu(II)ATSM in
No Results
41 ALS/MND
Available
Muscular Biomarkers in
42 Amyotrophic Lateral Sclerosis
Epidemiology and Genetics of
the Amyotrophic Lateral
43 Sclerosis in the French West
Pharyngeal Electrical
Stimulation in Amyotrophic
44 Lateral Sclerosis
Safety and Tolerability of
Perampanel in Amyotrophic
45 Lateral Sclerosis Patients
Perampanel Single Ascending
Dose Transcranial Magnetic
Stimulation Biomarker Study in
46 Amyotrophic Lateral Sclerosis
Study to Evaluate DNL747 in
Subjects With Amyotrophic
47 Lateral Sclerosis
No Results
Available
No Results
Available
No Results
Available
No Results
Available
Drug: Cu(II)ATSM
Macquarie University, Sydenham, New South Wales, Australia|Calvary Health Care Bethlehem, Caulfield, Victoria, Australia
https://ClinicalTrials.gov/show/NCT02870634
Other: Samples
Dietary Supplement: Blood sample and
environmental survey
Service de chirurgie orthopédique et traumatologique, CHRU de TOURS, Tours, France|Service de Neurologie, CHRU de TOURS, Tours, France
https://ClinicalTrials.gov/show/NCT02670226
Hospital University Center of Pointe-Ã -Pitre, Pointe-Ã -Pitre, Guadeloupe|Hospital University Center of Martinique, Fort-de-France, Martinique
https://ClinicalTrials.gov/show/NCT03367650
Device: Pharyngeal Electrical Stimulation
University of Ulm, Ulm, Germany
https://ClinicalTrials.gov/show/NCT03481348
Drug: Fycompa
Johnny S. Salameh, Beirut, Lebanon
https://ClinicalTrials.gov/show/NCT03377309
No Results
Available
No Results
Available
Drug: Perampanel|Other: Placebo
Mayo Clinic, Jacksonville, Florida, United States
https://ClinicalTrials.gov/show/NCT03793868
Drug: DNL747|Drug: Placebo
CHDR, Leiden, South Holland, Netherlands
https://ClinicalTrials.gov/show/NCT03757351
SSRIs vs. TCAs for Depression in
48 ALS Patients
A Study to Evaluate the Safety,
Tolerability and Efficacy of ILB
in Patients With Amyotrophic
49 Lateral Sclerosis
Tolerability, and
Pharmacokinetics of BIIB078 in
Adults With C9ORF72-
Associated Amyotrophic Lateral
50 Sclerosis
Efficacy and Safety of Plasma
Exchange With Albutein® 5%
in Patients With Amyotrophic
51 Lateral Sclerosis
Determine Initial Safety,
Tolerability, and
Pharmacokinetic Parameters in
Participants With Amyotrophic
52 Lateral Sclerosis
A Clinical Trial to Evaluate the
Safety and Efficacy of Fycompa
in Subjects With Amyotrophic
53 Lateral Sclerosis (ALS)
Treatment Effect of Edaravone
in Patients With Amyotrophic
54 Lateral Sclerosis (ALS)
Study of Two Intrathecal Doses
of Autologous Mesenchymal
Stem Cells for Amyotrophic
55 Lateral Sclerosis
No Results
Available
Drug: Tricyclic Antidepressants ("TCA")|Drug:
Selective Serotonin Uptake Inhibitors ("SSRI") Monteleone Hall, Saint Louis University, 1438 South Grand Blvd., Saint Louis, Missouri, United States
https://ClinicalTrials.gov/show/NCT02851914
No Results
Available
Drug: ILB
Sahlgrenska University Hospital, Gothenburg, Sweden
https://ClinicalTrials.gov/show/NCT03613571
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: BIIB078|Drug: Placebo
Research Site, La Jolla, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Cambridge, Massachusetts, United States|Research Site, Knoxville, Tennessee, United States
https://ClinicalTrials.gov/show/NCT03626012
No Results
Available
Biological: Albutein 5%
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
https://ClinicalTrials.gov/show/NCT02872142
No Results
Available
Amyotrophic
Lateral
Sclerosis
Amyotrophic
Lateral
Sclerosis
Drug: GDC-0134|Drug: Placebo|Drug:
Rabeprazole|Drug: Midazolam|Drug:
Caffeine
Forbes Norris Mda/als Ctr; Research Center, San Francisco, California, United States|Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Bioclinica Research, Orlando, Florida, United States|The Emory ALS Clinic, Atlanta,
Georgia, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Wake Research Associates, Raleigh, North Carolina, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United
States|Methodist Neurological Institute, Houston, Texas, United States|MUCH - Montreal Neurological Institute & Hospital, Montreal, Quebec, Canada|UMC Utrecht, Utrecht, Netherlands
https://ClinicalTrials.gov/show/NCT02655614
No Results
Available
No Results
Available
Drug: Perampanel|Drug: Placebo Oral Tablet Stony Brook University Medical Center, Stony Brook, New York, United States
https://ClinicalTrials.gov/show/NCT03020797
Neuromuscula
r Diseases
Drug: Edaravone|Drug: Riluzole
AMYOTROPHI
C LATERAL
SCLEROSIS
Other: Two intrathecal MSC injections
EMG Department, Alzahra Hospital, Isfahan, Iran, Islamic Republic of
https://ClinicalTrials.gov/show/NCT03272802
No Results
Available
University of Sao Paulo School of Medicine Clinics Hospital, Sao Paulo, SP, Brazil
https://ClinicalTrials.gov/show/NCT02917681
31
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0032.png
AMX0035 in Patients With
Amyotrophic Lateral Sclerosis
56 (ALS)
Predictive Factors for the
Diagnosis of Early Noninvasive
57 Ventilation Equipment
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis|Mot
or Neuron
Disease|Neuro
muscular
Diseases|Neur
odegenerative
Diseases|Spina
l Cord
Diseases|TDP-
43
Proteinopathie
s|Nervous
System
Diseases|Cent
ral Nervous
System
Diseases
Drug: AMX0035|Other: Placebo
Amyotrophic
Lateral
Sclerosis
Diagnostic Test: diagnosis variables
Barrow Neurological Institute, Phoenix, Arizona, United States|UC Irvine Medical Center, Orange, California, United States|Forbes Norris MDA/ALS Research Center - California Pacific Medical Center, San Francisco, California, United States|University of Florida Medical Center, Gainesville, Florida, United
States|Carol and Frank Morsini Center for Advanced Health Care - University of South Florida, Tampa, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kentucky Medical Center, Lexington,
Kentucky, United States|Ochsner Neuroscience Institute, New Orleans, Louisiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts,
United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Neurology Associates P.C., Lincoln, Nebraska, United States|Mount Sinai
Beth Israel, New York, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|The Penn Comprehensive ALS
Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Texas Neurology, P.A., Dallas, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|ALS Center at the Swedish Neuroscience Institute,
Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT03127514
University Hospital Toulouse, Toulouse, France
https://ClinicalTrials.gov/show/NCT03452618
Arimoclomol in Amyotropic
58 Lateral Sclerosis
No Results
Available
Amyotrophic
Lateral
Sclerosis
Drug: Arimoclomol|Drug: Placebo oral
capsule
St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center, Phoenix, Arizona, United States|HonorHealth Neurology, Phoenix, Arizona, United States|UC Irvine Health ALS and Neuromuscular Center, Orange, California,
United States|University of Miami, Miami, Florida, United States|University of Kansas Medical Center (KUMC) - Landon Center on Aging, Kansas City, Kansas, United States|Hospital for Special Surgery, New York, New York, United States|Providence Brain & Spine Institute, Portland, Oregon, United
States|University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center, Philadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Sunnybrook
Health Sciences Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada|Centre Hospitalier Regional Universitaire (CHRU) Montpellier - Hopital Gui De Chauliac, Montpellier, France|Groupe Hospitalier Pitie-Salpetriere - Centre d'Investigation Clinique
Neurosciences 1422, Paris, France|Instituti Clinica Scientifici Maugeri - IRCCS, Milano, Italy|Azienda Ospedaliero Universitaria (AUO) di Torino - Citta'della Salute e della Scienza di Torino, Torino, Italy|University Medical Center Utrecht, Utrecht, Netherlands|Hospital Universitario Vall d'Hebron ALS Unit. Consultas
Externas; Office: 9-10-11, Barcelona, Spain|Hospital Carlos III - Hospital Universitario La Paz, ALS Unit, Madrid, Spain|Umeå University Hospital, Umeå, Sweden
https://ClinicalTrials.gov/show/NCT03491462
Neurofeedback Rehabilitation
Based on Motor Imaging in
Patients in the Immobilization
59 Phase
No Results
Available
Acute Intermittent Hypoxia and
Breathing in Neuromuscular
60 Disease
Evaluation of the Safety and
Efficacy of ALS-L1023
Administered in Combination
With Ranibizumab in Patients
61 With Wet-AMD
Total Lymphoid Irradiation and
Anti-Thymocyte Globulin in the
Allogeneic Hematopoietic Cell
62 Transplantation
Anti T-lymphocyte
Immunoglobulin With Post
Transplant Cyclophosphamide
to Prevent GVHD Post
63 Allogeneic Transplantation
Cyclophosphamide Versus Anti-
thymocyte Globulin for GVHD
64 Prophylaxis After RIC Allo-SCT
A Systematic Investigation of
Phonetic Complexity Effects on
Articulatory Motor
Performance in Progressive
65 Dysarthria
Anti-thymocyte Globulins for
Graft-versus-host Disease
66 Prophylaxis
Antithymocyte Globulin and
Azathioprine Versus Basiliximab
and Mycophenolate Mofetil in
Living Donor Kidney
67 Transplantation
No Results
Available
Healthy
Subjects,
Patients With
Amyotrophic
Lateral
Sclerosis,
Patients With
Shoulder
Surgery
Device: Videogames
Amyotrophic
Lateral
Sclerosis
(ALS)|Neurom
uscular
Other: Acute Intermittent Hypoxia|Other:
Diseases
Sham Acute Intermittent Hypoxia
Hopital PITIE SALPETRIERE, Paris, France
https://ClinicalTrials.gov/show/NCT03545451
UF Clinical Research Center, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States
https://ClinicalTrials.gov/show/NCT03645031
No Results
Available
No Results
Available
Age-Related
Drug: ALS-L1023|Drug: Ranibizumab|Other:
Macular
Degeneration Placebo
AngioLab, Inc., Daejeon, Daejeon Gwangyeogsi, Korea, Republic of
HEMATOLOGI
C
MALIGNANCIE
S
Other: TOTAL LYMPHOID IRRADIATION
A.O.U. San Giovanni Battista, Torino, Italy
https://ClinicalTrials.gov/show/NCT03725501
https://ClinicalTrials.gov/show/NCT01081405
No Results
Available
No Results
Available
Graft Versus
Host Disease
Graft vs Host
Disease
Drug: Cyclophosphamide|Drug: anti-human
T-lymphocyte immunoglobulin (ATLG)
Drug: Cyclophosphamide|Drug: Anti-
Thymocyte Globulin|Drug: Conditioning
regimen
Chaim Sheba Medical Center, Ramat Gan, Israel
https://ClinicalTrials.gov/show/NCT03357159
Saint Antoine Hospital - Hematology Department, Paris, France
https://ClinicalTrials.gov/show/NCT02876679
No Results
Available
No Results
Available
Amyotrophic
Lateral
Sclerosis|Parki Behavioral: Phonetic complexity effects on
nson Disease speech motor performance
Leukemia,
GVHD, ATG,
Transplantatio
n
Drug: anti thymoglobulin
University of Kansas Medical Center, Fairway, Kansas, United States|University of Missouri-Columbia, Columbia, Missouri, United States
https://ClinicalTrials.gov/show/NCT03613038
Peking university people's hospital, Beijing, Beijing, China
https://ClinicalTrials.gov/show/NCT01856803
No Results
Available
Kidney
Transplant
Rejection
Drug: Antithymocyte Immunoglobulin
(Rabbit)|Drug: Interleukin 2 Receptor
Antagonist
Doctor Salma Center for Kidney Diseases, Khartoum, Sudan
https://ClinicalTrials.gov/show/NCT03789006
32
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0033.png
Total Body Irradiation +/- Total
Lymphoid Irradiation & Anti-
Thymocyte Globulin in Non-
myeloablative Hematopoietic
68 Cell Transplantation
Efficacy and Safety of Rabbit
Antithymocyte Globulin
3mg/kg in Kidney Transplant
Patients Under Steroid-free and
CNI Minimization Maintenance
69 Immunosuppressive Regimen
No Results
Available
Acute Myeloid
Leukemia|My
elodysplastic
Syndromes|M
yeloproliferati
ve
Disorder|Chro
nic
Lymphocytic
Leukemia|B-
cell
Lymphoma|T-
cell
Lymphoma|N
on Hodgkin
Lymphoma|Ho
dgkin
Lymphoma|Ch
ronic
Myelomonocyt
ic Leukemia
Radiation: Total body irradiation (TBI)|Drug:
Anti-thymocyte globulin (ATG)|Drug:
Tacrolimus|Drug: Mycophenolate mofetil
(MMF)|Radiation: Total lymphoid irradiation
(TLI)
Stanford University School of Medicine, Stanford, California, United States
https://ClinicalTrials.gov/show/NCT03734601
No Results
Available
Thymoglobulin
Dose
Drug: Thymoglobulin
Transplant ward of the Hospital do Fortaleza, Fortaleza, Ceará, Brazil
https://ClinicalTrials.gov/show/NCT03088280
Cytoxan, Fludara, and
Antithymocyte Globulin
Conditioning Followed By Stem
Cell Transplant in Treating
70 Fanconi Anemia
Music Intervention in the
Treatment of Sleep Disorders
71 for Depressed Patients
No Results
Available
No Results
Available
Fanconi
Anemia
Biological: Anti-Thymocyte Globulin|Drug:
Cyclophosphamide|Drug:
Fludarabine|Procedure: Hematopoietic Stem
Cell Transplantation|Drug:
Methylprednisolone|Drug: Filgrastim|Drug:
Cyclosporine|Drug: Mycophenolate Mofetil Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
https://ClinicalTrials.gov/show/NCT00630253
ECoG BMI for Motor and
72 Speech Control
Horse ATG in Patients With
Aplastic Anemia (AA) or
Low/Int-1 Risk Myelodysplastic
73 Syndrome (MDS)
No Results
Available
Insomnia|Dep
ression
Other: Music intervention
ALS|SCI -
Spinal Cord
Injury|Stroke|
Multiple
Sclerosis|Musc
ular
Dystrophies
Device: PMT/Blackrock Combination Device
Sanatorium Kilchberg AG, Kilchberg, ZH, Switzerland
https://ClinicalTrials.gov/show/NCT02376686
University of California San Francisco, San Francisco, California, United States
https://ClinicalTrials.gov/show/NCT03698149
No Results
Available
Leukemia
Carmustine, Etoposide,
Cytarabine, Melphalan, and
Antithymocyte Globulin
Followed by Peripheral Blood
Stem Cell Transplant in Treating
Patients With Autoimmune
Neurologic Disease That Did
Not Respond to Previous
No Results
74 Therapy
Available
Neurologic Stem Cell Treatment No Results
75 Study
Available
Low Dose ATG Plus Low Dose
PTCy as GVHD Prophylaxis in
76 Haplo-HSCT
Comparison of the Efficacy and
Safety of Sirolimus Versus
Everolimus Versus
Mycophenolate in Kidney
77 Transplantation
No Results
Available
Autoimmune
Disease
Neurologic
Disorders|Ner
vous System
Diseases|Neur
odegenerative
Diseases|Neur
ological
Disorders|Stro
ke|Traumatic
Brain
Injury|Cadasil|
Chronic
Traumatic
Encephalopath
y|Cerebral
Infarction|Cer
ebral
Ischemia|Cere
bral
Stroke|Cerebr
al
Hemorrhage|P
arkinson|Multi-
System
Degeneration|
MSA - Multiple
System
Procedure: Intravenous BMSC|Procedure:
Atrophy|Progr Intranasal BMSC
Graft-versus-
host-
disease|Proph
ylaxis
Drug: ATG
Drug: hATG|Drug: Cyclosporine|Drug:
Methylprednisone|Drug: Pegfilgrastim|Drug:
Filgrastim
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Biological: Anti-Thymocyte
Globulin|Procedure: Autologous
Hematopoietic Stem Cell
Transplantation|Drug: Carmustine|Drug:
Cytarabine|Drug: Etoposide|Other:
Laboratory Biomarker Analysis|Drug:
Melphalan|Procedure: Peripheral Blood
Stem Cell Transplantation|Drug:
Prednisone|Procedure: Syngeneic Bone
Marrow Transplantation
Colorado Blood Cancer Institute, Denver, Colorado, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT01624805
https://ClinicalTrials.gov/show/NCT00716066
The Healing Institute, Margate, Florida, United States|Euro-Arabian Hospital, Dubai, Sharjah, United Arab Emirates
https://ClinicalTrials.gov/show/NCT02795052
Shanghai First People's HOSPITAL, Shanghai, Shanghai, China
https://ClinicalTrials.gov/show/NCT03395860
No Results
Available
Kidney
Transplant
Infection
Drug: Sirolimus|Drug: Everolimus|Drug:
Mycophenolic acid
Hospital do Rim, São Paulo, Sao Paulo, Brazil
https://ClinicalTrials.gov/show/NCT03468478
33
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0034.png
Basiliximab vs Low-dose
Thymoglobulin Induction
Therapy in Low Risk Kidney
78 Transplant Patients
No Results
Available
Kidney
Transplant
Rejection|Kidn
ey Transplant;
Complications Drug: Basiliximab|Drug: Thymoglobulin
Aplastic
Anemia|Myelo
dysplastic
Syndromes|Fu
ngal Infection Drug: Posaconazole
Umae Hospital Especialidades 14 Adolfo Ruiz Cortines, Veracruz, Mexico
https://ClinicalTrials.gov/show/NCT03006419
Posaconazole Prophylaxis
During ATG Treatment for
79 hMDS/AA Patients
Combined Blood Stem Cell and
Kidney Transplant of One
Haplotype Match Living Donor
80 Pairs.
Haplotype Matched Related
and 3 Ag Matched Unrelated
Living Donor Kidney
81 Transplantation
Phase IIA Open Label Study to
Evaluate Efficacy and Safety of
BL-8040 Followed by (hATG),
Cyclosporine and
Methyprednisolone in Adult
Subjects With Aplastic Anemia
or Hypoplastic Myelodysplastic
82 Syndrome
No Results
Available
Seoul National University Hospital, Seoul, Korea, Republic of
https://ClinicalTrials.gov/show/NCT03318159
No Results
Available
ESRD
Drug: Immune Tolerance
Stanford University School of Medicine, Stanford, California, United States
https://ClinicalTrials.gov/show/NCT01165762
No Results
Available
Immune
Tolerance
Procedure: Immune tolerance after kidney
transplant|Drug: Donor blood stem cells and
T cells
Stanford University Medical Center, Palo Alto, California, United States
https://ClinicalTrials.gov/show/NCT03292445
No Results
Available
Ph II of Non-myeloablative
Allogeneic Transplantation
Using TLI & ATG In Patients w/
83 Cutaneous T Cell Lymphoma
No Results
Available
Aplastic
Anemia|Hypo
plastic
Myelodysplasti
c Syndrome
Mycoses|Seza
ry
Syndrome|Ly
mphoma, T-
Cell,
Cutaneous|Bo
ne Marrow
Transplant
Failure|Lymph
oma, Non-
Hodgkin|Cuta
neous T-cell
Lymphoma
Drug: BL-8040|Drug: horse anti-thymocyte
globulin (hATG)|Drug:
Methylprednisolone|Drug: Cyclosporine
MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT02462252
Drug: anti-thymocyte globulin|Drug:
cyclosporine
Biological: Anti-Thymocyte
Globulin|Procedure: Autologous
Hematopoietic Stem Cell
Transplantation|Drug:
Cyclophosphamide|Biological:
Filgrastim|Other: Laboratory Biomarker
Analysis|Drug: Mycophenolate
Mofetil|Procedure: Peripheral Blood Stem
Cell Transplantation|Drug: Plerixafor|Other:
Quality-of-Life Assessment|Other:
Questionnaire Administration
Stanford University School of Medicine, Stanford, California, United States
https://ClinicalTrials.gov/show/NCT00896493
Scleroderma Treatment With
Autologous Transplant (STAT)
84 Study
Autologous Stem Cell
Transplantation for Refractory
Systemic Lupus Erythematosus
85 (ASSIST)
No Results
Available
Systemic
Scleroderma
City of Hope Comprehensive Cancer Center, Duarte, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|University of Colorado, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Boston Medical Center,
Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Hospital for Special Surgery, New York, New York, United States|Weill Medical College of Cornell University,
New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|M D Anderson Cancer Center, Houston, Texas, United States|The University of Texas Health Science Center, Houston, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United
States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States|University of Calgary, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada
https://ClinicalTrials.gov/show/NCT01413100
No Results
Available
Systemic
Lupus
Procedure: Immunoablation and Autologous Universitätsmedizin Charité, Berlin, Germany|Universitätsklinik Düsseldorf, Düsseldorf, Germany|Universitätsklinikum Essen, Essen, Germany|Universitätsklinik Heidelberg, Heidelberg, Germany|Universitätsklinik Köln, Köln, Germany|Universitäsklinik Mainz, Mainz, Germany|Universitätsklinik
Erythematosus Hematopoietic Stem Cell Transplantation
Tübingen, Tübingen, Germany|Universitätsklinik Würzburg, Würzburg, Germany
Tetraplegia|Sp
inal Cord
Injuries|Amyot
rophic Lateral
Sclerosis|Brain
Stem
Infarctions|Loc
ked in
Syndrome|Mu
scular
Device: Placement of the BrainGate2
Dystrophy
sensor(s) into the motor-related cortex
Charcot
Arthropathy|D
iabetes
Drug: Zoledronic Acid|Drug:
Complications Methylprednisolone|Drug: Placebos
Acute
(Cellular)
Renal Allograft
Rejection
Drug: rATG
https://ClinicalTrials.gov/show/NCT00750971
BrainGate2: Feasibility Study of
an Intracortical Neural
Interface System for Persons
86 With Tetraplegia
Zoledronic Acid or
Methylprednisolone for Active
Charcot's Neuroarthropathy of
Foot in Patients With Diabetes
87 Mellitus
No Results
Available
Stanford University School of Medicine, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Case Western Reserve University, Cleveland, Ohio, United States|Providence VA Medical Center, Providence, Rhode Island, United States
https://ClinicalTrials.gov/show/NCT00912041
No Results
Available
Department of Endocrinology, PGIMER, Chandigarh, India
https://ClinicalTrials.gov/show/NCT03289338
Single Dose rATG for Renal
88 Allograft Rejection
No Results
Available
Houston Methodist Hospital, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT02102854
hATG+CsA vs
hATG+CsA+Eltrombopag for
89 SAA
Evaluation of NDV-3A Vaccine
in Preventing S. Aureus
90 Colonization
No Results
Available
No Results
Available
Severe Aplastic
Anemia
Drug: hATG|Drug: CsA|Drug: Eltrombopag
Staphylococcu
s Aureus
Biological: NDV-3A|Biological: Placebo
Hopital Jean Minjoz, Besancon, France|Hôpital Haut-Lévèque, Bordeaux, France|Hôpital Huriez, Lille, France|Centre Hospitalier Lyon-Sud, Lyon, France|Institut Paoli Calmettes, Marseille, France|St. Louis Hospital, Paris, France|Pontchaillou Hospital, Rennes, France|Hôpital Purpan, Toulouse, France|Uniklinik
RWTH Aachen, Aachen, Germany|Universitatsklinikum Essen, Essen, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Hannover Medical School, Hannover, Germany|University of Ulm, Ulm, Germany|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Istituto G. Gaslini children's
Hospital, Genova, Italy|San Martino Hospital, Genova, Italy|Fondazione IRCCS ca Granda Ospedale, Milan, Italy|Ospedale San Raffaele, Milan, Italy|`Federico II` Medical School, Naples, Italy|La Sapienza University Hospital, Rome, Italy|Policlinico Gemelli, Rome, Italy|AOU Città della Salute e della Scienza di
Torino, Turin, Italy|AMC, Amsterdam, Netherlands|UMCG, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|UMCU, Utrecht, Netherlands|Hospital Universitari Germans Trias I Pujol, Badalona, Spain|Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain|Hospital
Clinico San Carlos, Madrid, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Donostia Hospital, San Sebastian, Spain|Hospital La Fe, Valencia, Spain|University Hospital Basel, Basel, Switzerland|University Hospital Bern, Bern, Switzerland|University Hospital Zürich, Zürich, Switzerland|City Hospital, Belfast,
United Kingdom|St. James Hospital, Leeds, United Kingdom|King's College Hospital, London, United Kingdom|St. Bartholomew's Hospital, London, United Kingdom|City Hospital, Nottingham, United Kingdom
https://ClinicalTrials.gov/show/NCT02099747
Fort Benning, Fort Benning, Georgia, United States
https://ClinicalTrials.gov/show/NCT03455309
34
 SUU, Alm.del - 2018-19 (1. samling) - Endeligt svar på spørgsmål 280: Spm. om oplistning af de aktuelle studier i de nordiske lande, Tyskland og England indenfor ALS-området, til sundhedsministeren
2017082_0035.png
Optimizing Haploidentical
Aplastic Anemia
Transplantation (BMT CTN
91 1502)
PTCy-ATG vs ATG in
Haploidentical HSCT for Acute
Graft-versus-host Disease
92 Prophylaxis
No Results
Available
No Results
Available
Cord Blood (CB) Ex-vivo
Mesenchymal Stem Cell (MSC) No Results
93 Expansion + Fucosylation
Available
Drug: Antithymocyte Globulin (ATG)|Drug:
Fludarabine|Drug:
Cyclophosphamide|Radiation: Total Body
Irradiation (TBI)|Procedure: Haplo
Severe Aplastic HSCT|Drug: Tacrolimus|Drug:
Anemia
Mycophenolate mofetil (MMF)|Drug: G-CSF
Hematopoietic
Stem Cell
Transplantatio Drug: ATG|Drug: CTX|Drug: Mycophenolate
n
Mofetil
Drug: Busulfan|Drug: Rituximab|Drug:
ATG|Drug: Fludarabine|Drug:
Clofarabine|Radiation: Total Body
Irradiation|Procedure: Cord Blood
Transplant|Drug: Mycofenolate
Hematopoietic mofetil|Drug: Tacrolimus|Drug: Filgrastim-
/Lymphoid
sndz|Drug: Melphalan|Drug:
Cancer
Cyclophosphamide|Drug: Mesna
City of Hope National Medical Center, Duarte, California, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida
College of Medicine, Gainesville, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Indiana University
Medical Center/ Riley Hospital for Children, Indianapolis, Indiana, United States|University of Louisville/Kosair Children's Hospital, Louisville, Kentucky, United States|Johns Hopkins Unversity, Baltimore, Maryland, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Karmanos
Cancer Institute/Children's Hospital of Michigan, Detroit, Michigan, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United
States|Roswell Park Cancer Institute, Buffalo, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State College of Medicine/The Milton S. Hershey Medical Center, Hershey, Pennsylvania,
United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas/MD Anderson Cancer Center, Houston, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United
States|Children's Hospital of Wisconsin/Midwest Children's Cancer, Milwaukee, Wisconsin, United States
https://ClinicalTrials.gov/show/NCT02918292
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|The Third Affiliated Hospital, Sun Yat-Sen
University, Guangzhou, Guangdong, China|Xiangya Hospital, Central South University, Changsha, Hunan, China|Chenzhou First People's Hospital, Chenzhou, Hunan, China|Peking University People's Hospital, Beijing, China
https://ClinicalTrials.gov/show/NCT03689465
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT03096782
Personalized Natural Killer (NK)
Cell Therapy in Cord Blood
No Results
94 Transplantation (CBT)
Available
Natural Killer (NK) Cells With
HLA Compatible Hematopoietic
Transplantation for High Risk
No Results
95 Myeloid Malignancies
Available
Leukemia|Lym
phoma|Myelo
ma|Myeloprol
iferative
Diseases
Leukemia
Drug: Busulfan|Drug: Fludarabine|Drug:
Clofarabine|Drug: Rabbit ATG|Radiation:
Total Body Irradiation (TBI)|Procedure: Cord
Blood Infusions|Drug: Rituximab|Drug:
Cyclophosphamide|Procedure: Natural Killer
Cell Infusion|Drug: Melphalan|Drug: Mesna University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug: Busulfan|Drug:
Fludarabine|Procedure: Alloreactive NK
infusion|Drug: Interleukin-2|Procedure:
Stem Cell Infusion|Drug: G-CSF|Drug:
Tacrolimus|Drug: Methotrexate
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT02727803
https://ClinicalTrials.gov/show/NCT01823198
CMC-544 and Allogeneic
Transplantation for CD22
Positive-Lymphoid
96 Malignancies
No Results
Available
Gemcitabine/Clofarabine/Busul
fan and Allogeneic
Transplantation for Aggressive No Results
97 Lymphomas
Available
Drug: CMC-544|Drug: Fludarabine|Drug:
Bendamustine|Drug: Rituximab|Procedure:
Allogeneic Stem Cell Transplantation|Drug:
Lymphoma|Le Thymoglobulin|Drug: Tacrolimus|Drug:
ukemia
Methotrexate|Drug: G-CSF
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug: Gemcitabine|Drug: Clofarabine|Drug:
Busulfan|Procedure: Stem Cell
Infusion|Drug: Anti-Thymocyte
Globulin|Drug: Rituximab|Drug:
Filgrastim|Drug: Tacrolimus|Drug:
Lymphoma
Mycophenolate Mofetil
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
https://ClinicalTrials.gov/show/NCT01664910
https://ClinicalTrials.gov/show/NCT01701986
35